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1.1 Lung anatomy  
The lung is the body’s organ of respiration. The trachea carries air into the body from the 
nose/mouth. It then splits into two bronchi which branch off into the left and right lungs. 
These primary bronchi branch into secondary bronchi, which in turn branch into tertiary 
bronchi which then become bronchioles. Each level of branching sees a decrease in diameter 
and an increase in the number of bronchioles. The bronchi can have diameters > 5 mm while 
terminal bronchiole diameter can be as small as 5-10 µm. Their diameter is controlled by 
bronchial smooth muscle which is under autonomic control. At the end of the terminal 
bronchioles are the alveoli. The alveoli are the site of gaseous exchange in the lung. 
Pulmonary capillaries surrounding the alveoli carry CO2 and O2 to and from the alveoli, 
respectively. The alveolar and micro capillary walls together make up what is known as the 
respiratory membrane. This consists of the alveolar epithelial lining (a layer of type I and type 
II alveolar cells and associated alveolar macrophages), an epithelial basement membrane, a 
capillary basement membrane and endothelial cells of the capillary (figure 1). Despite having 
several layers, the respiratory membrane is very thin (~ 0.5 µm). This allows for the rapid 
diffusion of O2 and CO2 across the membrane. It has been estimated that the lungs contain 
over 3×108 alveoli giving it a surface area of about 70-100 m2 for the exchange of gases [1]. 
In air-breathing animals, respiratory anatomy has evolved in such a way as to actively thwart 
inhalation of putative airborne particulates.  
A                                                                                   B 
Figure 1: A) The anatomy of the human lung (taken from www.aduk.org.uk/gfx/lungs) B) Alveoli of the 
terminal bronchioles. They are covered in capillaries and it is here that gaseous exchange takes place (taken from 
http://en.wikipedia.org/wiki/Alveoli).  
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The epithelium of the airways is a continuous sheet of cells lining the luminal surface. The 
airway epithelium has at least four major types of cells, including basal cells, ciliated cells, 
goblet cells and Clara cells. On the surface of the epithelium of the proximal respiratory tract, 
ciliated cells predominate. Together with basal cells and a small percentage of goblet cells, 
they form a pseudostratified epithelium, in which ciliated cells occupy the majority of the 
luminal surface and basal cells are in contact with the basement membrane [2]. 
Starting with the trachea and ending in the alveolar sacs, the thickness of respiratory 
epithelium decreases gradually from 60 µm in the tracheobronchial epithelium to 0.2 µm in 
the alveolar region. Alveolar epithelial type I cells represent the principle cell type lining the 
surface of the alveoli. They are thin and broad representing 8.3% of the cell population within 
the human lung. The major functions of these cells, which cover 93% of the alveolar space, 
are to provide a surface for gas exchange and to serve as a permeability barrier. 
Alveolar epithelial type II cells have a much smaller surface area per cell and they represent 
16% of the total cells in the lung. They play a basic role in synthesis, secretion and recycling 
of surface-active material (lung surfactant), and they respond to alveolar injury by dividing, 
retaining morphological features of type II cells or differentiating into type I cells. Both type I 
and type II cells rest on the alveolar basement membrane that is nearly continuous. Epithelial 
cells are joined together by well-developed tight junctions. These junctions impart important 
permeability properties to the epithelial cell layer [3]. 
The alveolar region of the lung contains alveolar macrophages as well. These help in the 
clearance of inhaled particles. Alveolar macrophages are aid cells and serve well as  primary 
defenders of the alveolar milieu [4]. 
 
1.2 Lung cancer 
The thorax is a common site of involvement by primary and metastatic malignancy. The lung 
is unique among all organs in having a very high degree of exposure to the internal 
environment through the pulmonary blood flow and from the outside by exposure to air flow. 
Patients suffering from metastatic cancer have circulating cancer cells in their blood that are 
shed from the primary tumour. Hence, the lungs are continually exposed to these neoplastic 
cells. Fortunately, the natural defense mechanism in the lungs scavenge most, if not all, of the 
cells that are deposited in the pulmonary capillaries and interstitium. However, a few cells 
survive and proliferate into metastases. Thus, the lungs are a common site of metastatic 
disease [5].  
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Lung cancer, which includes cancer of the trachea and bronchi, is the third most common 
cause of death in the UK after heart disease and pneumonia. It is responsible for around a 
quarter of all cancer deaths. Pamela Mason reported that the mortality rate worldwide is 
highest in Scotland, closely followed by England and Wales. In England and Wales, lung 
cancer was responsible for nearly 29,000 deaths in 2002 with a male to female ratio of 
approximately two to one. The lung cancer incidence and death figures in UK are worse than 
other European and USA averages. The incidence number in 2002 in the world for men was 
965,241 and for women was 386,891 [6]. 
Although the mortality rate for this disease has levelled off in men, it is still the most common 
cause of cancer death in this population group, and men account for 60% of all lung cancer 
cases. The incidence continues to arise in women, accounting for one in six of all cancer 
deaths. This is directly related to changes in smoking habits. In women, lung cancer is 
generally the second most common cause of cancer death after breast cancer. Risk increases 
with age - lung cancer is less common in people under the age of 40.  
The prognosis in lung cancer patients is generally poor. About 80% of patients die within a 
year of diagnosis and only 5.5% are alive after five years. This is due to the speed with which 
the disease progresses and also to the nature of the patients, most of whom are older and often 
suffer from smoking related illnesses, including chronic obstructive pulmonary disease 
(COPD) and cardiovascular disease. Overall, patients with metastatic disease to the lung as 
well as those with locally advanced primary lung cancers, carry poor prognoses and are not 
usually amenable to curative therapy with surgery or with chemotherapy or radiation [5]. 
There are two main types of lung cancer based on the characteristics of the disease and its 
response to treatment. Non-small-cell lung carcinoma (NSCLC) accounts for 80% of all lung 
cancers. NSCLC is divided into:  
1. Squamous carcinoma, which is the most common type, accounting for 35% of all lung 
cancer cases. The cells are usually well differentiated and locally spread. Widespread 
metastases occur relatively late. 
2. Large-cell carcinoma, which accounts for 10% of all lung cancers. It is less well 
differentiated than the first type and metastasises earlier. 
3. Adenocarcinoma, which accounts for approximately 27% of lung cancers. It arises 
from mucous glands and from scar tissues. Metastases is common to the brain and 
bones. It is the most common type of lung cancer associated with asbestos and is 
proportionally more common in non-smokers, women and older people. 
4. Alveolar cell carcinoma, accounting for 1-2% of lung cancers. 
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The second major type is the small-cell lung carcinoma (SCLC), which accounts for 20% of 
all lung cancers. Arising from endocrine cells, these tumours secrete many polypeptide 
hormones. Some of these hormones provide feedback to the cancer cells and cause tumour 
growth. This type of tumour grows rapidly, taking approximately three years from initial 
malignant change to presentation. 
Surgery is a treatment option in some patients with stage I or II NSCLC. Radiotherapy and 
chemotherapy can be offered. 
Due to the importance of the lung for survival, it is often not possible to remove the tumours 
completely without dramatically reducing lung function. Thus, lung tumours are treated by 
radiation therapy or chemotherapy. Both types of treatment cause painful toxicity to the 
patient that may require a premature end of the therapy even though the tumour cells are 
successfully killed. The reason for this is that all cytotoxic drugs kill normal cells as well as 
cancerous cells, and this causes severe side effects. Furthermore, because of the blood 
circulation in the body, only a small fraction of the drug actually reaches the target tumour, 
and most of the drug acts on normal tissues or is rapidly eliminated. Therefore, to obtain a 
therapeutic effect, a relatively high dose of drug must be administered and usual drug 
formulations are used in a balance between killing the tumour (efficacy) and killing the 
patient (toxicity) [5-7]. 
Chemotherapy plays an important role in treating many patients with both NSCLC and SCLC. 
For patients with early-stage NSCLC, drugs can be used either following surgery (i.e., 
adjuvant chemotherapy) or before surgery is carried out (i.e., neoadjuvant chemotherapy). The 
goal of chemotherapy is to help "cure" the patient and improve long-term survival rates. 
Patients with SCLC and advanced NSCLC can also benefit from chemotherapy, with the aim 
of drug treatment being to prolong life, improve or maintain quality of life and control 
symptoms without causing unacceptable toxicity [7]. 
It has been reported that drug treatment plays an important part in the treatment of many 
patients with lung cancer and can help cure the disease. Where cancer is of the type or stage 
such that remission is unlikely to be achieved, chemotherapy can still prolong life, or improve 
or maintain a patient's quality of life. The development of biological agents targeting tumour 
cells might potentially result in these aims being achieved with less toxicity to patients [7-9]. 
One way to reduce the toxicity of the drug to the normal tissue is to direct the drug to the 
tumour cells with a drug delivery system. This is similar in concept to the use of a cruise 
missile to destroy only a military target while leaving surrounding buildings intact. Targeted 
drug delivery to lung tumours may prove to be the most efficacious and economical means by 
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which to treat lung cancer, since small groups of tumour cells that have spread away from the 
main tumour and are too few in number to be detected, can be exposed to a high level of drug 
by these "smart bombs". The bomb in this research is called a liposome. The liposome is a 
microscopic balloon, smaller than a red blood cell, formed from lipids. Cytotoxic drugs can 
be carried inside the liposome, where they do not come in contact with the cells. The lipids 
can be broken down by metabolism inside the body and the drug is then released. The 
technology for encapsulating drugs in liposomes has been thoroughly worked out by many 
laboratories around the world [10]. 
A standard treatment method for patients with extensive-stage SCLC is combination 
chemotherapy, with or without prophylactic cranial irradiation (PCI). Extensive SCLC has 
been associated with an untreated median survival of only a few months. The use of 
combination chemotherapy, such as: 1-etoposide with cisplatin or carboplatin, 2-doxorubicin 
(DOX) and cyclophosphamide with etoposide or vincristine, and 3-cisplatin, DOX, 
cyclophosphamide and etoposide, is associated with a response rate of over 50% and a 
median survival of 8-12 months. The use of adjunctive radiation therapy does not help in 
extending survival in extensive disease [9]. 
 
1.3 Doxorubicin  
The treatment of cancer with medication (as opposed to surgery or radiation) is especially 
helpful when the cancer in question is not localised to one body area. Using medication 
allows body blood vessels to carry the medication to even remote or otherwise inaccessible 
areas. This form of treatment is called "chemotherapy". 
In order for chemotherapy to be effective, the medications must destroy tumour cells and 
spare the normal body cells that may be adjacent. This is accomplished by using medications 
that affect cell activities that go on predominantly in cancer cells but not in normal cells. Most 
chemotherapy agents focus on the rapid cell division that characterises the spread of cancer 
cells.  
DOX is anthracycline cytostatic antibiotic and is used against a variety of malignant solid 
tumours. It is clinically proven to be an effective anti-neoplastic against a number of 
malignancies in the treatment of cancers, including breast, ovarian, bladder and lung cancer, 
as well as non-Hodgkin's lymphoma, Hodgkin's disease and sarcoma. However, its toxicities 
and low therapeutic index have limited its use. 
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Figure 2: Chemical structure of doxorubicin (C27H29NO11).  
 
One of the most common brand names of DOX is Adriamycin®. DOX is a type of anti-cancer 
drug called an "anthracycline glycoside". It works by impairing DNA synthesis. One way in 
which DOX works is by binding to the cancer cells’ DNA (the genetic code) and blocking an 
important enzyme (topo-isomerase II). This causes DNA to get tangled up and the cancer 
cells cannot divide and grow. 
DOX is a red (as consequence of being highly conjugated compound (figure 2)) powder, 
which can be used as solution for injection into a vein (intravenously) or infused through a 
fine tube, inserted into a vein (cannula) or may be used through a central line. It is given 
slowly over a 10 minute in an IV drip rather than as a single quick shot. Chemotherapy is 
usually given as a course of several cycles of treatment. The treatment plan for DOX depends 
on which cancer one is having treatment for. 
DOX is a very serious anti-cancer medication with definite potential to do great harm as well 
as great good. Myelosuppression occurs in 60-80% of patients, and it is the dose limiting 
toxicity in most patients. The cytotoxic effects of DOX are thought to be related to 
intercalation with nucleotide bases and cell membrane lipid binding activity. The intercalation 
inhibits nucleotide replication of DNA and RNA. DOX also interacts with topo-isomerase II 
that forms breaks in DNA complexes, thus stopping the synthesis of DNA and RNA. Cellular 
membrane binding of DOX can alter a variety of cellular functions. 
The reduction of DOX by cellular enzymes results in the production of free hydroxyl radicals 
(OH˙). The cardiac tissue does not have the enzymes to counteract the oxidative free radical 
build-up, and therefore is more prone to cellular damage and cardiotoxicity. This might result 
in irreversible myocardial infarction or fatal congestive heart failure, which may occur years 
after therapy has been discontinued. Because of the cumulative cellular damage, there is a 
maximum lifetime dose of DOX. Its dose-limiting toxicity is myocardial damage although 
mucositis, stomatitis, and myelosuppression are other well-recognised side effects. 
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The toxicities have led to rational development of delivery systems with an improved 
therapeutic index, less cardiotoxicity, and more selectivity for tumour tissue [10-12]. 
 
1.4 Liposomal drug delivery systems 
Since Bangham’s original description of bilayered phospholipid (PL) vesicles in 1965, 
liposomes have received much attention as transporters of pharmacological agents. These 
vesicles, ranging in size from 0.025 µm to greater than 20 µm, are composed of single or 
multiple PL membranes surrounding an aqueous compartment. According to their hydrophilic 
or hydrophobic tendencies, drugs can be entrapped in the aqueous or membrane phases, 
respectively. The preclinical evaluation of their use in the treatment of malignant disease has 
generated a considerable body of literature [13]. 
Liposomes are liquid crystals formed when naturally occurring PLs are equilibrated with 
excess water or aqueous salt solution. Some examples of the PLs commonly used in liposome 
production include lecithin, cholesterol (Chol), dipalmitoyl phosphatidylglycerol (DPPG), and 
hydrogenated soy-bean phosphatidylcholine (HSPC). The liquid crystals formed usually 
consist of two or more bimolecular lipid layers, or lamellae, which are separated by aqueous 
layers. These types of systems are referred to as multilamellar liposomes [8]. Water-soluble 
drugs can be entrapped in the liposomes within the aqueous core and aqueous layers while 
lipid-soluble drugs can be solubilised within the hydrocarbon interiors of the lipid bilayers. 
Molecules with both hydrophilic and lipophilic character are arranged in stable conformations 
within the liposome (figure 3A). 
The net charge of a liposome can be varied by incorporation of lipids with negative or 
positive charges. For example, a long-chain amine will give positively charged vesicles, and 
diacetyl phosphate will give negatively charged vesicles. Positively charged liposomes have 
been used experimentally as carriers for anionic DNA [9]. 
Liposomes have been either employed as carriers of chemotherapeutic agents or biological 
response modifiers. Most of the chemotherapeutic agents used have been DOX or cisplatin 
derivatives. Muramyl peptides have been used as macrophage activators to invoke anti-
tumour biologic responses in the host. Phase I and II trials using liposomes in cancer patients 
consistently demonstrate their safety. Encapsulation is often associated with a favourable 
effect on the therapeutic index, which is usually attributable to a reduction in toxicity of the 
active compound. Low grade fever and mild fatigue are the most common toxicities related 
specifically to the lipid constituents. Although objective tumour responses and stable disease 
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during treatment have been observed in early studies, further clinical trials are required to 
define the role of liposomal anti-tumour therapy in medical oncology. 
The incorporation of drugs into liposomes has several theoretical advantages. They protect 
their contents from interaction with plasma components, while favourably altering the 
pharmacokinetics and biodistribution of the free compound. For example, preclinical data 
demonstrated that DOX encapsulated in liposomes was significantly less cardiotoxic than the 
free compound and the lower toxicity correlated with lower cardiac levels of the drug. The 
reduced toxicity may be associated with a slower release of DOX, since it has been shown 
that continuous infusion DOX is less cardiotoxic to humans. Since liposomes do not readily 
penetrate biological membranes, they can be used for the controlled release of drugs within 
body cavities such as the pleural, peritoneal or intrathecal spaces.  
Although simple PL membranes will naturally target to the reticuloendothelial system (RES), 
manipulations of the liposome surface can be used for organ-specific or tumour-specific 
targeting.  
By altering their physical parameters such as size, electrostatic charge, PL profile, and 
membrane characteristics, liposomes can be engineered to efficiently encapsulate different 
types of drugs and effectively transport them within the circulation. Each drug encapsulated in 
a liposome must be regarded as a unique pharmacologic entity dependent upon the 
components of the liposome and the conditions under which drug encapsulation takes place. 
Small changes in liposomal preparation or composition can have profound effects on drug 
bioavailability, activity, and toxicity. 
Since liposomes produced by standard methods are sequestered primarily by the RES, they 
can be used to target therapy directly to malignant disease of the liver and spleen or activate 
macrophages for immunomodulation. By manipulating the physical properties of vesicles, for 
example, using small unilamellar vesicles composed of uncharged lipids, the RES can be 
avoided, circulation time increased, and tumour-targeting augmented.  
There are two types of commonly used liposomes: 
Multilamellar vesicles (MLVs; l-5 µm) and unilamellar vesicles (UVs; 0.05-0.2 µm). Because 
MLVs are composed of concentric layers of PLs, the aqueous compartment is reduced, 
allowing for better encapsulation of lipophilic drugs. These drugs associate with the inner and 
outer PL membranes. 
When MLVs are subjected to sonication or extrusion through filters, UVs are formed. Small 
UVs (SUVs) measure less than 0.1 µm; large UVs (LUVs) measure between 0.1 and 0.25 µm. 
Generally, UVs are better suited for delivery of hydrophilic drugs. Since large liposomes are 
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rapidly sequestered by the RES, SUVs are employed to increase liposome circulation time. In 
general, the smaller the vesicle, the longer the circulation time. Small vesicles are utilised for 
slow drug release in the circulation and for non-RES targeting. 
Animal data suggest also that liposomal DOX is less myelosuppressive than the free drug and 
is less likely to cause soft-tissue necrosis. 
Gabizon et al. reported a phase I clinical trial in which liposome-encapsulated DOX was used 
to treat 32 patients with metastatic cancer after failure of conventional chemotherapy. The 
liposomes were composed of phosphatidylcholine (PC), phosphatidylglycerol (PG), Chol, and 
α-tocopherol succinate in a molar ratio of 7:3:4:0.2, respectively. The mean size was in the 
range of 0.3-0.5 µm. Liposomes were infused at a concentration of 0.5-2.0 mg/ml, at a rate of 
2-3 ml/min through a peripheral vein. Interestingly, gastrointestinal toxicity was mild without 
the use of prophylactic antiemetics. Fever was the most common toxicity (37%), whereas 
stomatitis and myelosupression were the dose-limiting toxicities. The maximum tolerated 
dose (MTD) was 120 mg/kg. Of the 18 patients evaluated for anti-tumour effect, one partial 
response and five marginal responses were observed. The duration of response was only 3 to 
8 months. All responders had primary or metastatic hepatic involvement; two patients had 
been previously treated with intravenous DOX. Gabizon concluded that liposomal DOX can 
be safely administered at higher dose levels than the free drug and that phase II studies 
starting at a dose of 100 mg/kg are indicated [11]. 
Excluding cardiotoxicity, toxicities in all of the clinical trials utilising intravenously 
administered liposome-encapsulated doxorubicin (LED) parallel those of free DOX. 
Myelosuppression was dose-limiting and all investigators noted a significant incidence of 
nausea, vomiting and alopecia.  
Macrophages recognise liposomes as foreign particles through a process known as 
opsonisation. The liposomes are "labelled" by the RES by attaching antibody molecules. 
These "labels" are recognised by the macrophages and the liposomes are taken up and 
destroyed. A surface modification to the liposomes by attaching polyethylene glycol (PEG) 
chains enables the liposomes to resist opsonisation, thus allowing them to escape macrophage 
uptake and extend their residence time in the blood to hours or days. These "PEGylated" 
liposomes are also known as Stealth® liposomes (figure 3B) [14]. 
In some instances it may be of therapeutic benefit to have liposomes taken up by 
macrophages (e.g., macrophage located microbial or viral diseases) and this concept of 
passive targeting of macrophages offers possible therapeutic opportunities. 
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It is also possible to make liposomes site-specific by covalently attaching ‘homing devices’ to 
the outside bilayers. Attaching receptor-specific ligands to the surface of liposomes and the 
idea of immunoliposomes where antibodies or antibody fragments are bound to the surface of 
the liposome, have been investigated. Here, the aim is active targeting to a desired site, not 
just passive targeting of macrophages (e.g. immunoliposomal DOX targeted to human 
CD34(+) leukaemia cells) These ideas are summarised below in figure 3B [12]. 
Liposomes possess the ability to encapsulate drugs, proteins, enzymes and nucleic acid and 
these liposomal systems have been used intravenously, orally and intramuscularly to decrease 
toxicity, increase specific uptake of drug and to control drug release.  
They may also be useful in pulmonary drug delivery systems from a delivery, targeting, 
sustained release and toxicity-limiting point of view. Administration to the lung directly can 
deliver the drug to the site of action and therefore avoid stability problems of IV delivery, in 
which liposomes may release their drug content in the blood before reaching the target site. 
Free drug in solution is generally absorbed rapidly from the airways to the circulation. By 
retaining the drug in liposomes, it may be possible to increase the drugs contact time at the 
active site and retard its absorption into the bloodstream. This would mean a lower dosage 
requirement and a reduction in systemic toxicity associated with high levels of the drug in 
systemic circulation [8].  
 
 
 
A                                                                            B 
Figure 3: Diagrammatic representation of a liposome in which the bilayers of polar PLs alternate with aqueous 
compartments A: Possibility of entrapment of different drugs in liposomes (taken from http://blog.case.edu), B: 
Liposomes can be modified with different molecules either for targeting or for stabilisation (taken from 
www.unizh.ch/onkwww/lipos.htm). 
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1.5 TfR-based targeting for anti-cancer therapeutics 
An attractive strategy to enhance the therapeutic index of drugs is to specifically deliver these 
agents to the defined target cells, thereby keeping them away from healthy cells, which are 
also sensitive to the toxic effects of the drugs. This would allow for more effective treatment 
achieved with a better tolerance. 
Many attempts are being made to explore the potential of specific and target-oriented delivery 
systems. Examples include polymer drug delivery systems based on liposomes, and ligand-
receptor combinations. The last case has received major attention in the past few years due to 
the potential of non-immunogenic, site-specific targeting to ligand specific biosites of the 
naturally existing ligands and their receptors. The best-characterised and efficient cellular 
mechanism of uptake of transferrin (Tf) has been exploited for the delivery of anticancer 
drugs, proteins, and therapeutic genes into primarily proliferating malignant cells that 
overexpress transferrin receptors (TfR). 
TfR-targeted therapy has emerged as an interesting drug-delivery tool with dual functionality. 
For example, targeting of TfR can lead to delivery of therapeutic agents into tissues of choice 
or across epithelial barriers of choice. The seemingly contradictory effects can be achieved by 
focusing the targeting strategies toward different aspects of TfR-related biology.  
One of the best explored avenues for TfR-based drug targeting strategies involves the use of 
anti-cancer based therapeutics conjugated to Tf (or to TfR recognising antibody) to 
preferentially direct the drug towards TfR rich cancer cells. High levels of TfR expression 
have been demonstrated in many tumours and significantly, studies have also shown that the 
TfR are expressed more abundantly in malignant tissues than in their normal counterparts 
[15]. TfR are also more abundantly expressed in rapidly dividing cells than in quiescent cells 
because of their pivotal role in iron uptake and the absolute requirement for iron in rapid cell 
proliferation [16]. Therefore, TfR expressed on cancer cells have been seen as a suitable 
target for the delivery of therapeutics by receptor-mediated endocytosis. 
Many anti-cancer agents have been considered for conjugation to Tf by varying methods, 
including direct chemical linkage, liposomal packaging of toxin and linkage to Tf, 
conjugation of DNA/polylysine complexes to Tf, and conjugation of liposome/DNA 
complexes to Tf. A great variety of cytotoxic agents have been conjugated to Tf and 
investigated as potential anticancer therapeutics. Some of the more notable examples have 
been methotrexate, DOX, cisplatin, ricin A, daunorubicin, and toxin CRM107 [17]. 
Conjugation of these toxins to Tf has the dual benefits of reducing toxicity in undesired 
tissues while increasing the targeting efficiency to the cancerous cells. Of special note is that 
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conjugation to Tf significantly enhances the effectiveness of these agents in many multi drug-
resistant cell lines. For example, Tf-DOX was 5–10 times more effective than DOX- control 
in killing DOX-resistant cell lines, whereas in DOX-sensitive cell lines, the conjugate was 
only four to five times more effective than the control. The exact mechanism by which Tf 
conjugation allows DOX to effectively bypass the drug-resistance machinery of the resistant 
cell lines is not fully understood; however, it is conceivable that internalisation of the Tf-
DOX conjugate allows for sequestration into the endocytic pathway, away from drug efflux 
proteins (such as PGP and/or MDR), which normally reside at the plasma membrane [18].  
A variation on the theme of using toxins conjugated to Tf has been investigated to increase 
efficiency of uptake at the cellular surface. This approach relies on the formulation of the 
toxin in liposomal delivery vehicles to further enhance the efficiency of cellular uptake. 
For example, when Tf-liposome therapy was combined with conventional radiation therapy, 
complete tumour regression was observed in human prostate cancer and the treatment group 
showed no signs of relapse up to six months later [17]. Further developments in Tf-based 
targeting of anti-cancer drugs will most likely play important roles in anti-cancer therapy. 
Cells take up iron by using a variety of mechanisms. In higher organisms, one principal 
pathway of cellular iron acquisition is by the receptor-mediated uptake of Tf-bound iron, 
which is one of the best understood processes in cell biology. Figure 4 shows the current 
model of iron uptake from Tf via TfR-mediated endocytosis. Briefly, the process is triggered 
by the binding of Fe2-Tf to a specific cell-surface TfR. After endocytosis via clathrin-coated 
pits, which bud from the plasma membrane as membrane bound vesicles or endosomes, the 
Fe2-Tf·TfR complex is routed into the endosomal compartment. Upon maturation and loss of 
the clathrin coat, the endosome becomes competent to pump protons in a process energised by 
ATPase, and the endosomal lumen is rapidly acidified to a pH of about 5.5. At this pH, the 
binding of iron to Tf is weakened, leading to iron release from the protein. The free Fe3+ 
released to endosomes is reduced to Fe2+ on the cis-side of the endosomal membrane probably 
mediated by oxidoreductase. Fe2+ is subsequently transported out of the Tf cycle endosome by 
the divalent metal transporter DMT1, i.e., from the endosomal membrane to the cytosol. Once 
in the cytosol, iron is utilised as a cofactor for aconitase, the cytochromes, RNA reductase, 
and haeme, or stored as ferritin. After release of iron into the endosome, the resultant apo-
Tf·TfR complex is then recruited through exocytic vesicles back to the cell surface. At 
extracellular physiological pH, apo-Tf dissociates from its receptor due to its low affinity at 
pH 7.4, and released into the circulation to be reutilised. ATP-mediated energy is necessary 
for sustaining TfR-mediated endocytosis and recycling. 
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It has been shown that the number of receptors displayed on the cell surface is proportional to 
iron uptake and that iron deficiency induces TfR gene expression, which implies the 
significance of TfR in iron uptake. Furthermore, surface display of TfR is affected by its total 
cellular concentration, as well as its distribution and rate of recycling between the cell surface 
and cell interior. The efficiency of TfR function is also influenced by other proteins, including 
SFT (stimulator of iron transport) which stimulates iron uptake by both Tf and non-Tf 
pathways [19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The transferrin cycle. HOLOTRANSFERRIN (HOLO-TF) binds to transferrin receptors on the cell 
surface. The complexes localise to clathrin-coated pits, which invaginate to initiate endocytosis. Specialised 
endosomes form, and become acidified through the action of a proton pump. Acidification leads to protein 
conformational changes that release iron from transferrin. Acidification also enables proton-coupled iron 
transport out of the endosomes through the activity of the divalent metal transporter 1 protein (DMT1). 
Subsequently, APOTRANSFERRIN (APO-TF) and the transferrin receptor both return to the cell surface, where 
they dissociate at neutral pH. Both proteins participate in further rounds of iron delivery. In non-erythroid cells, 
iron is stored as ferritin and haemosiderin [taken from 16]. 
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1.6 Inhalation therapy 
The lung's anatomy and its transport function between the external environment and the 
systemic circulation are perfectly matched. The alveolar capillary membrane is only two cells 
in thickness and extends over a vast area (70-100 m2). The physiological mechanisms 
controlling airway function and pulmonary hemodynamics also strive to produce optimal 
opportunity for external/internal exchanges to occur. Thus, the lungs represent a significant 
portal between the external and internal environments. Inhalation therapy, as the name 
suggests, involves the delivery of drugs to the respiratory tract for either local or systemic 
effects. The most common use of inhalation therapy is for the treatment or prophylaxis of 
respiratory conditions, such as bronchial asthma, COPD and cystic fibrosis. 
It is not surprising; therefore, that illicit or traditional drug delivery to the systemic tissues has 
been achieved via lung inhalation. By contrast few pharmaceutical agents are currently 
available for systemic delivery via the inhalation route. 
Patients are dependent on inhalation of some kind of aerosol, generated either from a liquid 
drug solution in a nebuliser, a dry powder inhaler (DPI), or a pressurised metered dose 
aerosol. In all instances, these devices produce a mist containing particles of varying sizes. 
Large 20-µm particles have a high degree of inertia and are deposited in the throat (to be 
swallowed). The smallest particles (diameter 0.2-2.0 µm) constitute "the respirable fraction" 
and are carried in inspired air into the respiratory bronchioles and alveoli. Between these two 
extremes is a broad range of particles whose fate depends heavily on the behaviour of the 
patient. In vitro tests routinely show small deviations in the pattern of particle deposition into 
artificial "lung" systems, whereas in vivo studies produce a much wider variation. However, 
some generalisations are possible. Deposition into the alveoli is small with, for example, only 
approximately 10% of the administered material is getting to the terminal airways from a 
pressurised metered dose aerosol. By contrast, approximately 80% are deposited into the 
upper airways. The fate of this airway-deposed material may be: removal from the lung via 
mucociliary clearance, metabolism within the airway mucosa, or absorption through the 
mucosa into the bronchial circulation. Thus, we might expect an inhaled pharmaceutical 
agent, provided by a pressurised metered dose inhaler (pMDI), to have a pharmacokinetic 
distribution which favours pharmacological action on the airways rather than systemic 
activity [20]. 
The delivery of drugs to the lungs by inhalation has been investigated extensively and a large 
number of formulations are now in use. Formulations are usually powders for inhalation, 
which may or may not be pressurised, or nebulised solutions from which the drug is inhaled 
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as a mist. There are a number of preparations for inhalation which are the subject of an 
individual monograph in the Pharmacopoeias. Examples include powders for inhalation such 
as sodium cromoglicate powder for inhalation, pressurised inhalations such as 
beclomethasone pressurised inhalation, and nebuliser solutions such as salbutamol nebuliser 
solution. These are all examples of drugs acting locally to treat diseased lung states. 
There are many advantages associated with inhalation therapy. The delivery of a drug directly 
to its site of action can result in a much quicker onset of action, compared with parenteral or 
oral delivery. This may be highly desirable, for example when delivering bronchodilating 
drugs for the treatment of asthma. It may be possible to administer smaller doses locally, 
compared with parenteral or oral routes, thereby reducing the incidence of adverse side 
effects. Drugs with poor oral bioavailability may benefit from direct pulmonary delivery. For 
example, sodium cromoglicate is a mast-cell-stabilising anti-allergic agent, active at the lungs, 
which is poorly absorbed orally. And isoprenaline is a sympathomimetic bronchodilator, 
which is rapidly metabolised when given orally. In addition, first-pass metabolism of the drug 
in the liver can be avoided by pulmonary delivery. The lung is also an effective gateway for 
the delivery of drugs to the systemic circulation due to its large surface area with thin 
absorption barriers and abundance of capillaries. It also has less degradative enzyme activity 
than other routes; e.g., the gut, meaning it is a more stable environment to peptide- and 
protein-based drugs [21]. 
Although the inhalation route has many advantages it also has some disadvantages. Only a 
small percentage of the dose leaving a delivery device will actually reach its intended target in 
the lower respiratory system. The delivered drug quantity depends on the patient's ability to 
use the inhaler system correctly and/or control of their breathing [8]. Some drug is not inhaled 
correctly, while some has too small particle size and is breathed out. If the target sites are the 
smaller bronchioles and alveoli, particles which are too large may not be able to reach them. 
The optimal particle size for penetration to these peripheral pulmonary regions is 0.5–5 µm. 
Some drugs with beneficial local effects may have toxic systemic effects and their absorption 
from the lungs would therefore be undesired. (e.g., cytotoxic anti-cancer drugs). Pulmonary 
delivery of drugs is complicated by: (1) the need for training patients to coordinate breathing 
and inhaling of aerosols; (2) rapid absorption of most drugs, necessitating frequent dosing 
which often is responsible for systemic side effects; (3) poor aqueous solubility of drugs 
which may cause local irritation and inflammation in the airways or prevent the use of 
aerosols entirely; and (4) poor cytosolic penetration of drug to treat intracellular pathogens. 
Another therapeutically undesirable aspect of pulmonary drug delivery is rapid absorption of 
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most drugs from the lung, necessitating frequent dosing, e.g., of bronchodilators and 
corticosteroids [22]. 
For these reasons, novel ways of delivering drugs to the pulmonary system are actively being 
considered and researched. One approach which has been investigated is the use of liposomes 
as carriers in inhaled systems. 
 
1.7 Liposomes for inhalation 
Topical modes of application of liposomes, including the pulmonary route, have been 
explored for tissue-selective, and potentially cell-targeted drug delivery.  
Liposomes are believed to alleviate some of the problems encountered with conventional 
aerosol delivery due to their ability to: (1) serve as a solubilisation matrix for poorly soluble 
agents; (2) act as a pulmonary sustained release reservoir; and (3) facilitate intracellular 
delivery of drugs, specifically to alveolar macrophages. Consequently, liposomes may 
provide a means to prevent local irritation of lung tissue and reduce pulmonary toxicity, 
prolong local therapeutic drug levels, and generate high intracellular drug concentrations. 
Cumulatively, this would result in reduced systemic spill-over and an increase in apparent 
drug efficacy. 
There are many disease states which could potentially benefit from treatment with aerosolised 
liposome-encapsulated drugs. A number of possible therapies employing inhaled liposomes 
have been investigated. The majority of studies focus on the potential for targeting of the lung 
with drugs for local effect. 
A film of surfactant lies at the interface between the alveolar subphase fluid and gas phases. It 
is a stable film that reduces surface tension at the interface, thus stabilising the air spaces and 
facilitating gaseous exchange. This pulmonary surfactant system is made up of PLs 
(synthesised in alveolar epithelial type II cells) which are combined with other surfactant 
components such as proteins and other lipid components, of which cholesterol (Chol) is the 
most abundant (approximately 10% by mass), the other neutral lipids occurring in trace 
amounts only (table 1) [23].  
In the normal lung, surfactant clearance and surfactant release balance to maintain a stable 
surface film. Situations do exist where this balance is not maintained and this can lead to 
alveolar collapse and fluid accumulation in the lungs. This condition is most common in very 
premature babies, many of which do not have the ability to produce pulmonary surfactant. 
Certain mixtures of exogenous PLs have shown the ability to adsorb from the alveolar 
subphase and spread to a monolayer which reduces surface tension. Liposome suspensions of 
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these PLs have been tested for activity as surfactant replacements in pre-term animals [24, 25] 
and humans [26]. The studies showed that the replacement therapy was successful and in the 
last one none of the treated babies died, compared with 8 of the controls. 
The use of inhaled liposomes for the treatment of cancer in the lungs has been investigated. 
Juliano et al. carried out much of the work in this area in the late 70s and early 80s. 
The first study demonstrated the effect of liposomal encapsulation on the pharmacokinetic 
behaviour of anti-tumour drugs. Cytosine Arabinose (Ara-C), vinblastine, actinomycin D and 
daunomycin all showed enhanced retention in the bloodstream and tissues [27]. 
 
Table 1. Surfactant composition in bronchoalveolar lavage fluid from healthy persons (Griese 
1999) 
Component (content or activity) 
Total protein mg/mL (0.04±0.15) 
Total PL mg/mL (0.01±0.13) 
PL class (% total) 
PC (53.1±83.8) 
PG (8.3±27.4) 
Phosphatidylinositol (1.2±13.5) 
Phosphatidylethanolamine (0.3±21.0) 
Phosphatidylserine (0.0±5.7) 
Sphingomyelin (0.8±8.3) 
Lysophosphatidylcholine (0.0±4.5) 
Surfactant proteins (SP) mg/mL 
SP-A (0.8±15.0) 
SP-B (0.7±15.3) 
SP-D (0.9±1.3) 
 
In another study, they attempted to use this idea of enhanced retention to obtain localised, 
organ-specific action of anti-tumour drugs. Again, Ara-C was used. They reported that 
liposomes instilled into the trachea of rats became widely distributed into the air spaces in the 
lungs and that, while free Ara-C rapidly escaped the lung after administration, liposomal Ara-
C remained in the lung for long periods and only slowly redistributed to the blood and urine. 
They also reported that a dose of liposomal Ara-C effectively inhibited DNA synthesis in the 
lung but not elsewhere in the body (i.e., intestine and bone marrow), while the same dose of 
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free Ara-C caused DNA synthesis inhibition at these remote sites. They went on to suggest 
that this approach may be useful in treating small pulmonary metastases or secondary 
metastases that may occur, for example, in advanced breast cancer. This approach would not 
be effective in the treatment of large lung tumours as they often block the airways, making 
inhaled delivery difficult. Although the trial focused on Ara-C, mainly because of its well 
known and predictable pharmacology, the authors suggest that another anti-metabolite drug 
with known activity against lung tumours (5-fluorouracil) might be better suited for clinical 
use. They cite unpublished evidence that this is indeed the case [28].  
Another anticancer drug which has been investigated for possible use as an inhaled liposome 
preparation is interleukin-2 (IL-2), a lymphokine which stimulates the proliferation of T-
lymphocytes and thus amplifies immune response to an antigen. It also acts on B-
lymphocytes, and modulates interferon-gamma production and natural killer cell activation. It 
has proven in vitro anti-tumour activity but systemic in vivo toxicity has been a problem. 
Khanna et al. reviewed the use of IL-2 liposomes inhalation therapy in dogs in two separate 
studies [29, 30]. The first study confirmed an increased leukocyte cell count after inhalation 
of IL-2 liposomes versus inhalation of free IL-2 [29]. The second study reported that pet dogs 
with naturally occurring pulmonary metastases and primary lung carcinomas accepted 
inhalation treatments with IL-2 liposomes easily. It was concluded that nontoxic and effective 
treatment of pulmonary metastases of osteosarcoma is possible with nebulised IL-2 liposomes 
[30]. 
A phase I clinical trial of nebulised IL-2 liposomes in 2000 reported that no significant 
toxicity was observed in nine patients with pulmonary metastases (three cohorts of three 
patients; each cohort at a different dose). It was concluded that the delivery of IL-2 liposomes 
by inhalation is well tolerated but that further studies were required to determine its efficacy 
as a viable anti-cancer therapy [31].  
The lung is also a common site for infection by bacteria and fungi. Local delivery of bacterial 
and fungal antibiotics is another possible use for inhalation therapy, and liposomes have also 
been studied in this context. 
A study in 2000 compared aerosol characteristics and in vivo deposition of liposomal and 
non-liposomal amphotericin B. Amphotericin B is a polyene antifungal antibiotic effective 
against a wide range of fungal infections including invasive pulmonary aspergillosis. The 
results showed that liposomal amphotericin B (AmBisome®) was more stable towards 
nebulisation than non-liposomal amphotericin B. However, although it was effective, aerosol 
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concentrations showed no advantage over non-liposomal amphotericin B, i.e., the delivered 
dose was the same for both [31]. 
A recent study (2004) investigated the design of liposomal aerosols for delivery of rifampicin 
to alveolar macrophages using the "active targeting" approach. Alveolar macrophages are the 
densest site of tuberculosis (TB) infection. PC and Chol-based liposomes were used. They 
were modified by imparting negative charge to the surface or by coating them with alveolar 
macrophage-specific ligands. In vitro airway penetration was 1.5–1.8 times higher for the 
liposome encapsulated drug than for the plain drug aerosol. The study concluded that 
encapsulating anti-TB drugs in surface-altered liposomes and delivering them to the 
respiratory tract as an inhaled aerosol will improve chemotherapy versus pulmonary TB [32]. 
Liposomes have also been investigated for their possible use in inhaled bronchodilator 
preparations. These preparations are used in the management of reversible airway obstruction 
in asthma and in some COPD patients [33].  
Sympathomimetic amines act as bronchodilators by stimulating β2-adrenergic receptors found 
on bronchial smooth muscle. They do, however, possess some β1-adrenergic activity. 
Stimulation of β1-adrenoreceptors in the cardiovascular system can cause tachycardia. 
Liposomal systems may offer a way to deliver these drugs to the bronchioles for prolonged 
local effect while retarding their entry into the systemic circulation and thereby reducing 
systemic side effects such as tachycardia. 
The ability of metaproterenol sulphate (a β2-agonist) to protect anaesthetised, mechanically 
ventilated dogs against acetylcholine-induced bronchoconstriction was investigated by 
Cabezas et al. in 1971 [34]. Free and liposome-encapsulated metaproterenol were used. The 
parameters measured were the protection from acetylcholine challenge and the increase in 
heart rate. It was found that the protection offered by the encapsulated drug was at least 
equivalent to that of the free drug. More importantly, it was found that there were 
substantially smaller increases in heart rate when metaproterenol was encapsulated within 
liposomes. It was concluded that liposomes offered a useful way to reduce the systemic side 
effects associated with inhaled sympathomimetic amines. 
Some prostaglandins (e.g., PGE1 and PGE2) have been shown to have bronchodilating effects 
beneficial to asthmatic patients. However, irritation of the upper respiratory tract and 
aggravation of respiratory function have been reported. Mizushima et al. investigated the 
irritant effect of aerosolised PGE1 versus aerosolised liposomal PGE1 in a study in 1983 [35]. 
They found the irritant effect of lipo-PGE1 aerosol on the upper respiratory tract in man to be 
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10 times weaker than that of non-lipo-PGE1. Their bronchodilating actions were similar. 
Lipo-PGE1 would be the preferred option for clinical use. 
Budesonide (BUD) is a corticosteroid used in the prophylactic management of asthma. 
Systemic side effects are a problem with these inhaled corticosteroids. These include impaired 
tissue repair and immune function and increased susceptibility to infection. Liposomal 
encapsulation of BUD controls the release of the drug, thus maintaining therapeutic 
concentrations in the lung while reducing the amount of drug in circulation and thereby 
reducing systemic toxicity. Joshi and Misra (2001) outlined the production and stabilisation of 
liposomal budesonide for DPI [36]. Small multilamellar liposomal vesicles (SMLVs) loaded 
with BUD were successfully prepared and stabilised by lyophilisation in DPI formulations 
with a reasonable shelf-life. Their findings demonstrate the possibility of delivering this 
liposomally entrapped BUD to terminal bronchioles. 
Their ability to retard absorption of drug from the lungs implies that liposomes may also have 
a use in the sustained release of drugs into the systemic circulation. One interesting study 
investigated the use of inhaled liposome-encapsulated fentanyl as a post-operative analgesic 
[37]. Inhalation therapy using non-liposomal fentanyl provided satisfactory but brief post-
operative pain relief. Using a mixture of free and liposome-encapsulated fentanyl (FLEF) led 
to rapid onset of analgesia, due to the free drug in formulation, followed by the controlled 
release of the drug from liposomes at therapeutic levels over 24 hours.  The study 
demonstrated several advantages of inhaled liposomal fentanyl over other routes of opioid 
drug delivery in providing pain relief. Inhaled therapy is simple and noninvasive. It avoids the 
oral route which is not ideal in post-operative patients who may be nauseous and could vomit. 
It also avoids first pass metabolism of the drug. The plasma concentrations of drug were 
maintained at a higher therapeutic level than those from IV administration over 24 hours. The 
initial peak in plasma fentanyl levels present in IV administration was avoided. 
The systems suitable for the delivery of liposomes to the respiratory tract have been 
extensively reviewed by Niven et al. Particular emphasis was put on the factors influencing 
the nebulisation of liposomes in three articles from 1990-1992 [8, 38, 39]. Niven and Schreier 
in 1994 [40] and Desai et al. in 2002 [41] reviewed the delivery of liposomes in dry powder 
form. 
Niven noted that, if a drug was to leak rapidly from liposomes while being aerosolised, then 
the effectiveness of the preparation would be reduced or lost completely. In his studies he 
used various liposomes which encapsulated 5,6-carboxyfluorescein (CF). The level of 
encapsulated CF before and after nebulisation was used to determine ability to resist leakage.  
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His first paper described the effects of nebulisation on a range of liposomes carrying a neutral, 
net positive or net negative charge. The results showed that for all liposome compositions 
tested there was a release of encapsulated CF to the surrounding buffer solution during 
nebulisation and, furthermore, the lipid composition of liposomes had a definite effect on 
their ability to retain drug during nebulisation. He concluded that these effects should be 
seriously considered when formulating a drug-liposome preparation for inhalation after 
aerosolisation [8]. 
In the second study, Niven investigated the effect that altering the size of liposomes would 
have on the release of encapsulated drug during nebulisation. The results showed a clear 
relationship between liposome size and percentage of CF lost during nebulisation. The 
smallest liposomes (0.2 µm diameter) showed the least CF loss (~7.9%) while, unextruded, 
referred to as the largest liposomes (> 5 µm diameter) showed the greatest loss (~76.8%). A 
suggestion to explain these findings was that the first several surrounding bilayers are more 
"tightly" packed than subsequent layers and thus present a rate-limiting barrier to the release 
of encapsulated solute. In addition, the outer bilayers are more exposed to the effects of 
nebulisation than the inner ones. The collision nebuliser used in the study produced aerosol 
particles with a mass median aerodynamic diameter MMAD of ~1.2 µm. It was suggested 
that, in general, if vesicles are nebulised for short periods and prepared significantly smaller 
than the mean size of the aerosol droplets, the majority of solute may be retained inside the 
vesicle. The conclusions of this study were that the release of drug from the liposomes is 
biphasic in nature and that smaller liposomes release less solute during nebulisation. It is 
important when considering liposome size, therefore, to reach a balance which minimises the 
unwanted release of solute from liposomes during nebulisation without compromising their 
entrapment efficiency (i.e., deliverable dose) [8, 38]. 
In the third paper, the effects of operating conditions and local environment on the stability of 
liposomes were investigated. These effects included those of nebuliser jet air pressure, buffer 
pH, buffer osmotic strength and temperature on the stability of the liposomes. The study 
concluded that to minimise leakage of CF from liposomes of HSPC:DPPG at a 9:1 ratio, a) 
the pressure should be kept to a minimum; b) the pH should be high enough to ensure 
ionisation of the CF or other anionic drug; c) the buffer medium should be hypertonic; and d) 
the temperature should not be greater than the gel-to-liquid crystalline phase transition [39].  
The 1994 study by Schreier and Niven described the formulation of lyophilised liposome 
cakes, their micronisation and aerosolisation using a DPI. The in vivo distribution of the 
powders when aerosolised in a silicone elastomer throat attached to an Anderson cascade 
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impactor was studied. The results demonstrated that milled micronised liposome powders can 
be effectively aerosolised at a fixed flow rate [40]. 
Desai et al. (2002) investigated the effect of lyophilisation and jet-milling on liposome 
integrity. They reported that lyophilisation resulted in considerable leakage of a model drug at 
lower concentrations of lactose, and jet-milling further augmented the leakage for all the 
lyophilised formulations. In an attempt to overcome these problems, they investigated the 
feasibility of formulating PL-based powders that result in spontaneous formation of liposomes 
in an aqueous environment. Lyophilisation was not involved in their production, and jet-
milling, when not preceded by lyophilisation, did not reduce encapsulation efficiency. Some 
practical examples were tested (e.g. ciprofloxacin) and it was found that jet-milled PL-based 
powder formulations showed high encapsulation efficiencies (~95%) compared with a high 
amount of leakage (> 50%) observed due to jet-milling of lyophilised liposome formulations 
[41]. 
Abu-Dahab et al. (2001) demonstrated how using lectin-functionalised liposomal preparations 
were able to enhance cell association to human alveolar cell line (A549 cells) and primary 
human alveolar cells. (Lectins have been classed as second generation bioadhesives due to 
their ability to recognise and bind to exposed carbohydrate residues on glycoproteins, which 
are found on the surface of epithelial cells.) It was also demonstrated that these lectin-
functionalised liposomal preparations are stable towards nebulisation [42]. 
As these studies suggest, we are gaining more and more insight into the formulation issues 
associated with liposomes for inhalation. The safety issues associated with inhaled liposomes 
have also been investigated in some detailed literature [43]. 
 
1.8 Fate of inhaled particles 
The fate of inhaled particulates in the respiratory tract depends upon the dynamic interactions 
of three factors: (1) the physical characteristics of the aerosol; (2) the function and anatomy of 
the respiratory tract in health and disease; and (3) the diverse particle clearance mechanisms 
operant in the lung. An extensive literature exists on the theoretical and experimental aspects 
of each of these factors as they apply to aerosol inhalation in general [2].  
Several dynamic clearance mechanisms actively purge the lung of deposited particles. 
Swallowing, expectoration and coughing constitute the first sequence of clearance 
mechanisms operant in the naso/oropharynx and tracheobronchial tree. A major clearance 
mechanism for inhaled particulate aerosols, including liposomes, is the "mucociliary 
escalator". It consists of ciliated epithelial cells reaching from the naso/oropharynx and the 
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upper tracheobronchial region down to the most peripheral terminal bronchioles. Incessant 
beating of the cilia, in concert with mucus secreted by goblet cells, contributes to an 
extremely efficient clearance mechanism. The major clearance mechanism in the alveolar 
regions of the lung is uptake by pulmonary alveolar macrophages.  
As such, the respiratory tract is organised as a sequential filtering system consisting of the 
naso/oropharynx, the tracheobronchial tree, and the pulmonary parenchyma. Aerosol particles 
< 100 µm generally do not enter the respiratory tract and are trapped in the naso/oropharynx, 
whereas particles < 40 µm can deposit in the upper parts of the tracheobronchial tree. 
Particles must generally have an average aerodynamic diameter < 5 µm in order to reach the 
alveolar space. In addition to anatomical constraints, physical mechanisms govern aerosol 
particle deposition in the respiratory tract. A major physical determinant is inertial impaction, 
which occurs more in the naso/oropharynx and upper tracheobronchial regions with increased 
airflow velocity. In general, the faster the respiratory rate, and the larger the inhaled particle, 
the more likely inertial impaction occurs. Sedimentation is operational in the more peripheral 
regions of the tracheobronchial tree (small airways) and in the pulmonary parenchyma, where 
air velocity is relatively low. Very small (sub-micron size) aerosol particles travel essentially 
unhindered to the alveolar region as their deposition is governed by diffusion, i.e., random 
motion while being suspended in the surrounding gas phase. This process occurs both during 
inspiration and expiration [22].  
Liposomes, unlike other inhaled particulates reaching the alveoli, are also cleared via 
incorporation into the surfactant PL pool, where processing, uptake, and recycling of 
endogenous (and liposomal) PLs by alveolar type II cells take place. 
Despite the fact that targeting of liposomes to specific cells in the lung appears to be an 
attainable goal, a large fraction of lipid delivered to the lung will eventually be removed from 
the respiratory tract by clearance either via the mucociliary escalator or via incorporation into 
the surfactant pool as well as by uptake into alveolar macrophages. 
Since mucociliary clearance is highest in the central airways, relative liposome distribution in 
the central vs. peripheral lung spaces will determine the rate of removal of liposomes and, 
thus, the duration of drug action. Furthermore, since mucociliary clearance may be impaired 
in the diseased lung, elimination data extrapolated from studies in healthy human volunteers 
will have to be verified in the diseased target population. 
Much is known about the pulmonary fate of exogenous PL, mainly due to the work with 
artificial lung surfactant employed to treat respiratory distress syndrome in newborns.   
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Overall, the rate of removal of exogenous PLs was found to be within the range of 
endogenous surfactant turnover time of 2-7 h. One may conclude that exogenous PL delivered 
via aerosol will most likely associate with the surfactant pool and not disturb the physiologic 
processes associated with surfactant turnover. 
As mentioned above, inhaled particles are dealt with by the lung in different ways depending 
on the region of lung which receives the deposition. Large particles impacting in the 
oropharynx are swallowed soon after inhalation. Medium-sized particles deposit within the 
tracheal-bronchial tree and are swept out of the lung by mucociliary clearance. Finally, the 
smaller particles which enter the alveoli are either engulfed by the macrophages of the 
pulmonary RES, or remain suspended in the air to be exhaled with the next breath. Liposomes 
seem to be handled by the lungs in a similar way. The fate of alveolar liposomes is more 
controversial.  
The absorption of intact liposomes across the alveolar-capillary membrane is also possible. 
Detailed studies, however, of the fate of radiolabelled liposome components show that the 
overall kinetics for the movement of liposome PLs and Chol from the alveoli, to the lung 
tissue and hence into the circulation, were similar to but a little delayed compared with non-
liposome surfactants. These data suggest that the liposomes break down within the alveoli and 
that the lipid constituents enter the surfactant pool to be absorbed and re-utilised [20]. These 
kinetic studies of liposome materials suggest that the inhaled lipids are dealt with as 
constituents of the surfactant pool. As such there seems little possibility of accumulation 
within the lungs to provoke unwanted side effects. In addition, extensive studies of the long-
term effects of inhaled liposomes have not revealed any alteration in histopathology in the 
primate, or alteration in pulmonary function in the guinea pig.  
The PLs used in liposome production are naturally occurring PLs. Lipids account for nearly 
20% of the total dry tissue weight of the lung. Some are associated with the pulmonary 
surfactant system while the rest are associated with membrane, transport and energy 
metabolism systems. It has been shown that exogenous PLs administered to the lungs readily 
associate with the large pool of endogenous lipids with no apparent physiological or 
pathological disturbance of lung function.  
In one study performed by Oyarzun et al. (1980), the instillation of radiolabelled liposomes 
into lungs of rabbits in amounts ~10% of total alveolar surfactant pool was investigated. 
Results showed it caused no unwanted pulmonary responses; i.e., arterial blood gases and pH, 
lung appearance, protein content and cell constituency were comparable to normal animals 
[44]. In another study, by Myers et al. (1993), the pulmonary effects of chronic exposure to 
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liposome aerosols in mice were investigated. They found that chronic exposure produced no 
untoward effects on survival, histopathology and macrophage function in the mice [45]. 
The same group reported on the effects of liposome aerosol inhalation on pulmonary function 
in healthy human volunteers and concluded that inhalation of small particle PC liposomes had 
no deleterious effects on pulmonary function in these individuals [45]. 
It also appears unlikely that phospholipase-mediated hydrolysis of liposome components 
happens to any great extent at the respiratory epithelium, which means that reactive or 
potentially irritating free fatty acids or lysophosphatides should not be released from 
liposomes administered by inhalation. 
These studies all conclude that liposomes themselves offer little inherent threat to the 
pulmonary function of a patient when administered by inhalation and can therefore be 
considered as a safe and viable option for aerosol delivery. 
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1.9 Conclusions: 
Liposomes offer many advantages as drug carriers to the lungs. They can accommodate a 
wide variety of drugs or macromolecules within their multilamellar structure including 
proteins, enzymes, chemotherapy and nucleic acids. They are stable for long periods in vivo, 
but nonetheless they are eventually fully catabolised. 
They can be used to passively target macrophages while modifications to their surface 
structure can help them avoid opsonisation (e.g., attaching PEG chains to their surface) or 
actively target certain sites in the body (e.g., attaching receptor specific ligands). 
They have been shown to be useful in the delivery of drugs for local effect in the lungs 
including the delivery of exogenous pulmonary surfactant to pre-mature babies; the delivery 
of anti-cancer drugs to treat pulmonary metastases; the delivery of anti-fungal and anti-
bacterial antibiotics to treat pulmonary infection; the delivery of bronchodilators for 
symptomatic relief in asthma and COPD patients; and the delivery of corticosteroids for 
prophylactic treatment of these conditions. 
They have been shown to be effective in sustained release preparations which use the lung as 
a depot for delivery to the systemic circulation (e.g., in post-operative analgesia). 
Liposomes have been successfully formulated for inhalation as nebulised solutions and as 
lyophilised or jet-milled dry powders for inhalation. 
Novel ways of formulating PL-based powders that result in spontaneous liposome formation 
in aqueous environments have been investigated for delivering liposomes for dry powder 
inhalation in an attempt to reduce drug leakage associated with lyophilisation and jet-milling. 
Studies on the stability of liposomes towards nebulisation have shown that their stability 
depends on their lipid composition and size, as well as on environmental conditions, such as 
temperature, air pressure, buffer pH, and osmotic strength.  
Safety studies have shown that liposome-aerosols offer little inherent threat to the pulmonary 
function of patients when administered by inhalation and can therefore be considered to be a 
safe and viable option for drug delivery. 
Many opportunities exist for the use of liposomes in inhalation therapy and many 
formulations have shown promise in clinical trials. Further work is required to refine and 
develop these formulations before they can be considered as viable therapies or alternative 
therapies from efficacy, safety and economic points of view. 
The direct exposure of the lung to the outside environment together with the easy accessibility 
make novel and innovative therapies possible for delivering of therapeutic agents directly to 
the lungs. This targeted therapy can be exploited for the therapy of lung cancer and 
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pulmonary metastatic disease because of such obvious advantages as low systemic toxicity, 
high pulmonary concentration, increased lymphatic absorption, and easy administration by the 
patient (e.g., at home). 
There has been a significant amount of work done over the past three decades investigating 
this approach, mostly by means of animal studies. There have also been some human trials 
with encouraging results. However, most of the research has focused on strategies for 
immunomodulation. More recently, there has been increasing interest in using gene therapies, 
as well as in direct delivery of chemotherapeutic agents to the lung. 
We propose to turn the liposome into a "smart bomb" by attaching homing molecules to a 
lipid anchor and including these in the liposome.  
The address we will use is called the transferrin protein (Tf). Tumour cells often have 
receptors on their surface, designated CD71 receptors that stick to bind Tf. The problem for 
using Tf to target the tumour is that all nucleated cells in the body, such as red blood cells, 
erythroid cells, and brain cells, express TfR [46]. Thus, the Tf can only be used to target the 
liposome exclusively to the tumour cells if these cells significantly over-express the surface 
marker CD71 s, which is exactly the case in tumour cells.  
In order to enhance the amount of drug delivered by Tf, these can be entrapped in Tf-
conjugated liposomes, instead of coupling the drugs directly to Tf. 
In all studies employing Tf-labelled liposomes for parenteral application, the half life of these 
liposomes was a critical point. PEG-modified liposomes were used to decrease the clearance 
from circulation by the RES [47]. 
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1.10 Setting objectives 
The promise of an enhanced therapeutic effect on lung cancer using Tf-modified liposomal 
aerosols led us to the studies discussed in this thesis. The specific objectives of this PhD 
project were: 
 
1. To investigate pulmonary epithelial cell types (both healthy and cancerous) for (over)-
expression of TfR.  
2. To design Tf-conjugated-liposomes using different modification protocols, as well as 
techniques to confirm this conjugation step. 
3. To encapsulate doxorubicin in liposomal drug carriers and to assess the binding-uptake 
properties of the liposomes in healthy and tumour cell types. Furthermore, to determine the 
cytotoxicity of these systems.  
4. To study the nebulisation of liposomal formulations conjugated with Tf by air-jet and 
ultrasonic nebulisers, as well as the stability of the nebulised systems. Furthermore, to assess 
the stability of the systems after incubation in lung surfactant. 
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2.1 Abstract 
 
Introduction Targeted drug delivery is a current issue of research in drug delivery. The 
expression of transferrin receptors (TfR, CD71) is significantly elevated in many cancers, and 
thus the TfR is a promising candidate for tumour-specific drug delivery.  
Purpose In this study, the extent of TfR expression levels in different lung cancer cell lines 
was assessed using fluorescence-activated cell sorting (FACS). Additional studies were 
carried out using a model of human alveolar epithelial cell in primary culture (hAEpC). 
We studied the localisation of TfR expression in different lung epithelial cell types (i.e., 
bronchial epithelial cells and alveolar epithelial cells) by confocal laser scanning microscopy 
(CLSM).  
Results TfR were found to be expressed to a significantly higher extent in bronchial epithelial 
cells compared with their alveolar counterparts. In addition, cells of cancerous origin (i.e., 
A549 cell line) showed an expected higher TfR expression level than normal alveolar 
epithelial type II cells in primary culture. CLSM revealed TfR to be located primarily at 
basolateral sites of cells with the exception of cells undergoing mitotic proliferation, which 
also showed TfR in their luminal surfaces, due to  loss in cell polarity. 
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2.2 Introduction 
 
2.2.1 Transferrin/transferrin receptors in tumours 
Tf is a plasma protein that functions as the major iron transporter protein. Many in vitro 
studies have demonstrated that plasma Tf, which is synthesised in the liver, is essential for 
cellular proliferation. Thus, a number of cell lines grown continuously in defined (serum-free) 
media all demonstrate that Tf, along with several hormones and smaller organic compounds, 
is required for cellular proliferation. Most studies have supported the notion that Tf functions 
to maintain cellular proliferation by providing iron. These studies concluded that Tf acts as a 
promoter of cell growth, based on its transport of iron in plasma. It could be hypothesised, 
therefore, that specialised cellular proliferation in vivo, of tissues that are not well 
vascularised, might be limited by insufficient delivery of Tf-bound iron from plasma. There is 
good evidence, however, that under certain conditions some tissues synthesise Tf, permitting 
specialised proliferation. One example, the Sertoli cell of the testes, demonstrates synthesises 
of Tf to provide iron to proliferating spermatocytes [1].  
The Tf that is produced in the lung cancer cells acts as an autocrine promoter of cellular 
proliferation, in a similar fashion to a number of other growth factors synthesised by 
malignant cells. That autocrine secretion of Tf promotes cell growth is supported by the fact 
that Tf synthesis markedly increases shortly before and during the period when the cells are 
entering active phases of the cell cycle, a time when it appears that Tf, and particularly iron, is 
necessary in order for cell division to proceed [2]. 
An increase in Tf synthesis appears to precede increased expression of TfR, and this latter 
event is clearly important in maintaining cellular proliferation. In a study performed by 
Vostrejs et al. (1988), experiments were carried out to examine the effects of various agents 
that would affect iron metabolism and cellular proliferation of NCI-H5 10 cells, which is a 
small-cell lung cancer line. At low plating density, growth of these cells is dependent on 
added Tf, while at higher plating density, the addition of Tf-iron to the media is associated 
with a more rapid initial rate of proliferation, in contrast to cells grown in Tf-free medium. 
The authors concluded that in normal cells Tf synthesis is required for proliferation, but 
appears to be not an absolute requirement. On the other hand, this is not the case in the highly 
proliferating cells as in tumours, in which the Tf synthesis is necessary for furthering their 
proliferation [3]. 
There was a clear observation of a preferential response to Tf in certain cell lines of the rat 
mammary adenocarcinoma. TfR expression of those cells correlated with metastatic capability 
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[4]. Others have also found that TfR expression in neoplasms associates with tumour stage, 
progression, or predicted survival [5]. In a series of immunohistological studies, a correlation 
of this nature was seen in melanomas, breast carcinomas, bladder cell transitional cell 
carcinomas, a maxillary cancer, and non small-cell lung cancer [6].  
Tumour cell responses to factors that regulate growth, motility, adhesion, and other cellular 
responses in the normal organ environment, have been shown to be involved in successful 
metastasis to particular organ sites. Tf, along with the synthesis of other autocrine promoters 
of cell growth, may permit tumour cell growth in vivo in areas not well vascularised. 
Synthesis of this important plasma growth factor may explain why SCLC has an extremely 
short doubling time for a tumour even without much vascularisation [3]. One may hypothesise 
that specific agents that would affect iron metabolism, including monoclonal antibodies 
against Tf or TfR, as well as liposomal drug carrier carrying anticancer drugs labelled with 
Tf, may provide new strategies in the treatment of small-cell lung cancers. 
 
2.2.2 Role of transferrin 
Tf exerts a proliferative effect on cells in culture by supplying iron for key synthesis 
processes required for cell growth. Tf binds two atoms of iron, one at each of two sites 
located at the amino terminal and carboxy terminal domains of the protein. 
Iron-replete Tf interacts with a cell surface TfR, a homodimeric disulfide-linked glycoprotein 
of Mr 190,000. The receptor ligand complex is internalised in structures that mature into 
acidic endosomes, the low pH of which causes the release of the bound iron from the 
complex. Iron is then translocated to areas of need, such as sites of synthesis of mitochondrial 
electron transport proteins and ribonucleotide reductase. The latter enzyme consists of two 
non-identical R1 and R2 subunits; the iron saturated state of R2 is required for activity. 
Maintenance of the function of this enzyme is essential for the synthesis of DNA and the 
proliferation of cells [7]. 
 
2.2.3 Transferrin in the lung 
The large surface area of the lower respiratory tract presents a challenge to pulmonary host 
defense. In contrast to the upper airways, the epithelium of alveoli is devoid of the protective 
mucus barrier and the ciliated cells that enable the constant clearance of foreign material in 
the upper airways. Whereas alveolar macrophages may provide a formidable first line of 
defense against pathogenic organisms, of particular concern is the presence of excessive 
levels of free iron in the surface fluid lining the alveolar epithelium in the distal lung. 
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Increased levels of free iron in the distal lung (as a consequence of pathological conditions 
such as smoking or chronic inhalation of metallic dusts) have been associated with tissue 
injury and fibrosis, primarily attributable to the ability of iron to catalyse the formation of 
highly reactive hydroxyl radicals [8].  
Excessive levels of free iron in the lower lung have also been associated with facilitating the 
growth of intracellular mycobacteria. The task of sequestering free iron lies with the iron-
binding proteins, of which Tf is the primary constituent in the surface fluid lining the 
airspaces of the lower lung. Tf is an 80-kDa glycoprotein that is responsible for transporting 
iron, via its two ferric-binding sites, throughout the vasculature. In addition to this primary 
role, Tf has been implicated as the major source of antioxidant capacity in the lung. Indeed, 
the levels of Tf, as a percentage of total protein, detected in bronchoalveolar lavage fluid have 
been found to be high (4.0%–5.6%) compared with values for plasma (3.0%). The presence of 
such high levels of apo-Tf in surface fluid lining the alveolar epithelium suggests that there 
may be a specialised transport mechanism for Tf from the systemic circulation to the alveolar 
fluid. The tight epithelial barrier of the alveoli excludes a passive paracellular transport route 
for the large Tf molecule, consistent with the hypothesis that the transport of Tf into, and 
possibly out of, alveolar lining fluid might be regulated by an active transcellular transport 
process. Endocytosis of Tf by the TfR and subsequent transcytosis into alveolar lining fluid 
would be a likely mechanism for this process. However, the extent and nature of TfR 
distribution among the cells of the rat alveolar epithelium remain unknown.  
In a study performed by Wiedera et al. it was demonstrated that alveolar type II epithelial 
cells express significant TfR, and that synthesis of TfR is down regulated upon 
transdifferentiation from type II to type I cell-like phenotypes. Exposure of alveolar epithelial 
cells cultures to keratinocyte growth factor (KGF) results in retention of TfR, indicating that 
the maintenance of type II cell phenotype results in the retention of TfR synthesis. In addition, 
the synthesised TfR is limited exclusively to the basolateral surface of monolayers of alveolar 
epithelial cells. This indicates that alveolar type II cells are probably involved in the 
transcytotic transport of Tf between plasma and alveolar lining fluid [6]. 
 
2.2.4 Transferrin receptor and lung cancer 
The lungs are the common site of both metastasis and 1° neoplasia. The average lung cancer 
mortality rate is 90% and this is the leading cause of cancer-related deaths in both men and 
women. 
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One reason for the poor survival rate is that traditional methods of treatment, such as surgical 
resection, radiation and chemotherapy, have failed to eradicate lung cancer. Systemic 
chemotherapy has been employed with little success due to development of toxic side effects 
of the anticancer drugs, which are given by the oral or intravenous route of administration.  
In cancer therapy, the major goal is preferential destruction of malignant cells, while sparing 
normal tissues. Although most anti-cancer drugs could be chemically modified to accumulate 
in tumour tissues, their selectivity is not optimal, which will result in cytotoxicity to normal 
structures. Targeted drug delivery could be an alternative for tackling these problems giving 
enhanced accumulation in tumour cells' [9]. 
An attractive strategy to enhance the therapeutic index of drugs is to specifically deliver these 
agents to the defined target cells, thereby, keeping them away from healthy cells, which are 
also sensitive to the toxic effects of the drugs. This would allow for more effective treatment 
along with better tolerance. Many attempts are being made to explore the potentials of 
specific and target-based drug delivery systems, among them liposome-based delivery 
systems, and ligand-receptor-mediated delivery systems [10, 11]. TfR have been widely 
explored for receptor-mediated delivery of anticancer agents and in enhancing the transport of 
drugs across the blood brain barrier and more recently, across the epithelial cells.  
In polarised cells, Tf can be transcytosed from the apical to basolateral membrane. This 
mechanism is exploited in TfR-mediated drug delivery across the blood-brain barrier as well 
as across the epithelial barrier of the small intestine. TfRs are present in high density in 
human GI epithelium, and Tf can resist tryptic and chymotryptic degradation. Shen and co-
workers were the first to realise the potential of TfR-mediated transport in improving oral 
delivery of therapeutic agents. They conjugated Tf to insulin via disulfide linkages and 
demonstrated that the conjugation of insulin to Tf resulted in a 5- to 15-fold increase in the 
transport of insulin across the Caco-2 cell monolayer. As pointed out earlier, since this 
enhancement is specific for the conjugated protein and takes place without causing the tight 
junctions to open even momentarily, this approach is most desirable in terms of toxicity and 
damage to the epithelium [12]. 
In a study done by Whitney et al. 1996, the authors were aiming to define the frequency of 
expression of transferrin receptor in lung cancer specimens and to gather preliminary data 
regarding the prognostic value of this tumor-related antigen. By studying the tissue 
immunoreactivity with a murine monoclonal antibody directed against transferrin receptor in 
patients with non small-cell lung cancer who underwent surgical resection during the period 
from January, 1988, to May, 1991, they concluded that transferrin receptor is expressed in the 
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majority of lung cancers and the presence of transferrin receptor in NSCLC may be an 
indicator of poorer prognosis in certain groups of patients [4]. 
In lung cancer, lymphoma and breast cancer, it has been shown that the expression of TfR 
correlates with tumour differentiation, probably implying some prognostic value. A soluble 
form of TfR (sTfR) in human serum has been shown to be proportional to the density of 
cellular TfR. This utility idea was used by measuring sTfR in the serum and bronchoalveolar 
lavage (BAL) fluid of patients with lung cancer and patients with chronic obstructive 
pulmonary disease in a study performed in 1997 by Dowlati et al. BAL fluid was centrifuged 
to separate the supernatant from the cellular component. Cells were lysed in a detergent and 
cell-associated TfR was measured by enzyme-linked immunosorbent assay (ELISA). The 
results have shown that BAL supernatant and cell-associated TfR were able to detect lung 
cancer with a sensitivity of 91%, a specificity of 59%, and positive and negative predictive 
values of 81% and 71%, respectively. The authors concluded that BAL cell-associated TfR 
may help in the differential diagnosis of lung cancer vs. pneumonia [13]. 
In the search for tumour-related antigens with survival predictive value, previous studies have 
yielded varied conclusions regarding the expression of the TfR in lung cancer [14].  
Drug-resistant tumour cells express a number of upregulated proteins. A study done by 
Kuvibidila et al. (2004) showed twice the concentration of TfR on the surfaces of drug-
resistant SCLC cells as compared to sensitive cells, an observation which is consistent with 
similar data obtained by the same methods on drug-resistant leukaemia cells [15]. Because the 
expression of TfR is up-regulated by iron need, TfR levels increase with increased cell 
proliferation, while decreasing when cell proliferation is reduced.  
In another study, with the preliminary data regarding the prognostic value of this tumour-
related antigen, tissue immunoreactivity was studied with a routine monoclonal antibody 
against TfR in patients with NSCLC who underwent surgical resection at the Medical Center 
Hospital of Vermont during the period from January 1988 to May 1991. The results show that 
normal lung tissues did not stain for TfR; however, 13 of 17 (76%) adenocarcinomas, 13 of 
14 (93%) squamous cell carcinomas, and the one large cell carcinoma stained positively for 
TfR. Straining for TfR was graded according to pattern and intensity. The study conclusions 
were that TfR is expressed in the majority of lung cancers and that the presence of TfR in 
NSCLC may be an indicator of poorer prognosis in certain groups of patients [16]. 
The goal of this study is to measure the levels and locations of TfR expression in different 
lung epithelial cell types (i.e., bronchial epithelial cells and alveolar epithelial cells) by means 
FACS and CLSM  
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2.3 Materials and methods 
 
2.3.1 Cell culture conditions 
Primary culture of human pneumocytes 
hAEpC II were isolated from human non-tumour lung tissue, which was obtained from 
patients undergoing lung resection. The use of human material for isolation of primary cells 
was reviewed and approved by the respective local Ethical Committee (State Medical Board 
of Registration, Saarland). Isolation was performed according to a protocol previously 
described by Elbert et al. (1999) [17], with a slight modification of the enzymatic digestion. 
Briefly, the chopped tissue was digested using a combination of 150 mg trypsin type I (T-
8003, Sigma, Deisenhofen, Germany) and 0.641 mg elastase (LS022795, CellSystems, St. 
Katharinen, Germany) in 30 ml balanced salt solution (BSS; 137 mM NaCl, 5.0 mM KCl, 0.7 
mM Na2HPO4 7 H2O, 10 mM HEPES (N-[2-hydroxy-ethyl]piperazine-N´-[2-ethanesulfonic 
acid]), 5.5 mM glucose, penicillin (100 units/ml) and streptomycin (100 µg/ml), pH 7.4) for 
40 min at 37°C. The AEpC II cell population was purified from the crude cell mixture using a 
combination of differential cell attachment, centrifugation with a percoll density gradient, and 
cell sorting with magnetic beads (anti-HEA (EpCAM) MicroBeads, Miltenyi Biotec, Bergisch 
Gladbach, Germany) [18]. The average yield of hAEpC cells was 0.8 × 106 cells/g tissue (n = 
19) with a purity of > 90% determined by staining cells for alkaline phosphatase. Purified 
hAEpC II cells were then seeded at a density of 300,000 cells/cm2 on collagen/fibronectin-
coated polyester filter inserts (Transwell Clear, 12 mm in diameter, 3460, Corning, 
Bodenheim, Germany) using saline-adenine-glucose-mannitol medium (SAGM) (Cambrex 
Bio Science, Verviers, Belgium) supplemented with penicillin (100 U/ml), streptomycin (100 
µg/ml), and with addition of low serum (1% FBS) in order to suppress fibroblasts. After 
approximately eight days in culture, the hAEpC exhibited a morphology similar to that of 
alveolar type I epithelial cells [19, 20].  
 
A549 cell line 
The A549 cell line has been a popular model for human alveolar adenocarcinoma [21]. A549 
cells were obtained from BioWhittaker (Walkerville, MD, USA) via Boehringer Ingelheim 
Bioproducts (Ingelheim, Germany) and used at passage numbers 92-95 in this study. A549 
cells were cultured in RPMI-1640 medium (Sigma) supplemented with 10% FBS at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were plated in 25 ml culture flasks and 
polyester filter inserts (Transwell Clear, 24 mm in diameter, 3450, Cornin, Bodenheim, 
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Germany) and allowed to grow till confluency (~ 5-7 days after seeding). The medium was 
changed every other day. 
 
Calu-3 cell line 
Calu-3 is a human bronchial epithelial cell line isolated from an adenocarcinoma of the lung 
[22]. This cell line has been shown to exhibit serious cell properties and to form confluent 
monolayers of mixed phenotype, including ciliated and secreting cells. Calu-3 cells were 
purchased from ATCC (Manassas, VA, USA) and used at passage numbers 70-73. The cells 
were grown in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS, 
0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 µg/ml streptomycin and 100 
U/ml penicillin) at 37°C in a humidified atmosphere containing 5% CO2. Cells were plated in 
75 ml culture flasks and polyester filter inserts (Transwell Clear, 24 mm in diameter, 3450, 
Corning, Bodenheim, Germany) at a density of 105 cells/cm2. The medium was changed every 
other day.  
 
16HBE14o- cell line 
The 16HBE14o- cell line was a gift from Dieter C. Gruenert (California Pacific Medical 
Center, San Francisco, CA, USA). This continuous cell line was generated by transformation 
of normal bronchial epithelial cells obtained from a one-year-old heart-lung transplant patient 
[22, 23]. Transformation was accomplished with SV40 large T antigen using the replication-
defective pSVori- plasmid. Passages 2.48-52 were used in this study. Cells were seeded in 
tissue culture flasks and polyester filter inserts (Transwell Clear, 24 mm in diameter, 3450, 
Corning, Bodenheim, Germany) at a density of 105 cells/cm2 and grown in EMEM 
supplemented with 10% FBS, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 100 
µg/ml streptomycin and 100 U/ml penicillin G, at 37°C in a 5% CO2 incubator. The medium 
was changed every other day. 
 
2.3.2 FACS analysis 
Freshly isolated hAEpC II cells were washed in phosphate-buffered saline (PBS; 129 mM 
NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4×7 H2O, 1.3 mM KH2PO4; pH 7.4) after the isolation 
procedure and were then prepared for flow cytometry. hAEpC I cells cultured to day 8 post 
seeding, were detached from the culture plastics using Accutase (Chemicon, Hampshire, UK) 
followed by washing with PBS and prepared for flow cytometry as described below. A549, 
16HBE14o- and Calu-3 cells were also detached from the culture plastics by using the same 
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procedure after reaching confluency (see above). Mouse monoclonal anti-transferrin receptor 
antibody (CBL137, Chemicon, Hofheim, Germany) at a 1:50 dilution was incubated with the 
cells for 60 min at 37°C. For the isotypic control, mouse IgG1 (Sigma) was used. Following 
the incubation, cells were twice re-suspended in PBS and then incubated with a 1:100 dilution 
of FITC-labelled goat anti-mouse F(ab')2 fragments (DakoCytomation, Hamburg, Germany) 
for 20 min at 37°C. After washing, cells were analysed by flow cytometry using a 
FACSCalibur (BD, Heidelberg, Germany) with CellQuest software. Samples were analysed 
using excitation at 488 nm. Forward scatter was used to gate the cell subset of interest and 
eliminate debris, dead cells and cell aggregates. 
 Five thousands cells were counted in triplicate for each cell type investigated. To exclude any 
autofluorescence from the cells, instrument settings were adjusted to favour of using untreated 
cells. To quantify TfR and to prove the reproducibility in different experiments, TfR-positive 
cells were gated accordingly and the mean FL-1 in the gated population was compared in two 
preparations.  
 
2.3.3 Immunofluorescence confocal laser scanning microscopy 
Mouse monoclonal anti-TfR antibody (clone: RVS-10, Chemicon) was diluted 1:100 in PBS 
containing 1% (w/v) BSA. Mouse IgG1κ (MOPC-21, Sigma) was used as isotypic control. 
Transwell-grown respiratory epithelial cells were stained on days 5 to 8 after seeding. All 
cells were fixed for 10 min with 2% (w/v) paraformaldehyde (PFA) and blocked for 10 min in 
50 mM NH4Cl, followed by permeabilisation for 8 min with 0.1% (w/v) Triton X-100. After 
60 min incubation with 100 µl dilution of the primary antibody, the cell layers were washed 
three times with PBS before incubation with 100 µl of a 1:100 dilution of Alexa Fluor 488-
labelled goat anti-mouse F(ab´)2 fragment (Invitrogen, Karlsruhe, Germany) in PBS 
containing 1% (w/v) BSA. One µg/ml of propidium iodide was then added for counterstaining 
cell nuclei. After 30 min incubation, the specimens were washed three times with PBS and 
embedded in FluorSave anti-fade medium (Calbiochem, Bad Soden, Germany). Images were 
obtained with a confocal laser scanning microscope (CLSM, MRC-1024, Bio-Rad, Hemel 
Hempstead, U.K.) with the instrument settings adjusted so that no positive signal was 
observed in the channel corresponding to green fluorescence of the isotypic controls. 
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2.4 Results  
 
2.4.1 FACS  
In the FACS experiments, five different types of respiratory epithelial cells were chosen, 
originating from two different areas of the human lung, the bronchial and the alveolar tissue. 
The bronchial area was represented by two continous cell lines, Calu-3 (cancerous) and 
16HBE14o- (immortalised normal bronchial epithelial cells). 
The alveolar area was represented by the A549 cell line (cancerous), and human alveolar 
epithelial cells in primary culture. Three preparations of each cell type were used in duplicate. 
The first one was only purified and washed with buffer without further manipulation and used 
as control for estimation of gate area by setting forward-scatter as well as side-scatter. The 
second one was incubated with isotypic-Ab in order to allow the subtraction of non-specific 
interaction; while the last one was incubated with TfR-Ab. Results were shown as dot plots 
(figure 5). As seen in figure 5, sample of the gained data shows increased forward scatter 
signal which was observed in case of the bronchial cell types suggesting a larger cell size. All 
the other samples were gated the same (data not shown).  
 
 
Figure 5: Dot plot of the selected region for events for the Calu-3 cells incubated with 1. No Ab as control, 2. 
Non specific Ab as negative control and 3. Specific Anti.TfR antibody.  
 
Dot plot data were then analysed and converted to mono-histograms or overlaid-histograms. 
The comparison of these histograms led us to the following observations:  
1- In case of hAEpC II, there is only little difference between the control and specific Ab 
histograms, implying that the TfR are not present in this cell type (figure 6). 
2- In case of hAEpC I, there was no difference between the dot plots and histograms, of 
control and cells incubated with Tf antibody, further confirming the role of TfR as a 
proliferation marker (figure 7). 
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3- In the A549 cell line, TfR seems to be expressed at a higher level, compared to hAEpC II. 
This finding supports literature data that a higher expression level for TfR can be found in 
cancer cells (figure 6). 
4- Both studied bronchial cell lines showed a clear difference between the control and cells 
associated with the anti TfR-Ab, which proves significant expression of TfR in these cell 
lines (figure 6). 
                                Dot plot          Histogram         Dot plot       Histogram          Overlay 
                                                control                              anti-TfR antibody                histograms                                  
 
 
hAEpC II 
 
 
A549  
 
 
16HBE14o-  
 
 
 
Calu-3  
 
 
 
Figure 6: Dot plots and histograms of the all cell lines and hAEpC II that were used in the experiments. The first 
column represents the dot plots of the used samples incubated with no antibody. The second column represents 
the histograms of the same samples. Column 3 represents the dot plots are depicted the cells incubated with 
specific anti-TfR-antibody. In column 4 the histograms of these dot plots are shown. Column 5 shows overlay-
histograms of the two histograms of each sample. 
 
 
 
 
 
 
 
 
 
Figure 7: Overlay histogram of  control and sample of hAEpC I. 
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For comparison, all histograms are overlaid in the graph shown in figures 8, as well as the 
mean values for TfR signal in comparison to the isotypic control are depicted in the bar chart 
in figure 9. Both graphs indicate that the expression of TfR on the cells surfaces is 
significantly higher in Calu-3 > 16-HBE14o- > A549 which is then undetected in hAEpC. 
 
Figure 8: Flow cytometry of transferrin receptor (TfR, CD71) expression in different pulmonary epithelial cell 
types. Freshly isolated alveolar type II cells and type I-like cells after 8 days in primary culture reveal a low 
signal for TfR. Signals for alveolar A549 cells are higher, followed by 16HBE14o- and Calu-3 bronchial 
epithelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Mean value of TfR signal in comparison to isotypic control 
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2.4.2 Transferrin receptor localisation 
By immuno-CLSM the localisation of TfR was assessed in the different cell types. In general, 
all cell types showed TfR molecules located predominantly at their basolateral membranes 
(figure 10A). Cells undergoing mitotic proliferation at the time of fixation showed an 
additional strong signal for TfR on their apical aspect as well due to the loss of their 
polarization (figure 10B).  
 
 
Figure 10: Localisation of TfR by immuno-confocal laser scanning microscopy. A) Human alveolar epithelial 
cells after eight days of primary culture show a type I cell-like phenotype with TfR (green) located 
predominantly at their basal aspect. B) Calu-3 bronchial epithelial cells undergoing mitotic proliferation at the 
time of fixation showed an additional strong signal for TfR on their apical membranes. Cell nuclei were 
counterstained with propidium iodide. Scale bars represent micrometers. 
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2.5 Discussion 
Flow cytometry of TfR expression in freshly isolated hAEpC II cells, as well as in hAEpC I-
like cells after eight days in primary culture reveal very low signals not significantly different 
from the control values (figure 8). By flow cytometry we also revealed that TfR expression 
levels in A549 cells, which were derived from an adenocarcinoma of the lung show properties 
similar to those of AEpC II [24], were much higher than corresponding levels for normal 
pneumocytes. These findings are comparable to results in the literature, reporting that TfR 
expression in non proliferating cells is low or frequently undetectable. In a parallel study 
performed using rat alveolar epithelial cells (rAEpC) in primary culture (Widera et al., 2003), 
data showed that TfR expression is down regulated upon transdifferentiation to the type I-like 
phenotype and the TfR expression might be specific for the hAEpC II phenotype. However, in 
our study both types showed no significant difference from the control cells [6].  
The signal was higher for the two bronchial epithelial cell lines, Calu-3 and 16HBE14o-, with 
no significant difference between them (figure 8). Again, this result is comparable to data 
mentioned in literature, which indicate that TfR is expressed on rapidly dividing cells with 
10,000 to 100,000 molecules per cell; commonly found on tumour cells or cell lines in culture 
[6]. According to the results above, we can conclude that the expression level of TfR in the 
cancerous cells in both alveolar and bronchial area in lung, is higher than in normal tissues. In 
addition, TfR were found to be expressed in bronchial tissues rather than in alveolar one 
(figure 9). Furthermore, CLSM of the cells (hAEpC, A549, Calu-3, 16HBE14o-) in culture 
proved the basolateral localisation of TfR in all cells, as well as apical localisation in 
cancerous cells. Consequently, application of the proposed chemotherapy by inhalation will 
probably enhance the uptake of the drug by the cancerous cells, while sparing the normal cells 
(figure 11).  
 
Figure 11: The arrow indicates the application side of the inhaled    
                   therapy which is faced by the apical side of the alveolar 
                   epithelial cells (taken from http://upload.lung.ch). 
 
 
With the aid of these interesting findings, in which we have investigated the expression level 
of our target receptor, we can move further in the project to develop targeted drug delivery 
systems for local aerosol therapy of lung cancer, since we believe that such therapy could 
further increase the effectiveness of anti-tumour treatment while systemic side effects might 
be further reduced. 
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Chapter 3 
 
 
Tf conjugation to liposomal surfaces 
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3.1 Abstract 
 
Introduction Site-specific delivery of drugs and therapeutics can significantly reduce drug 
toxicity and increase the therapeutic effect. Tf is a suitable ligand for conjugation to drug 
delivery systems to achieve site-specific targeting, due to its specific binding to TfR, 
expressed on several cell types of therapeutic interest.   
TfRs have been reported to be highly expressed on the surfaces of tumour cells and the well 
characterised and efficient mechanism of internalisation of Tf has been exploited for the 
delivery of anticancer drugs, proteins, and therapeutic genes into primariy proliferating 
malignant cells. Liposomes are effective vehicles for drugs, genes and vaccines and can be 
easily modified with proteins, antibodies, and other appropriate ligands, resulting in attractive 
formulations for targeted drug delivery.  
Purpose In this study, we employed atomic force microscopy (AFM) and transmission 
electron microscopy (TEM) to confirm the achieved conjugation of Tf to liposomes by three 
different coupling methods. In addition, the conventional assay for quantification of protein 
amount, bicinchoninic acid (BCA), and PL content (according to Steward) were performed. 
Results AFM and TEM were able to display Tf-molecules on the liposomal surfaces and can 
be routinely used to obtain additional visual information on the protein-drug carrier 
conjugation in a fast and reliable manner.  
 
 . 
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3.2 Introduction 
 
3.2.1 Advantages of ligand-targeted liposomes 
Anticancer drug therapy is fraught with systemic toxicities resulting from cytotoxicity 
towards normal cells. Cancer cells share many common features with the normal host cells 
from which they originate, so finding unique targets against which anticancer drugs can be 
selectively directed is difficult. Many anticancer drugs have a marginal selectivity for 
malignant cells because they target the reproductive apparatus in cells having high 
proliferation rates. However, anticancer drugs having this mechanism of action naturally 
result in high toxicities against rapidly dividing normal cells, for example, hair follicles, germ 
cells and haematopoeitic cells, leading to dose-limiting side effects like mucositis, stomatitis, 
alopecia and reproductive effects. The side effects associated with chemotherapy limit the 
dose or cumulative doses that can be administered to patients, which can lead to relapse of the 
tumour and often to the development of drug-resistance. The medical community has sought 
alternative therapies that improve selective toxicities against cancer cells, i.e., therapies that 
increase efficacy and/or decrease toxicity, resulting in an increase in the therapeutic indices of 
the anticancer drugs. Many anticancer drugs, following intravenous administration, have large 
volumes of distribution resulting from their rapid uptake into all the tissues of the body. One 
successful approach has been to use drug carriers like liposomes to alter the pharmacokinetics 
and biodistribution of anticancer drugs. In general, liposome encapsulation of drugs results in 
(sometimes dramatic) reductions in their volume of distribution and significant increases 
within tumour accumulation [1].  
Liposomes (PL bilayer vesicles) are the most advanced of the particulate drug carriers and are 
now considered to be a mainstream drug delivery technology. Both classical and Stealth® 
liposomes rely on "passive" targeting to increase the localisation of anticancer drugs to solid 
tumours. Growing solid tumours, as well as regions of infection and inflammation, have 
capillaries with increased permeability as a result of the disease process (e.g., tumour 
angiogenesis). Pore diameters in these capillaries can range from 100 to 800 nm. Drug-
containing liposomes that have diameters in the range of approximately 60–150 nm are small 
enough to extravasate from the blood into the tumour interstitial space through these pores. 
Normal tissues contain capillaries with tight junctions that are impermeable to liposomes and 
other particles of this diameter. This differential accumulation of liposomal drugs in tumour 
tissues relative to normal cells is the basis for the increased tumour specificity for the 
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liposomal drugs relative to free (non liposomal) drugs. In addition, tumours lack lymphatic 
drainage and therefore, there is low clearance of the extravasated liposomes from tumours. 
Passive targeting can result in increases in drug concentrations in solid tumours of several-
fold relative to those obtained with free drugs. The mechanism of action of the liposomal 
drugs is thought to result from sustained release of drug from the liposomes and diffusion of 
the released drug throughout the tumour interstitial fluid, with subsequent uptake of the 
released drug by tumour cells. 
In attempts to increase the specificity of interaction of liposomal drugs with target cells and to 
increase the amount of drug delivered to these cells, recent efforts in the liposome field have  
been focusing on the development of ligand-targeted liposomes (LTLs). These liposomes  
utilise targeting moieties coupled to the liposome surface to selectively deliver the drug- 
liposome package to the desired site of action (active targeting) [2].  
While ligands can be readily attached to the surface of either classical or Stealth® liposomes, 
ligand-targeted Stealth® liposomes have clear pharmacokinetic advantages over ligand-
targeted classical liposomes for in vivo applications, and the former are used almost 
exclusively for applications involving active targeting. The main advantages of LTLs are that: 
Relatively few ligand molecules per liposome (10–20) are required to selectively deliver high 
payloads of drugs to target cells via the mechanism of receptor-mediated internalisation. 
Unlike other delivery systems such as drug-ligand conjugates or ligandotoxins, which deliver 
few molecules of drug or toxin (<10) per ligand molecule, LTLs can be exploited to deliver 
thousands of molecules of drug using few tens of molecules of ligands on the liposome 
surface [3].  
 
3.2.2 Choice of target receptor 
It was the German bacteriologist Paul Ehrlich who in late nineteenth century, coined the term 
"magic bullet", meaning a chemical that travels through the body and selectively kills 
diseased cells without harming neighbouring healthy ones. Drug delivery with "magic bullets" 
to cells, tissues or organs is now medically described as "active targeting". With the 
availability of suitable ligands, this approach takes advantage of relatively abundant 
expression of a particular receptor on the target cell relative to non-target cells [4,5]. 
Targeting moieties may include antibody molecules or fragments thereof, low molecular 
weight compounds, naturally occurring or synthetic ligands like peptides, carbohydrates, 
glycoproteins, or receptor ligands; that is essentially any molecule that selectively recognises 
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and binds to target antigens or receptors over-expressed or selectively expressed on cancer 
cells can serve as a targeting moiety.  
 
3.2.3 Internalisation 
The ability of the target cell to internalise LTLs is an important selection criterion in choosing 
a targeting ligand. If the ligand triggers receptor-mediated internalisation of the entire 
liposome–drug package into the cell interior, then arguably more drug will be delivered to the 
target cells. This mechanism should work well for drugs like DOX or methotrexate that 
escape degradation by lysosomal enzymes and low pH. However, for drugs like cytosine 
arabinoside (ara-C) that are acid labile and/or do not survive lysosomal degradation, 
liposomal targeting to internalising epitopes will be less efficacious.  
If non-internalising ligands are used, liposome contents will be released over time at or near 
the cell surface, and (a portion of) the released drug will enter the cell by passive diffusion or 
other normal transport mechanisms. Although increased concentrations of drug may be 
achieved at the cell surface by this mechanism, it can be argued that, in the dynamic in vivo 
environment (e.g., plasma or lymph), the rate of diffusion and redistribution of the released 
drug away from the cell will exceed the rate at which the drug enters the cell, particularly for 
drugs like DOX, which have a large volume of distribution.  
Targeting to non-internalising epitopes might be efficacious in solid tumours through the 
bystander effect, in which cells lacking the target epitope can be killed by drug released at the 
surface of neighbouring cells having bound liposomes. Internalisation of ligands into the 
target cells is also required for other targeted therapeutics, such as immunotoxins and 
antibody–drug conjugates. Internalisation of ligand-targeted therapeutics depends on various 
factors such as type of receptor or epitope, antigen/receptor density, antibody valency, and 
rate of internalization and re-expression of the target epitope [6-10].  
 
3.2.4 Chemical linkage  
Various therapeutic agents have been chemically linked to Tf. Several studies have been 
reported to link DOX with Tf via the formation of a Schiff base. Glutaraldehyde has 
frequently been used for this purpose. Briefly, certain amounts of Tf and DOX both dissolved 
in 150 mM NaCl were directly mixed and followed by the addition of glutaraldehyde (in 150 
mM NaCl) drop wise. The coupling procedure was stopped by the addition of ethanolamine. 
The conjugate was subjected subsequently to purification and characterisation. The conjugates 
prepared in such a way were found to exhibit cytotoxicity. 
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Although direct coupling methods are easy to carry out, they have some disadvantages in that 
polymeric products are likely to be formed during the preparation, and the resulting 
conjugates are poorly defined chemically with respect to the link between drugs and carrier 
proteins. A new coupling approach has been attempted, in which the stability of the bond 
between the Tf and the drug can be finely tuned. This was achieved by synthesis of the first 
derivatising the drug with a spacer group, such as a maleimide spacer, and then attaching the 
drug derivative to the carrier protein (e.g., Tf). In this way, the bond between the drug and the 
spacer can act as a cleavage site, allowing the drug to be released inside the cells [11]. 
A liposomal carrier system, which was produced by using SUVs made of pure PLs 
chemically cross-linked to human Tf, liposome-entrapped -interferon ( -IFN) when 
conjugated with Tf-polylysine (Tf-PLL) exhibited the antiproliferative effect against murine 
bladder tumour cell MBT2. Cell uptake of Tf-PLL-liposome was markedly enhanced in a 
dose-dependent manner. There was also a strong correlation between anti-proliferative 
activity and uptake of liposome by the tumour cells, indicating that Tf-PLL-liposome 
promotes intracellular delivery of -IFN and enhances the effect of -IFN against MBT2 cell 
growth [12]. 
Tf-pendant type immunoliposome (TF-PEG-ILP) was shown to have a higher uptake in K-
562 cells in vitro compared with non-targeted liposomes. The TF-PEG-ILP, examined in the 
B16 melanoma-bearing mice, exhibited a prolonged circulation time, a low liver uptake and 
concomitantly high accumulation into the tumour tissue and a longer residence time. 
Liposomes conjugated with anti-TfR have also been used for specific drug delivery [12]. A 
liposome-immoblised anti-Tac (a monoclonal antibody directed against the IL-2 receptor) and 
anti-TfR (a monoclonal antibody directed against TfR) were compared for specific binding, 
internalisation, and intracellular drug delivery to adult T-cell leukaemia (ATL). The authors 
found that drug-containing liposomes conjugated to anti-Tac were more than tenfold times 
more effective in inhibiting growth of ATL cells than the nonspecific control conjugates. 
Anti-Tac conjugates caused minimal growth inhibition of Molt-4 cells over the concentration 
range effective against the ATL cells. Anti-TFR-coupled liposomes gave better growth 
inhibition of HUT-102 and MT-1 cells (40- to 60-fold) than anti-Tac conjugates. Both anti-
Tac-directed and anti-TFR-directed liposomes are effective for intracellular drug delivery to 
ATL cells and may represent a useful method of treatment in this disease. [13]. 
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3.2.5 Techniques for coupling ligands to liposomes 
A variety of techniques for coupling targeting ligands to liposomes have been described. In 
general, coupling methods for the formation of LTLs should be simple, fast, efficient, and 
reproducible, yielding stable, non-toxic bonds. The biological properties of the ligands, e.g., 
target recognition and binding efficiency, should not be substantially altered by attachment to 
the lipids. The LTLs should have stabilities and circulation half-lives long enough to allow 
them to reach and interact with the target cells. Further, the coupling reaction should not alter 
the drug loading efficiency and drug release rates in a negative way [8]. 
Several methods have been developed for coupling water-soluble proteins to the surfaces of 
liposomes in attempts to prepare stable liposomes with high binding-affinity for cell 
membranes. Such proteoliposomes may serve as efficient carriers for transfer of drugs, 
enzymes and nucleic acids into cells.  
A particular useful protein-liposome coupling procedure involves covalent modification of 
functional groups on the proteins with lipid residues, imparting to the proteins increased 
hydrophobicity and affinity for liposomal membranes. Using this type of approach to prepare 
homogeneous liposomes with defined properties, it is essential to understand in more detail 
how lipid-modified proteins interact with each other in aqueous solution and incorporate into 
liposomal membranes [7].  
A number of possibilities for covalent attachment of ligands to sterically-stabilised liposomes 
exist. Ligands can be linked to polar headgroups of PLs forming sterically stabilised 
liposomes (S-liposomes) (figure 12A). Alternatively, the attachment site can be positioned at 
the end of the polymer chain using some of the liposomes-grafted PEG chains as 
macromolecular spacers between the antibody and the liposomes surface (figure 12B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Different approaches for coupling of proteins to sterically stabilised liposomes. 
 
A
B
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3.2.6 Coupling strategies 
Initially, ligands were coupled to PL headgroups, e.g., phosphatidylethanolamine, at the 
surface of Stealth® liposomes, but the steric barrier imparted by the PEG polymer resulted  in 
low coupling efficiencies and interfered with target binding of the LTLs, particularly when 
higher concentrations of PEG with high molecular weights were present. To avoid this, 
ligands were coupled to the PEG terminus. This strategy avoids masking of the ligands by the 
PEG layer, and provides perfect accessibility to the ligand molecules for their target cells. 
Several end-functionalised derivatives of PEG have been synthesised for coupling antibodies 
to the PEG-terminus [8]. 
One of the commonly used coupling groups is malemide (Mal)-PEG. Mal-PEG coupling 
methods rely on the formation of thioether bonds between proteins and liposomes, which 
results in efficient formation of a stable bond. In this method, protein molecules are thiolated 
using 2-iminothiolane (Traut’s reagent) and reacted with maleimide groups on the PEG-
termini. A disadvantage with this method is that the free thiol groups may react among 
themselves to produce disulphide bonds leading to cross-linking of proteins molecules or 
proteioliposomes, causing unwanted aggregation and too rapid clearance from circulation. 
However, the presence of PEG serves to inhibit aggregation to a large extent. Another 
problem is that the random introduction of thiol groups in the protein molecule may interfere 
with the biological properties of the molecule, leading to interference with the binding of the 
protein to its receptor, receptor activation and/or endocytosis. 
The other covalent bond which can be used is the amide bond, which could be established to 
attach the protein to the liposomal surface. N-glutaryl PE or DSPE-PEG-COOH are used as a 
membrane anchors for coupling of Tf to the liposome surface. In this method, the free amino 
groups of proteins are linked to the carboxylic carrier in the presence or absence of water-
soluble carbodiimide and using N-hydroxysulfosuccinimide as a carboxyl activation agent. 
The advantage of this method is that it is not necessary to modify the protein prior to the 
coupling reaction. 
In a different approach, Stealth® liposomes can be converted into LTLs by a versatile ‘post 
insertion technique’. Ligands are coupled to end-functionalised groups in PEG micelles and 
the ligand-PEG conjugates are then transferred in a simple incubation step from the micelles 
into the outer monolayer of pre-formed, drug-loaded liposomes. This method allows a 
combinatorial approach to the design of targeted liposomes that minimises manufacturing 
complexity, allowing a variety of ligands to be inserted into a variety of pre-formed liposomes 
containing a variety of drugs. This allows the ligand-targeted therapeutics to be tailored to 
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patient’s disease profile without the need for separate manufacturing procedures for each 
ligand/drug combination. Also, since the conditions for the successful insertion of the ligand 
is now decoupled from the conditions for the preparation of and loading of drug into 
liposomes, conditions can be optimised for independently drug loading and ligand insertion. 
Targeted liposomes prepared using the post-insertion approach have been shown to have in 
vitro drug leakage rates, cell association and cytotoxicity profiles and therapeutic efficacies 
comparable to those of liposomes prepared by conventional coupling procedures like the Mal-
PEG coupling method [9]. 
 
3.2.7 Transmission electron microscopy 
An electron microscope visualizes the structural information carried by scattered electrons. In 
a fixed-beam transmission electron microscope, scattered electrons emerging from the 
irradiated sample are collected over a narrow solid angle and focused by the objective lens 
onto the image plane as seen in figure 13 A. Here, elastically scattered electrons interfere with 
the unscattered electrons to produce a phase-contrast image, whereas the inelastically 
scattered electrons generate a diffuse background image that can, in some microscopes, be 
eliminated by an energy filter. In the transmission electron microscope (TEM), which was 
first introduced in the late sixties, the objective lens focuses the beam onto an atomic-scale 
sample volume. All scattered electrons can then be collected by a variety of detectors placed 
behind the specimen and their information exploited to the fullest extent. 
An image is generated simply by stepping the focused beam along a sampling grid. Therefore, 
the image may be considered as a large collection of individual scattering experiments. 
Various types of signals that can be discriminated by scattering angle and energy-loss transfer 
convey different structural and chemical information and may be captured simultaneously in 
different channels. This sequential and controlled acquisition of information lends itself to 
quantitative analyses that are difficult to realize with other instruments. In addition, as there is 
no limitation on the solid angle and the energy-loss interval over which the scattered electrons 
may be collected; 60-100% of them contribute to the image. This provides a unique 
opportunity to image beam-sensitive biological macromolecules at low dose [14, 15]. 
 
3.2.8 Atomic force microscopy 
AFM belongs to the broad family of scanning probe microscopes in which a proximal probe 
is exploited for investigating properties of surfaces with subnanometer resolution. At the 
beginning the emphasis was mainly on the improved imaging resolution compared to that of 
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optical microscopy, but, soon after, it became clear that AFM was much more than just a 
high-resolution microscope. The possibilities of spectroscopic analysis, surface modification 
and molecular manipulation gave rise to a real breakthrough in the realm of AFM use. In 
biological applications, the most appealing advantage of the AFM as a high-resolution 
microscope in comparison with other techniques such as TEM is that it allows measurements 
of native biological samples in physiological-like conditions avoiding complex sample 
preparation procedures and artefacts connected with them. The use of mild imaging 
conditions opened the way to dynamic studies in which conformational changes and 
molecular interactions could be followed in real time at the single-molecule level. 
The set of samples of biological interest studied by AFM ranges nowadays from the smallest 
biomolecules, such as phospholipids, proteins, DNA, RNA, to subcellular structures (e.g., 
membranes), all the way up on scale to living cells and tissues. Not only structural properties 
can be investigated, but also mechanical or chemical and functional properties are the focus of 
many AFM applications. 
As illustrated in figure 13 B, the AFM works by scanning, in a raster fashion, a very tiny tip 
mounted at the end of a flexible micro-cantilever in gentle contact with the sample. This 
relative motion is performed with sub-Ångström accuracy by a piezoelectric actuator (usually 
a tube, sometimes a tripod). Interacting with the sample the cantilever deflects and the tip–
sample interaction can be monitored with high resolution exploiting a laser beam impinging 
on the back of the cantilever. The beam is reflected towards a split photo-detector giving a 
sort of optical lever which amplifies cantilever deflections. In almost all operating modes, a 
feedback circuit, connected to the cantilever deflection sensor and to the sample vertical piezo 
element, keeps tip–sample interaction at a fixed value by controlling the tip–sample distance. 
The amount of feedback signal, measured at each scanning point of a 2D matrix, is used to 
form a 3D reconstruction of the sample topography which is then displayed as an image [16, 
17].  
 
 
 
 
 
 
  
 
                                                                                                3. Tf conjugation to liposomal surfaces 
 
 
62
 
 
 
 
 
 
 
 
 
                                          A                                                                 B 
Figure 13: Schematic diagram of A) TEM (taken from 14) B) AFM (taken from 16). 
 
In work reported here, three different methods of linking Tf to DSPC/Chol liposomes were 
used in a comparative manner [10,18-22]. The goal of this study has been to visualise the 
actual protein binding, using two independent microscopic methods, i.e., AFM and TEM. 
AFM is a surface analytical method that can generate nano-scale topographic images by 
scanning a fine silicon tip across a surface. For its ability to provide high-resolution imaging 
under physiological, non-destructive conditions without the necessity of previous fixation of 
the sample, AFM has developed into a powerful tool for studying structural details. TEM is 
widely used to image structures near the atomic level. While the maximum resolution is lower 
in TEM than in AFM, the contrast and image formation is much better understood in TEM 
than in AFM. Thus, these two imaging methods may provide complementary information and 
support each other.  
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3.3 Materials and methods 
 
3.3.1 Materials  
Reagents were obtained from the following sources; 1,2-Dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-glutaryl (N-glutaryl-PE), 1,2-Distearoyl-sn-glycero-3-
phosphocholine (DSPC), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol) 2000] (DSPE-PEG2000-COOH) were purchased from Avanti 
Polar Lipids (Alabaster, AL). N-(3-Dimethylaminopropyl)-N΄-ethylcarbodiimide 
hydrochloride (EDC), human holo-transferrin, 2-iminothiolane (Traut's reagent), Sepharose 
CL-4B, goat anti-human transferrin antibody and the BCA kit for protein determination were 
from Sigma (Seelze, Germany). Chol was obtained from Riedel-de Haën (Seelze, Germany). 
Sulpho-N-hydroxysuccinimide (S-NHS) was obtained from Perbio Science (Bonn, Germany). 
1,2-Distearoyl-sn-glycero-3-phosphocholine-(polyethylene glycol) 2000-maleimide (DSPE-
PEG2000-MAL) was from Nektar (Huntsville, AL). Centrisart-10 and -20 (molecular weight 
cut off: 10 kDa and 20 kDa, respectively) concentrators were from Vivascience (Hannover, 
Germany). 
 
3.3.2 Liposome preparation 
The liposomes were prepared from Chol, DSPC and the corresponding linker lipid at the 
following molar ratios: DSPC:Chol:linker (6:3:0.6 mol%). Briefly, a mixture of PL and Chol 
in chloroform:methanol (2:1) was dried to a thin lipid film in a rotary evaporator (Büchi, 
Essen, Germany). The solution to be encapsulated was then added to result in a final lipid 
concentration of 10 mg lipid/ml corresponding buffer. After vortexing, the sample was 
incubated for 10 min at a temperature above the transition temperature of the lipids (53°C for 
DSPC:chol) in a cabinet drier [23]. Unilamellar liposomes were prepared by extruding the 
resulting multilamellar vesicles eleven times through a 200-nm polycarbonate membrane, 
followed by extrusion eleven times through a 100-nm membrane using a Liposofast Basic 
Device (Avestin, Mannheim, Germany).  
 
3.3.3 Coupling of transferrin to the liposomes 
In the first two methods, an amide bound between N-glutaryl-PE or DSPE-PEG2000-COOH as 
linker lipid is formed to link Tf to the liposome surface. In both methods, a bond between free 
amino groups of the protein and carboxylic groups of the linker is formed in the presence of a 
water-soluble carbodiimide (Scheme 1). The difference, however, is that method 2 uses 
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sulpho-N-hydroxysuccinimide (S-NHS) in addition to N-(3-dimethylaminopropyl)-N΄-
ethylcarbodiimide hydrochloride (EDC). S-NHS is a water soluble analogue to NHS which is 
used to modify carboxyl groups to amine-reactive NHS esters. This is accomplished by 
mixing the NHS with a carboxyl containing molecule and a dehydrating agent, EDC, which 
reacts with the carboxyl group first and forms an amine-reactive intermediate, an O-
acylisourea. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: The expected coupling reaction of transferrin to the surface of liposomes using N-glutaryl PE and 
DSPE-PEG2000-COOH as linker lipids. 
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Method 3 relies on the formation of thioether bonds between the protein and the liposome. 
Here, the Tf molecules are thiolated using Traut's reagent and react with maleimide groups on 
the PEG-terminus (scheme 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2: The expected coupling reaction of transferrin to the surface of liposomes 
 
Method 1: N-glutaryl-PE. 2 mg EDC were added per 1 µmol of lipid in PBS and incubated 
for 6 h at room temperature. Excess EDC was then removed by ultrafiltration using a 
Centrisart-10 concentrator. In the next step, 125 µg Tf/µmol PL was added and incubated 
overnight at room temperature. Free Tf was separated from the liposomes by passing the 
liposome suspension through a Sepharose CL-4B gel [18,19]. 
Method 2: DSPE-PEG2000-COOH. The lipids were re-suspended in an appropriate amount of 
400 mM citrate/5 mM phosphate buffer (pH 4.0). Then, 1 ml PBS (pH 7.5) and 360 µl of both 
EDC (0.25 M in H2O) and S-NHS (0.25 M in H2O) were added per 10 µmol of lipid. The 
mixture was allowed to incubate for 10 min at room temperature, before adjusting to pH 7.5 
with 1 M NaOH. 125 µg Tf/µmol PL was added and gently stirred for 8 h at 4°C. Unbound 
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protein was removed by passing the liposome suspension through a Sepharose CL-4B gel 
column [20]. 
Method 3: DSPE-PEG2000-MAL. The lipid mixture was hydrated with PBS (pH 7.4). Then, 
125 µg Tf/µmol PL (in PBS) was added to 2 ml borate-EDTA buffer (0.15 M Na borate, 0.1 
mM EDTA, pH 8.5) containing 400 nmol of fresh Traut's reagent. This mixture was incubated 
in the dark for 60 min on a rotational shaker (at 110 rpm). The thiolated Tf was concentrated 
by ultrafiltration (Centrisart-20) to a volume of 0.2 ml, diluted with 2 ml PBS (pH 8.0) and 
concentrated again to 0.2 ml. The Tf was immediately added to the liposomes and left to react 
overnight at room temperature without further agitation. Lastly, the transferrin-conjugated 
liposomes were separated from free Tf by Sepharose CL-4B gel filtration [20,21]. 
 
3.3.4 Photon correlation spectroscopy 
Liposomal size determination of Tf-conjugated and plain liposomes was carried out using a 
Zetasizer 3000 HS (Malvern Instruments, Herrenberg, Germany) equipped with a photon 
correlation spectroscopy unit. The scattered light was detected at a scattering angle of 90°. 
Measurements were performed at 25°C. For all measurements, samples were diluted 50-fold 
in distilled water to obtain comparable viscosities. PCS gives information about the mean 
diameter of the bulk liposome population and the width of the diameter distribution via the 
polydispersity index (PI). Mean values and standard deviation were calculated from at least 
three determinations. 
 
3.3.5 ζ-potential measurements 
The ζ-potential measurements of the Tf-conjugated and plain liposomes were carried out in 
the standard capillary electrophoresis cell of a Zetasizer 3000 HS at pH 7.4 in the presence of 
NaCl to adjust the conductivity to 50 µS/cm. Measurements were performed at 25°C with 
automatic duration. The instrument was routinely calibrated with a –50 mV latex standard 
(Malvern). The electrostatic mobility was converted into the ζ-potential using the Helmholtz-
Smoluchowski equation. The mean values and standard deviation were calculated from three 
independent measurements (three runs each). 
 
3.3.6 Phospholipid concentration 
PL concentration was assayed according to Stewart’s protocol [24]. Briefly, the standard 
curve was obtained by adding 2 ml of ferrothiocyanate reagent to different concentrations of 
DSPC, ranging from 0 to 0.5 mg/ml. The test tubes content was vortexed vigorously for 15 
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sec, centrifuged at 1000 rpm for 5 min and the lower layers were removed with a Pasteur 
pipette. Absorbance of the formed complex was assessed using a plate reader (Cytofluor II, 
PerSeptive Biosystems, Wiesbaden, Germany) at a wavelength of 485 nm. Liposome samples 
were treated similarly after dehydrating the aliquots of liposome suspension (100µl) under a 
nitrogen stream and re-dissolving them in 2 ml of chloroform. 
 
3.3.7 Protein assay and Tf-binding efficacy 
The average amount of transferrin conjugated to the liposome (i.e., amount of PL) was 
quantified as described by Derycke et al. [22]. 100 µl of liposome suspension were added to 
400 µl of methanol. The mixture was vortexed and centrifuged (10 sec at 9,000 g). Then, 200 
µl of chloroform were added and the sample was vortexed and centrifuged again (10 sec at 
9,000 g). For phase separation, 300 µl of water were added and the sample was vortexed 
again and centrifuged for 1 min at 9,000 g. The upper phase was carefully removed and 
discarded. Three hundred µl of methanol were added to the chloroform phase and the 
interphase with the precipitated protein. The sample was mixed and centrifuged to pellet the 
protein (2 min at 9,000 g). The supernatant was removed and the protein pellet was dried 
under a stream of air. The pellet was then dissolved in 20 µl of PBS (pH 7.4) and the 
concentration was determined with BCA protein assay using pure holo-transferrin as standard. 
The coupling efficiency was calculated as µg Tf/µmol PL. 
 
3.3.8 Transmission electron microscopy 
The coupling of transferrin to liposomes was assessed by transmission electron microscopy 
using two approaches: negative staining and immuno electron microscopy.  
For negative staining, a formvar-coated copper grid (300 mesh, hexagonal fields) was placed 
on 15 - 30 µl droplets of liposome suspensions for 2-3 min at room temperature. To improve 
adhesion of the liposomes on the formvar film, grids were pre-treated with glow discharge in 
the argon plasma of a sputter coater for 2 min. After adhesion of liposomes, grids were 
washed on four droplets of MilliQ water before they were placed on a drop of uranyl acetate 
(2%) for 2 min. Finally, grids were dried at room temperature after removing the excess 
liquid.  
Immuno electron microscopy was done with liposome suspensions after filtration through a 
centrifugal filter (molecular weight cut off 100 kDa; Microcon, Millipore, Schwalbach, 
Germany) in order to reduce the amount of free unbound transferrin. Droplets (10-15 µl) of 
liposomal suspension were put on parafilm and brought in contact with a copper grid for 2-3 
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min (see above). Grids were then washed twice with PBS and pre-treated for 2 min with 
PBS/glycine (50 mM) followed by TBS/BSA-C (0.1% acetylated bovine serum albumin in 
Tris-buffered saline; Aurion, Wageningen, The Netherlands) for 2 min to block non specific 
binding. The anti-transferrin antibody was diluted at 1:20 in TBS/BSA-C and applied for 15 
min at room temperature, followed by washing twice with TBS/BSA-C. Liposomes were 
finally negatively stained with uranyl acetate (see above).  
Transmission electron microscopy was performed with a Tecnai 12 Biotwin (FEI Co., 
Eindhoven, The Netherlands) using 120 kV acceleration voltage. Images were recorded with a 
CCD camera (Megaview III; Soft Imaging Systems, Münster, Germany) at a resolution of at 
least 1376X1032 pixels. 
 
3.3.9 Atomic force microscopy 
The liposomal formulations with and without Tf modification were prepared as described 
above and diluted in ultrapure water (MilliQ, 18.4 MΩ, pH 5.5). Not later than one hour after 
preparation, the liposomes were directly transferred onto a silicon chip by dipping it into the 
liposome suspension. Atomic force microscopy was performed on a Digital Nanoscope IV 
Bioscope (Veeco Instruments, Santa Barbara, CA). The microscope was vibration-damped. 
Commercial pyramidal Si3N4 tips (NCH-W, Veeco Instruments) on a cantilever with a length 
of 125 µm, a resonance frequency of about 220 kHz and a nominal force constant of 36 N/m 
were used. All measurements were performed in tapping mode to avoid damage of the sample 
surface. The scan speed was proportional to the scan size and the scan frequency was between 
0.5 and 1.5 Hz. Images were obtained by displaying the amplitude signal of the cantilever in 
the trace direction, and the height signal in the retrace direction, both signals being 
simultaneously recorded as described previously [25]. The results were visualised either in 
height or in amplitude mode. 
 
3.3.10 Statistical analysis 
Results are expressed as mean ± S.D. Significance (P < 0.05) of differences in the size, 
polydispersity (PI) and zetapotential values from several (n ≥ 3) data groups were determined 
by one-way analysis of variances (ANOVA), followed by Neumann-Keuls-Student post-hoc 
tests. 
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3.4 Results 
 
3.4.1 Characterisation of liposomes 
The physical properties of the liposomes before and after coupling of Tf are given in tables 2 
and 3. The size of the liposomes before conjugation of Tf was in the range of 120 nm for 
method 1 (N-glutaryl-PE) and 150 nm for method 2 (DSPE-PEG2000-COOH), while 
liposomes prepared according to method 3 (DSPE-PEG2000-MAL) were of a size around 165 
nm. After the addition of Tf, the average sizes increased between 5 to 10 nm for all samples 
under investigation, with the lowest increase (i.e., ~ 3 nm) for method 3 and increases of ~ 7, 
6 nm for methods 1 and 2, respectively. The PI did not show any significant alteration, 
indicating that the stability of the liposomes was not negatively affected by any of the 
methods.  
DSPC is slightly negatively charged at pH 7.4, and this imparted a negative charge on the 
surface of blank liposomes Values for the ζ-potential were between – 20 mV and – 40 mV for 
the Tf-free liposomes. In case of N-glutaryl-PE (method 1) and DSPE-PEG2000-COOH 
(method 2), the conjugation of negatively-charged Tf (IP 5.9) resulted in a significant 
decrease of the ζ-potential, while no significant change could be observed for liposomes 
prepared according to method 3 (DSPE-PEG2000-MAL). 
 
Table 2. Size and polydispersity index (PI) of liposomes before and after coupling of 
transferrin determined optically (values represent the mean ± SD of three batches).  
 
Liposome composition 
 Before                                     After 
addition of transferrin 
 
    Size (nm)               PI                Size (nm)            PI 
DSPC:chol:N-glutaryl-PE 121.40±5.57 0.250±0.03 129.00±1.66 0.230±0.01 
DSPC:chol:DSPE-PEG2000-COOH 148.43±2.97 0.197±0.02 154.80±0.85 0.157±0.01 
DSPC:chol:DSPE-PEG2000-MAL 166.00±10.41 0.133±0.02 169.33±8.76 0.147±0.01 
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Table 3. ζ-potential of liposomes before and after coupling of transferrin at pH 7.4 (values 
represent the mean ± SD of three batches). 
 
Liposome composition 
Before 
coupling 
(mV) 
After 
coupling 
(mV) 
DSPC:chol:N-glutaryl-PE -31.67±1.53 -42.33±2.08 
DSPC:chol:DSPE-PEG2000-COOH -20.67±1.15 -32.33±2.08 
DSPC:chol:DSPE-PEG2000-MAL -21.67±1.15 -21.33±1.53 
 
 
3.4.2 Tf-binding efficacy 
The amounts of Tf (assessed by the BCS assay) in correlation with the amount of total PL  in 
the different formulations are given in table 4. While the amount of PL was comparable 
between all three methods, there were significant differences in the protein content of the 
samples. Method 2 resulted in 108.76 µg Tf / µmol PL, method 1 in 84.93 µg Tf / µmol PL, 
and method 3 exhibited the lowest protein content with 11.87 µg Tf / µmol PL. 
 
Table 4. Transferrin amount, PL amount and coupling efficiency using three different linker 
lipids (values represent the mean ± SD of three batches). 
 
Liposome composition 
Tf amount 
(µg/ml) 
PL amount 
(mg/ml) 
Coupling 
efficiency  
(µg Tf/µmol PL)
DSPC:chol:N-glutaryl-PE 840.57±43.43 8.26±0.20 84.93 
DSPC:chol:DSPE-PEG2000-COOH 1075.69±35.59 7.44±0.22 108.76 
DSPC:chol:DSPE-PEG2000-MAL 124.82±12.45 8.35±0.10 11.87 
 
3.4.3 Transmission electron microscopy 
The different preparations of liposomes were visualised by transmission electron microscopy 
after negative staining with uranyl acetate. Transferrin-conjugated liposomes revealed a 
particulate surface coating, which was absent in the corresponding unconjugated liposome 
preparations (figure 14 A, B). Surface particles on transferrin-conjugated liposomes showed a 
maximal length of about 10 ± 3.6 nm (n = 50). The space between the transferrin-conjugated 
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liposomes was also filled with particulate material, while in preparations of unconjugated 
liposomes, the background between the liposomes appeared to be unstructured. The degree of 
particulate decoration varied among the three coupling methods. Liposomes produced 
according to method 2 showed a higher density of particles on their surfaces compared to 
liposomes produced according to methods 1 and 3 (data not shown). 
In order to investigate whether the particulate decoration found on the conjugated liposomes 
was due to binding of transferrin, specific antibodies raised against human transferrin were 
added before the negative staining procedure. Liposome suspensions were filtered with a 
centrifugal filter to remove unbound protein or reagents prior to the measurement. As a result, 
the transferrin-conjugated liposomes were clearly decorated by fluffy dark structures. In some 
cases these structures were arranged on the liposome surface like spokes on a hub (figure 14 
C). Non conjugated liposomes only occasionally showed a slight decoration with similar 
structures at their surface (figure 14 D). The different decoration of conjugated and non 
conjugated liposomes is indicative of antibody complexes in conjugated liposomes. Taken 
together, these data suggest that transferrin molecules were exposed on the surface of 
transferrin-conjugated liposomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: TEM of liposomes prepared with DSPE-PEG2000-COOH (method 2) Bar = 50 nm.. A, B Liposomes 
after negative staining with uranyl acetate. Liposomes that have been conjugated with transferrin (A, Tf+) 
display small particles on their surface, while control preparations (B, Tf-) appear to be smooth and undecorated. 
C, D Liposomes immunolabelled with anti-transferrin antibody. The conjugated liposomes (C, Tf+) reveal a 
fluffy darkly stained decoration (arrows). In the control (D, Tf-) only a few liposomes are slightly decorated. 
Note the background between the liposomes is decorated equally in both preparations. 
C 
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3.4.4 Atomic force microscopy 
Atomic force microscopy was employed to visualise all liposomal formulations under wet 
conditions and to confirm the particle size and morphology measurements performed by PCS 
and TEM. For size determination, all visible particles within a representative scan area were 
individually evaluated. The obtained data can generally deviate from the results of PCS 
measurements, because of an interaction of the soft and flexible liposomes with the surface of 
the silicon wafer. However, the individual particle evaluation allowed excluding such 
artefacts from further analysis. 
The plain liposome formulations using N-glutaryl-PE, DSPE-PEG2000-COOH, and DSPE-
PEG2000-MAL showed average vesicle sizes of 165 ± 16 nm (n = 45), 157 ± 12 nm (n = 57), 
and 172 ± 9 nm (n = 29), respectively. PCS produced respective values of 121 nm, 148 nm, 
and 166 nm (table 2). The covalent coupling of Tf to the liposome surface led to an increase 
in diameter between 5 and 15% (192 ± 22 nm for N-glutaryl-PE, 168 ± 17 nm for DSPE-
PEG2000-COOH, and 180 ± 12 nm for DSPE-PEG2000-MAL). In the case of both plain and 
modified liposomes produced according to method 1, the vesicle morphology was relatively 
unstable on the silicon support, resulting in a liposome spreading into flat rafts with sizes 
between 300 nm and 900 nm (data not shown). The incorporation of PEGylated lipids into the 
liposomes induced a steric stabilisation in the other two formulations with liposomes found to 
be round and of spherical shape (figure 15).  
The surface of plain liposomes was always smooth and no structures could be observed 
(figure 15 A, B). When Tf was linked to the liposomes, small globular structures, localised on 
the liposomal surface became visible, exhibiting the highest rate of appearance in liposomes 
produced according method 2 (figure 15 C, D). These particles had a size of 10.53 ± 1.45 nm 
(n = 27), comparable to data assessed by TEM.  From the molecular weight, the size of a 
single Tf molecule can be calculated to be 4-5 nm [26]. The determined size was slightly 
larger, indicating the formation of associates comprising of two or three Tf molecules. 
 
 
 
 
 
 
 
 
                                                                                                3. Tf conjugation to liposomal surfaces 
 
 
73
10.8nm    11.2nm     9.6nm
E
250 nm
B
1 µm
A
1 µm
C
250 nm
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: AFM images of liposomes prepared with DSPE-PEG2000-COOH. A, B Plain liposomal formulations. 
The liposomes show a smooth surface morphology. C, D Liposomes covalently modified with Tf. Small 
globular structures are visible at the surface. E Line scan of liposome surface. The globular structures were 
measured to be 10.53 ± 1.45 nm in diameter. 
 
 
 
 
 
 
 
                                                                                                3. Tf conjugation to liposomal surfaces 
 
 
74
3.5 Discussion 
It has been the goal of this study to visualise the binding of a protein, transferrin, to a colloidal 
drug carrier system using two independent microscopic methods, AFM and TEM. To achieve 
this, ligand-modified DSPC/Chol liposomes were prepared according to three previously 
published methods and investigated with regard to their physico-chemical properties and 
efficacy of Tf-modification. 
AFM and TEM were able to detect Tf at the liposomal surface on the molecular level in a fast 
and reproducible manner. Both microscopic techniques can deliver semi-quantitative visual 
information on the actual functionalisation of nano-scale drug carriers with protein or 
antibody molecules. While the use of AFM does not require any fixation or preparation of the 
sample prior the measurement, the advantage of TEM is the possibility to reach a higher level 
of specificity when using antibodies raised against the protein under investigation. 
Intriguingly, the three chosen conjugation reactions resulted in significant differences with 
regard to their coupling efficacy. This became apparent using both the conventional 
characterisation methods such as the BCA assay and the assessment of ζ-potential, but also by 
employing the newly introduced microscopic methods. Method 2, using DSPE-PEG2000-
COOH as linker lipid, exhibited the highest amount of bound Tf, while method 3, using 
DSPE-PEG2000-MAL, still showed significant amounts of bound Tf on the liposomal surfaces, 
but in comparison on a three-times lower scale. A possible explanation of this phenomenon is 
that in method 3, free thiol groups may react among themselves to produce disulphide bonds 
leading to cross linking of protein molecules before the actual conjugation to the linker. In 
addition, the random introduction of thiol groups in the Tf molecule may interfere with the 
biological properties of the molecule resulting in a lower affinity to its receptor [27]. The 
higher efficacy of method 2, in comparison to method 1, might be attributed to a stabilisation 
of the intermediate of this reaction by the additionally used S-NHS [28, 29]. 
In summmary, it can be concluded that the microscopic methods introduced herein, AFM and 
TEM, are able to present fast and reliable complementary visual information on the protein-
modification of colloidal drug carriers. When used in addition to conventional techniques, 
they can significantly enhance the process of characterisation of new systems for advanced 
drug delivery. 
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4.1 Abstract 
 
Introduction Many tumour cells show a phenotype with an increased expression level of 
TfR, CD71. Therefore, TfR appears to be an excellent candidate target for tumour-specific 
drug delivery. 
Purpose The objectives of this work were to assess levels of uptake and cytotoxicity of 
liposomal formulations with Tf modification in vitro, using lung cell culture models. 
Results The observed higher expression levels of TfR correlated well with enhanced uptake 
of the Tf-conjugated liposomes into the cancerous cell types, as well as with increased levels 
of cytotoxicity, when studies were conducted using doxorubicin-filled liposomes. The 
liposomal uptake was temperature-dependent and inhibitable by excess free Tf.  
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4.2 Introduction 
 
4.2.1 Drug resistance in cancerous tissues 
Drug resistance continues to be a major challenge in cancer treatment. Intrinsic or acquired 
drug resistance occurs frequently in most cancers, and often involves resistance to multiple 
agents simultaneously (multidrug resistance, MDR). A number of mechanisms for drug 
resistance have been described. These include: overexpressed drug export pumps, caused e.g., 
by P-glycoprotein (PGP) and multidrug-resistance protein (MRP); decreased drug uptake, such 
as altered folate carriers; inactivation of drugs, such as via glutathione-mediated reduction; 
overexpression of target enzymes, such as upregulated thymidylate synthase; altered drug 
targets, such as topoisomerase II; increased DNA repair capacity; reduced ability to undergo 
apoptosis; and many others.  
Among these mechanisms, the role of PGP in multidrug resistance has been one of the most 
intensively studied. PGP, encoded by the MDR1 gene, is a member of the ABC (ATP-Binding 
Cassette) transport protein family and is frequently overexpressed in the MDR phenotype. 
Other membrane-bound transporters capable of mediating drug efflux include multidrug-
resistance protein MRP and other related proteins. These proteins actively transport a variety of 
heterocyclic substrates, including cytotoxic drugs such as anthracyclines, vinca alkaloids, 
mitoxantrone, paclitaxel, and others, out of the cell. Alternatively they can sequester drug 
substances into other cellular compartments. 
Specific inhibitors of these resistance mechanisms have been widely pursued as a means to 
restore drug sensitivity. Although still actively under investigation, specific resistance 
inhibitors have yet to gain registration for clinical use. Progress towards therapeutic success has 
been hampered by such issues as inadequate specificity, both predictable and unforeseen 
toxicities, uncertainly about the true prevalence and contribution of the known resistance 
mechanisms, paucity of predictive assays to identify tumours dependent upon particular 
mechanisms, and multiplicity and redundancy of resistance mechanisms [1]. 
 
4.2.2 Overcoming drug resistance by liposomes 
An alternative strategy for overcoming drug resistance is based on new drug delivery systems 
to achieve selective drug accumulation in tumour tissues, tumour cells, or even compartments 
of tumour cells. Liposomal carriers have become clinically accepted in cancer treatment, and as 
such comprise examples of delivery systems that can enhance the utility of anticancer drugs. 
For example, long-circulating liposomes and other macromolecular carriers can increase drug 
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deposition in solid tumours, which may help to overcome drug resistance. Other liposome 
strategies include modifications for controlled release, which may increase drug bioavailability; 
and ligand-targeted liposomes, such as immunoliposomes or Tf-conjugated liposomes, which 
can internalise into tumour cells for intracellular drug delivery and maximal drug efficacy. 
Liposomes are membrane-bound vesicles capable of packaging drugs for various delivery 
applications. For cancer treatment, a number of distinct liposome classes have emerged, based 
on structural features and associated pharmacologic strategies for delivery. Thus far, the most 
clinically successful liposomal drugs for cancer treatment have been SUVs, which consist of a 
single PL bilayer enclosing an inner aqueous compartment for drug encapsulation. The 
pharmacokinetics and biodistribution of liposomes depend on properties such as size, surface 
charge, and membrane composition [2]. 
Current liposomal delivery systems can potentially provide pharmacologic advantages over free 
drug, including providing a means to overcome drug resistance. Liposome delivery can yield 
increases in the area-under-the-concentration-versus-time-curve (AUC) in plasma and tumour 
by 60 to 600-fold or greater. At this level, liposomal delivery may overcome the activity of 
multidrug transporter systems, perhaps even in highly resistant tumours. It should be noted, 
however, that actual plasma and tumour drug concentrations reflect total drug (free and 
liposome-encapsulated) in these two compartments [3].  
In order to create agents capable of targeting drug carriers to tumour cells, we and others have 
studied approaches for ligand-targeted liposomes, which combine Tf and liposome 
technologies. This system can be designed for specific recognition of a target antigen followed 
by receptor-mediated endocytosis. In principle, the therapeutic index can be increased by 
targeting liposomes and their contents directly into tumour cells, and this may be useful 
especially for resistant cancers. 
Evidence for this targeting includes studies with targeted liposomes containing either growth 
factor ligands or antibodies directed against growth factor receptors. For example, folate 
targeting has been pursued using liposomes conjugated to folic acid, which were rapidly 
internalised into tumour cells via the folate receptor. In vivo studies in a resistant murine lung 
carcinoma tumour model (M109R-HiFR) showed superior efficacy of folate-targeted liposomal 
DOX as compared with free drug or non-targeted liposomal DOX. The TfR has also been 
targeted by immunoliposomes. Anti-Tf immunoliposomes were used to deliver DOX in a 
DOX-resistant clone of human leukaemia cells (K562/ADR) [4]. Immunoliposome delivery 
was associated with minimal drug efflux and nearly equivalent DOX levels in resistant 
K562/ADR cells as compared with sensitive parental K562 cells. In contrast, free DOX was 
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efficiently effluxed and present at 45-fold lower drug levels in the resistant clone. In separate 
studies, anti-TfR immunoliposomes containing mAb OX26 were used to deliver radiolabelled 
digoxin in immortalised RBE4 rat brain capillary endothelial cells. Cellular uptake of digoxin 
was 25-fold higher using immunoliposomes, and was unaffected by the PGP inhibitor ritonavir 
[5]. 
 
4.2.3 Liposomal doxorubicin as anti-neoplastic 
DOX is an effective therapy for many cancers. Unfortunately, the free form is delivered to 
normal tissue as well as to cancerous tissues resulting in a great number of toxicities. Reduction 
of DOX by cellular enzymes results in build-up of oxidative free radicals. Cardiac tissue does 
not produce enzymes that degrade these oxidative free radicals. Therefore, cardiotoxicity may 
result in many patients and results in a maximum lifetime dose that severely limits usefulness.  
The development of PEG-liposomal delivery of DOX has improved the 
pharmacokinetic/pharmacodynamic profile of the drug. The PEG-liposomal DOX formulation 
increases the half-life, maximum concentration, and area under the curve. This results in a 
higher therapeutic index for DOX. 
In a study performed by Eavarone et al. (2000) using free- and liposomal-loaded DOX in C6 
gliomal cell model, the authors show that DOX encapsulation within liposomes lacking PEG 
chains allowed a 292% increase in uptake by glioma compared to liposomes of similar 
composition containing PEG. While PEG chains appear sterically unsuited for tumour uptake, 
the incorporation of PEG into the liposome membrane has been shown to increase circulation 
times dramatically and to decrease drug leakage during circulation. Ligands were coupled to 
the distal ends of the PEG chains in an attempt to increase uptake through receptor-mediated 
targeting while maintaining PEG stability. Tf was used as a targeting agent for glioma TfR, and 
albumin was used as a similar molecular weight protein control. Tf-coupled liposomes showed 
a 412% increase over non-carboxylated PEG-liposomal uptake and a 104% increase over 
albumin-coupled liposomal uptake, indicating that the increased efficacy of these liposomes is 
due to TfR targeting rather than to PEG modification or the addition of non-specific proteins 
[6]. 
 
4.2.4 Loading of liposomes with drugs 
The main medical and pharmaceutical application of liposomes is delivery of drugs and other 
bioactive agents for therapy or for in vivo diagnostics. Such applications will require sufficient 
loading of the drug into the liposomes. Classical liposomes, first described by Bangham, are 
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made up of amphiphilic PLs and cholesterol which, upon hydration, self-associate to form 
bilayers surrounding an aqueous interior. Hydrophilic drugs can be entrapped in the aqueous 
interior and hydrophobic drugs can be associated with the bilayer. 
Amphiphilic drugs that are weak bases or weak acids can also be loaded into the liposome 
interior using remote loading methods like the ammonium sulphate method for DOX or the pH 
gradient method for vincristine. A number of loading strategies are currently available (figure 
16). The selection of optimal loading procedure should be based on a scientific rationale [7]. 
  
                         
 
          
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Diagramatic representation of drug uptake in response to transmembrane pH gradients. A: the standard 
pH gradient method. B: Transmembrane gradient of ammonium sulphate. C: Ionophores 
 
The various agents can be classified into three groups based on their oil/water and 
octanol/water partition coefficients (Kp). The first group(group I) includes hydrophilic agents 
with very low oil/water and octanol/water Kp. The second group (group II) includes 
amphiphatic agents of low oil/water Kp but variable, and in some cases even high, 
octanol/water Kp, which is controlled by the pH and, to a lesser extent, by the ionic strength of 
the medium. Good examples of this group are the anthracyclines, to which DOX belongs. The 
third group (group III) includes hydrophobic agents having high oil/water and octanol/water 
Kp. These agents of group III are associated with the liposome bilayer(s) although their loading 
efficiency is rather low. Agents of group I do not interact with the liposome bilayer, and their 
A B C
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encapsulation is dependent on, and limited mainly by, the vesicle trapped volume. The smaller 
the liposome size, the lower the trapped volume and, therefore, the encapsulation rate. 
Drugs of group II offer a better chance to obtain loading at a dose needed for therapy in 
humans, even for small liposomes. This is explained either by the high affinity of the drug for 
the liposomal membrane, or by its ability to be remotely loaded, reaching a very high 
concentration in the intraliposomal aqueous phase. Some of the amphipathic weak bases of 
group II can diffuse through the liposome bilayer as unprotonated species which then become 
trapped in the intraliposomal aqueous phase due to a proton gradient which shifts then to group 
I. Therefore, they cannot cross the lipid bilayer and accumulate in the intraliposomal aqueous 
phase [8]. 
Amphiphathic amines, such as catecholamines, can be loaded by a pH gradient. Liposomes 
should be prepared in acidic medium, and the pH gradient created by elevating the pH of the 
extraliposomal acidic medium. This concept was extensively used and it has been demonstrated 
that liposomes loaded by such an approach, when compared with use of the free drug, have 
lowered toxicity and improved efficacy. Liposomes containing DOX which was remotely 
loaded through a pH gradient have already been used in clinical trials. Deamer and Harang 
demonstrated that a pH gradient can be created by a photochemical reaction. However, 
application of this approach for drug delivery is questionable, since it depends on liposomes 
containing ferrocyanide [9]. 
According to Haran et al. the remote loading approach could be achieved by creating an 
ammonium sulfate gradient ([(NH4)2SO4]lip>[(NH4)2SO4]med). This is used as the driving force 
for loading of amphipathic weak bases such as anthracyclines into liposomes. 
Small liposomes loaded by an ammonium sulphate gradient with either DOX or epirubicin 
were used extensively in animal studies involving rodents and dogs and also in clinical trials in 
humans. In all cases, liposomes loaded by this method show high stability of DOX during 
storage and during circulation in vivo, as well as better tumour localisation, lower toxicity and 
higher efficacy compared to either use of the free drug or the drug loaded into conventional 
liposomes [10]. 
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4.3 Materials and methods 
 
4.3.1 Cell culture conditions 
Primary culture of human pneumocytes 
Fresh human type II alveolar epithelial cells (hAEpC II) were isolated from non-tumour lung 
tissue which was obtained from patients undergoing lung resection as described previously in 
chapter II. For the uptake and binding study, the cells were seeded at a density of 300,000 
cells/cm2 on collagen/fibronectin-coated polyester filter inserts (Transwell Clear, 12 mm in 
diameter, 3460, Cornin, Bodenheim, Germany) using SAGM (Cambrex Bio Science, Verviers, 
Belgium) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and with 
addition of low serum (1% FBS) in order to suppress fibroblasts. Cells were grown either for 
three days (hAEpC II) or for eight days (hAEpC I). For the cytotoxicity study, same procedure 
was followed with seeding of the cells on 96-well plates. 
 
A549 cell line 
In this study, passage numbers 92-95 were used. A549 cells were cultured, as previously 
described, in RPMI-1640 medium (Sigma) supplemented with 10% FBS at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were plated in 25 ml culture flasks, polyester 
filter inserts (Transwell Clear, 24 mm in diameter, 3450, Corning, Bodenheim, Germany) or 
96-well plates at a density of 105 cells/cm2 to confluency. The medium was changed every 
other day. 
 
Calu-3 cell line 
Passage numbers 70-73 were used. The cells were grown in EMEM supplemented with 10% 
FBS, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 µg/ml streptomycin and 
100 U/ml penicillin) at 37°C in a humidified atmosphere containing 5% CO2. Cells were plated 
in 75 ml culture flasks, polyester filter inserts (Transwell Clear, 24 mm in diameter, 3450, 
Corning, Bodenheim, Germany) or on 96-well plates at a density of 105 cells/cm2 till 
confluency. The medium was changed every other day.  
 
16HBE14o- cell line 
Passages 2.48-52 were used in this study. Cells were seeded in tissue culture flasks, polyester 
filter inserts (Transwell Clear, 24 mm in diameter, 3450, Corning, Bodenheim, Germany) and 
96-well plates at a density of 105 cells /cm2 till confluency and grown in EMEM supplemented 
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with 10% FBS, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 100 µg/ml streptomycin 
and 100 U/ml penicillin G, at 37°C in a 5% CO2 incubator. The medium was changed every 
other day. 
 
4.3.2 Liposome preparation 
Liposomes were prepared using a slightly modified protocol according to our previously 
published method which is described in chapter III [11]. Briefly, liposomes were prepared from 
DSPC, Chol and the linker lipid DSPE-PEG2000-COOH at the ratio 6:3:0.6 mol%. For 
PEGylated liposomes phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] 
(MPEG2000-DSPE) was added at 0.6 mol%. All lipids were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). PL and Chol in chloroform:methanol (2:1) was dried to a thin lipid film 
in a rotary evaporator (Büchi, Essen, Germany). The lipids were re-suspended in an appropriate 
amount of 400 mM citrate/5 mM phosphate buffer (pH 4.0) containing the fluorescent dye 
calcein at 50 mM resulting in a final lipid concentration of 10 mg lipid/ml. After vortexing, the 
sample was incubated for 10 min at a temperature above the transition temperature of the used 
lipids (53°C for DSPC:chol) in a cabinet drier. Unilamellar liposomes were prepared by 
extruding the resulting multilamellar vesicles eleven times through a 200-nm polycarbonate 
membrane, followed by extrusion eleven times through a 100-nm membrane using a Liposofast 
Basic device (Avestin, Mannheim, Germany).  
For cytotoxicity studies DOX was encapsulated into the liposomes using the ammonium 
sulphate gradient method [8, 12]. Briefly, unilamellar liposomes were initially formed in buffer 
containing ammonium sulphate (250 mM final concentration) as described above. Non-
entrapped ammonium sulphate was removed by ultracentrifugation at 30,000×g for 60 min at 
4°C. Subsequently, liposome pellets were re-suspended using PBS containing 1.2 mM 
(NH4)2SO4 and 0.1 mg/ml DOX. Liposomes were then incubated at 60°C for 24 h, 
ultracentrifuged again to remove free DOX and re-suspended in PBS. 
Conjugation of Tf to the liposomal surfaces was achieved by adding 1 ml PBS (pH 7.5) and 
360 µl of both EDC (0.25 M in H2O) and S-NHS (0.25 M in H2O)  per 10 µmol of lipid. The 
mixture was allowed to incubate for 10 min at room temperature, before adjusting to pH 7.5 
with 1 M NaOH. 125 µg Tf/µmol PL was added and gently stirred for 8 h at 4°C. Unbound 
protein was removed by passing the liposome suspension through a Sepharose CL-4B gel 
column. Mean particle size of the liposomal suspension was determined by dynamic light 
scattering. PLs concentration was determined by the colorimetric method and the amount of 
protein was determined by the BCA assay [11]. Encapsulation efficacy of DOX was assayed 
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with a fluorescence plate reader (Cytofluor II, PerSeptive Biosystems, Wiesbaden, Germany) at 
excitation and emission wavelengths of 485 and 530 nm, respectively.  
 
4.3.3 Uptake studies 
Studies of uptake of the liposomal formulations were conducted in 96-well plates using cell 
layers grown to confluence after 5-8 days, depending on cell type. Four different types of 
liposomes were tested in this assay: plain DSPC:chol liposomes without any functionalisation, 
PEGylated DSPC:chol liposomes, Tf-conjugated DSPC:chol liposomes, and PEGgylated Tf-
conjugated DSPC:chol liposomes. The cells were washed with PBS followed by incubation 
with the liposomal formulation (final PL concentration 100 µM) for 30, 60, 90 or 120 min at 
37°C. The same setup was used for experiments carried out at 4°C and in the presence of free 
Tf (50 µg/ml) in PBS. For each time point and condition, three wells were measured. After 
incubation, cells were washed 3 times with ice cold PBS and surface-bound liposomes were 
removed using pronase (1 mg/ml), before assessing total fluorescence (corresponding to 
internalised liposomal calcein) with a Cytofluor II fluorescence plate reader at excitation and 
emission wavelengths of 485 and 530 nm, respectively. 
 
4.3.4 Cytotoxicity assay 
Respiratory epithelial cells were plated in quadruplicate in 96-well plates and left alone for 24 h 
to adhere, before exposing them to increasing concentrations of liposomal DOX (0.003–5.7µM) 
for 2 h at 37°C. Four wells for untreated cells and medium were also prepared. After the 
incubation period, cell layers were washed three times with PBS and 100 µl of fresh culture 
medium were added per well, before incubation was continued for 60 h at 37°C. Cell viability 
was determined with a colourimetric assay, Cell Proliferation Reagent WST-1 (Roche 
Diagnostics, Germany). The test is based on the cleavage of the tetrazolium salt WST-1 in 
formazan by mitochondrial dehydrogenases in viable cells [13]. The formazan dye was 
quantified by a scanning multiwell spectrophotometer (TECAN, Crailsheim, Germany) by 
measuring the absorbance of the dye at 440 nm. After the incubation period, Cell Proliferation 
Reagent WST-1 was added (10 µl/well) and the absorbance measured after 24h.  
 
4.3.5 Statistical analysis 
Data are presented as mean ± standard deviation (n), where n is the number of observations. 
Differences among group means were determined by one-way analysis of variance followed by 
post-hoc Newman-Keuls-Student procedures and p < 0.05 taken as the level of significance. 
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4.4 Results 
 
4.4.1 Characterisation of liposomes 
Physicochemical properties of the different liposomal preparations are given in table 5. The 
ammonium sulphate gradient method for encapsulation of DOX resulted in an average 
encapsulation efficiency of 96.7±5.0%.  
 
Table 5. Size, polydispersity index (PI) and zetapotential of liposomes before and after 
coupling of Tf (values represent the mean ± SD of three batches).  
 
Before                                                                     After 
                                                   addition of Tf 
 
 
Size (nm) Zetapotential 
(mV) 
Size (nm) Zetapotential 
(mV) 
DSPC 120.50 ± 4.57 -40.67 ± 1.53 129.00±1.66 -20.88 ± 2.08 
DSPC 5% PEG 126.40 ± 5.57 -32.31 ± 1.35 135.80±2.76 -19.12 ± 2.34 
 
4.4.2 Uptake studies 
In our experiments, the cellular uptake of liposomes was determined by measuring the 
fluorescence activity of calcein which was previously entrapped in the liposomes. Calcein is a 
very hydrophilic dye that normally does not cross cellular membranes [14]. Uptake of calcein 
into epithelial cells was found to be increasing over time for up to 2 h incubation. In figure 17 
A, rates of calcein uptake into Calu-3 bronchial epithelial cells are depicted as an example for 
all other cell types which showed similar tendencies. Tf-conjugated liposomes showed 
significantly higher rates of uptake than their unmodified counterparts. Addition of PEG into 
the liposomal membranes had only a slight effect on calcein uptake. When carried out at 4°C, 
experiments resulted in a significantly lower calcein signal after 2 h incubation compared to 
values achieved at 37°C for both Tf-modified liposomal formulations. An even stronger 
inhibition of uptake could be observed when large amounts of free Tf were present in the buffer 
during the incubation period. The effects of temperature decrease and Tf competition were 
much less pronounced for the unmodified formulations (figure 17A). A comparison of all cell 
types used in this study regarding their level of calcein uptake after 2 h of incubation at 37°C 
showed the lowest calcein accumulation in hAEpC II and hAEpC I-like primary cells (figure 
17B). Signals from the three continuous growing cell lines were all significantly higher with 
the highest values for uptake into A549 cells (figure 17B). 
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Figure 17: A) Uptake of calcein into Calu-3 bronchial epithelial cells from four different liposomal preparations. 
Plain liposomes (DSPC), PEGylated liposomes (DSPC-PEG), plain liposomes with Tf (DSPC-Tf)and PEGylated 
Tf-modified liposomes (DSPC-PEG-Tf). The uptake of calcein increased gradually with time and decreased 
drastically when experiments were carried out at 4°C and in the presence of excess free Tf. B) Uptake of calcein 
into A549, Calu-3, 16HBE14o-, hAEpC II and hAEpC I-like cells from four different liposomal preparations. The 
lowest calcein accumulation was found in hAEpC II and hAEpC I-like primary cells. Signals from the three 
continuous growing cell lines were all significantly higher with the highest values for uptake into A549 cells. Each 
data point represents the mean ± SD for n = 3.   
 
4.4.3 Cytotoxicity assay 
The effect of liposomal-DOX on the survival of the different respiratory cell types used in our 
study was assessed by the WST assay (figure 18). The cytotoxic effect was determined after 2 h 
of exposure to the liposomal formulation followed by washing and an additional 60 h of 
incubation in cell culture media. Alveolar epithelial cells in primary culture showed a low 
response with almost 70% surviving even the highest concentration of DOX used in this 
experiment (0.34 mg/ml). Survival of the other three cell types (i.e., A549, Calu-3 and 
16HBE14o-) showed much stronger concentration dependency and, more importantly, 
significantly increased levels of toxicity. At 0.02 mg/ml DOX more than 50% of the tested cells 
were killed with increasing rates for higher DOX concentrations. When incubated with 0.34 
mg/ml of free (i.e., not encapsulated) DOX, none of the cell types showed survival rates over 
10% . 
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Figure 18: Survival of hAEpC II (○), hAEpC I-like (●), A549 (◊), 16HBE14o- (■), and Calu-3 cells (□) following 
treatment with DOX-loaded Tf-conjugated liposomes. Survival was determined after 2 h of liposome exposure 
followed by washing and an additional 60 h of incubation in cell culture media using WST-1 assay. Each data 
point represents the mean ± SD for n = 3. 
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4.5 Discussion  
TfR has emerged as a potential ligand to enable drug targeting and delivery of therapeutic 
agents that would normally suffer from poor pharmacokinetic characteristics. TfR-directed 
targeting has enabled the efficient delivery of therapeutic agents to sites of interest, including 
the central nervous system and malignant tissues. In addition, by utilizing knowledge of the 
intracellular sorting and recycling pathways of TfR, one can maximize the transepithelial 
delivery of peptide-based therapeutics. For example, TfR-based strategies can achieve 
accumulation of the carried drug within targeted tissues or delivery of the therapeutic entity 
across tissues of interest. Further understanding of the intra-cellular events that govern the 
destiny of internalized TfR will result in ever increasing interest in TfR as a pharmaceutically 
relevant molecule. 
The large surface area of the lower lung, together with its very thin air-blood barrier, provides 
excellent conditions for efficient gas exchange. The alveolar epithelium consists of two major 
cell types: the cuboidal type II cells, which produce lung surfactant and serve as precursors for 
the second very thin cell type I, which form about 93% of the alveolar surface. 
Among several lung epithelial cell lines, obtained from broncho-alveolar carcinoma or by 
immortalisation, A549 cells are best characterized. These cells show some biochemical and 
morphological characteristics of type II alveolar epithelial cells. Microvilli and lamellar bodies 
serving as intracellular storage compartments for lung surfactant have been identified. A549 
cells synthesize saturated PLs, the main component of lung surfactant. However, 
phosphatidylglycerols, which are specific for lung surfactant, are lacking. A549 cells as well as 
other lung epithelial cell line fail to develop substantial transepithelial electrical resistance, 
indicating the lack of a real epithelial barrier function to drug transport. 
For primary culture, type II cells have been isolated from rats, rabbits, and recently from 
humans. Similar to the in vivo situation, these cells lose their type II cell characteristics. In 
contrast to A549 cells, alveolar epithelial cells cultured on permeable filter supports develop 
high transepithelial electrical resistance values indicating the formation of tight junctions.  
Inhalational therapy for malignancy involving the lung is a quite new area of research; 
nevertheless, a number of studies using immune therapy with interleukins and interferons, and 
chemotherapy with aerosols of free 5-fluorouracil and 9-nitrocamptothecin, resulted in 
encouraging outcomes [15]. It is our aim to develop targeted drug delivery systems for local 
aerosol therapy of lung cancer, since we believe that such therapy could further increase the 
effectiveness of anti-tumour treatments while systemic side effects might be further reduced. 
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We investigated whether Tf-conjugated liposomes are suitable drug delivery systems for 
inhalational therapy of lung cancer. In comparison to unmodified liposomes, Tf-conjugates 
showed significantly higher uptake into respiratory epithelial cells of cancerous origin (i.e., 
A549, Calu-3 and 16HBE14o-), while in pneumocytes in primary culture uptake rates were 
much lower. These findings were in good agreement with levels of cytotoxicity of the 
formulations as determined by WST assay. Intriguingly, A549 cells showed a lower level of 
TfR expression than the bronchial in vitro models; nevertheless, uptake of Tf-modified 
liposomes into A549 cells was the highest of all investigated cell types. This initially surprising 
result is most likely caused by the lack of functional tight junctions in this cell line [16, 17]. 
Thus, transcellular diffusion is less restricted and the liposomes can be internalised not only by 
TfR of the apical but also the basal membranes. Uptake of liposomal calcein into cells was 
inhibitable both by low temperature and excess free Tf in the medium, strongly indicating that 
the uptake mechanism is an energy-driven, saturable process, as it has been described to be the 
case for TfR internalisation [18]. 
Receptor-mediated endocytosis pathways can be exploited for specific targeting of liposomes 
and intracellular delivery of liposome contents. Coupling liposomes to a ligand, that is directed 
towards an over-expressed receptor in cancer cells and that normally undergoes endocytosis, is 
a strategy that can improve selectivity and facilitate access of liposomes to the intracellular 
compartment. 
In conclusion, a DSPE-PEG2000-Tf conjugate was successfully synthesized as liposomes 
bearing an ammonium sulphate gradient for DOX loading. The conjugation of Tf to liposomes 
as a homing strategy resulted in increased uptake rates into tumour cells via TfR mediated 
endocytosis. Therefore, Tf-modified liposomes might be promising candidates for aerosol 
anticancer therapy in the lungs. However, further studies are necessary to investigate stability 
of these liposomal systems when undergoing nebulisation and when encountering lung fluids. 
As the next step, animal xenograft models of lung cancer should be employed to obtain 
important in vivo data.  
Evidence for the mechanism of receptor-mediated targeting was further supported by 
competitive binding assays. The addition of Tf to the incubation medium dramatically 
decreased drug uptake within Tf-coupled liposomes. Competition by free Tf therefore may play 
a large role in the efficacy of this system in vivo. 
These findings were supported in this part of the work by the fact that Tf-conjugated liposomes 
showed higher binding and uptake rates into cancer cells compared to their normal 
counterparts. Moreover, normal cells showed a higher resistance to the cytotoxic effect of 
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encapsulated DOX. Therefore, Tf-conjugated liposomes appear as promising drug delivery 
systems for an inhalational approach in lung cancer chemotherapy. 
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Nebulisation of liposomal formulations 
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5.1 Abstract 
 
Introduction Oral inhalation of anticancer drugs or drug delivery systems is a novel 
therapeutic approach in the treatment of lung cancer and requires formulations which are 
sufficiently stabile during nebulisation and subsequent interaction with the surfactant lining of 
the lungs.  
Purpose To assess the stability of plain and PEGylated transferrin-conjugated liposomes after 
nebulisation using two different nebulisers (the air-jet and ultrasonic types). Furthermore, to 
assess the integrity of the liposomal membranes after incubation in commercial lung 
surfactant solutions (Alveofact®). 
Results All liposomal formulations showed no significant changes in their size after 
nebulisation, independent of the type of nebuliser and the liposomal formulation. However, 
PEGylation was of advantage when it came to interactions between liposomes and the 
surfactant lining of the lungs. PEGylated liposomes were significantly more stable and 
retained >80% of their drug load over 48 h, which is more than sufficient time for the drug 
carriers to be taken up by over expressed transferrin receptors of cancer cells in the lung. In 
conclusion, PEGylated and plain Tf-conjugated liposomes are stable enough to undergo 
nebulisation in the course of an inhalational therapy, but PEG-stabilisation results in a higher 
degree of membrane integrity in lung surfactant.  
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5.2 Introduction 
 
5.2.1 Inhalation therapy 
Aerosolised administration of drugs to the lung has been employed for many years to treat 
primarily localised disease states within the bronchi. Since this route of administration can 
deliver therapeutic agents to the diseased regions whilst reducing their distribution to the 
other organs, this is an excellent example of targeted drug therapy. Hence, a more favourable 
therapeutic index can be obtained for the treatment of lung diseases when drugs are 
administered by inhalation rather than by the oral route. Bronchodilators, anti-inflammatory 
agents, mucolytics, antiviral agents, anticancer agents and PLs protein mixtures for surfactant 
replacement therapy are all routinely given as aerosolised formulations. 
The advantage of the aerosol mode of delivery is that the drug is deposited more uniformly 
over the respiratory tract, leading to local levels of the drug that may exceed the levels 
achieved by systemic administration. 
Drug delivery systems, such as microparticles, nanoparticles or liposomes, may enhance the 
stability of substances applied to the lung by offering protection against aggressive 
environmental factors. Moreover, such schemes can exhibit controlled release properties. 
Despite the advantages of inhalation delivery, there are also some related challenges to solve 
which are not associated with usual systemic delivery. The first major challenge is the 
atomisation of the drug formulation in a form suitable for inhalation. It is generally accepted 
that aerosol particles of 1–5 µm are required for deposition in the alveolar region of the lung, 
the region of the highest absorption. The primary factors influencing aerosol particle size and, 
ultimately, the site of aerosol deposition include the design of the inhalation device, as well as 
the physicochemical properties of the drug formulation. 
In addition to the size of the individual particles, their concentration as well as surface 
characteristics both play an important role in determining the physicochemical properties of 
the suspension and subsequent behaviour during nebulisation. Early nebulisation studies 
showed a high tendency towards aggregation. Such occurrences may not only affect the 
properties of the suspension during nebulisation, but may also influence the overall dose 
effectively applied to the patient as well as the release kinetics of the formulation once in the 
alveolar region. 
Aerosols are a highly desirable form of delivering medication to the lungs. Although they 
allow direct delivery of drug to target cells, aerosols can be inefficient. This is primarily due 
to anatomy and physiology of the airway, the breathing mechanism, operational factors 
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associated with the use of delivery devices, and factors inherent to device design. Crucial 
parameters are particle size, delivery efficiency and delivery rate [1].  
Three systems for the administration of aerosolised medications that are widely used: 
pMDI: the drug is either suspended or dissolved in a propellant and filled under pressure into 
a canister. Releasing a metered volume of the fluid causes the propellant to expand and 
evaporate rapidly, leaving the drug in the form of dry aerosol particles suitable for inhalation. 
DPI: disperse small powder particles for inhalation into the lung. Shear forces generated by 
the patient's inhalation flow are used to deagglomerate the drug particles, which are 
commonly adhered to carrier particles. 
Nebulisers: there are two types of medical nebulisers: the air-jet nebuliser, which is powered 
by compressed air, and the ultrasonic nebuliser, which derives the energy required to 
aerosolise drugs from high-frequency sound waves. 
An inhalation system has to produce a particle-size distribution suitable for delivery to the 
lungs. Ideally, the diameter of the aerosol particles or droplets should be in the range of 1 µm 
to 5 µm (respirable fraction). Particles in this size range will be deposited primarily by 
sedimentation in the peripheral lung regions, the bronchioli and alveoli. Sedimentation is the 
major mechanism of deposition in the therapeutic use of aerosols. 
 
5.2.2 Advantages of liposomes for inhalation 
A significant disadvantage of many existing inhaled drugs is the relatively short duration of 
resultant clinical effects, and most medications administered in aerosol form require 
inhalation at least 3-4 times daily. This often leads to poor patient compliance with the 
therapeutic regime and increases the possibility of associated side effects. Recently a number 
of methods have been investigated as potential pulmonary sustained-release systems for short-
acting drugs. These include the incorporation of drugs in liposomes and other biodegradable 
microspheres, the modification of chemical structure to produce either pro-drugs or drug 
conjugates with macromolecules, the use of sparingly soluble forms of the drug, and the 
preparation of magnesium hydroxide co-precipitates and complexes of the drug with 
cyclodextrins. Liposomes are one of the most extensively investigated systems for controlled 
delivery of drug to the lung, since they can be prepared with PLs endogenous to the lung as 
surfactants. 
The development of liposomal formulations for aerosol delivery has expanded the potential 
for more effective utilisation of an array of potent and effective drugs. Liposomal aerosols in 
pulmonary therapy have many advantages including carrier suitability for lipophilic drugs, 
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sustained release, and prevention of local irritation, increased potency, reduced toxicity, and 
uniform deposition of locally active drugs. Liposomes can also be produced with a wide range 
of sizes and can incorporate both hydrophilic and lipophilic drugs. Many drugs have been 
incorporated into liposomes with a view to improving their pulmonary delivery, and some 
have been tested in animal and human subjects. These include, for example, cytotoxic agents, 
anti-asthma drugs, antimicrobial and antiviral compounds, antioxidant agents, and drugs with 
systemic actions [2].  
Drug formulation plays an important role in producing an effective inhalable medication. Not 
only is it important to have a drug that is pharmacologically active, but it must also be 
efficiently delivered into the lungs to the appropriate site of action, and remain in the lungs 
until the desired pharmacological effect occurs. A drug designed to treat a systemic disease, 
such as insulin for diabetes, must be deposited in the lung periphery to ensure maximum 
systemic bioavailability. For gene therapy or antibiotic treatment in cystic fibrosis, prolonged 
residence of the drug in the lungs may be required and, to obtain the optimal therapeutic 
effect. Thus, a formulation that is retained in the lungs for the desired length of time, while 
avoiding the clearance mechanisms of the lung, may be necessary.  
Sustained release from a therapeutic aerosol can prolong the residence of an administered 
drug in the airways or alveolar region, minimise the risk of adverse effects by decreasing the 
systemic absorption rate, and increase the likelihood of patient compliance by reducing 
dosing frequency. A sustained-release formulation must avoid the clearance mechanisms of 
the lung, including the mucociliary escalator of the conducting airways and macrophages in 
the alveolar region. 
Liposomes have been studied for years, as a pulmonary drug delivery vehicle, and used as a 
means of delivering PLs to the alveolar surface for treatment of neonatal respiratory distress 
syndrome.  
Liposomes are highly versatile drug carriers. They can be formed from a variety of lipids 
leading to a wide range of physiochemical properties that can alter the trapping efficiencies 
and release rates of the drug. The physiochemical properties, such as liposome size, bilayer 
fluidity, surface charge, as well as the method of preparation, affect their in vivo behaviour. 
The vesicle size and number of bilayers are critical parameters in determining the extent of 
drug encapsulation. Small liposomes (≤0.1 µm) are opsonised less rapidly and to a lesser 
extent than large liposomes (>0.1 µm). Small liposomes also have a slower release rate. Niven 
et al. demonstrated that 80 min after nebulisation of the liposomal preparation, large 
multilamellar vesicles (1-5 µm) lost 77% of their content while vesicles with a diameter of 0.2 
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µm lost only 8%. The preferred size range for clinical applications has been suggested to be 
50–200 nm in diameter. Liposomes of this size would avoid phagocytosis by macrophages 
and still trap useful drug loads [3]. Design of drug carrying and targeted delivery systems 
using such small particles puts this branch of medicine within the regimen of nanotechnology. 
Bilayer fluidity also influences the behaviour of liposomes. Lipids have a characteristic phase 
transition temperature (Tc). The Tc depends on the length and saturation of the fatty acid 
chains and can vary from 20°C to 90°C. The lipids exist in different physical states above and 
below this temperature. Below the Tc, the lipids are in a rigid, well-ordered arrangement (gel 
phase), and above the Tc in a liquid-crystalline state (fluid phase). The presence of high Tc 
lipids (Tc >37°C) makes the liposome bilayer less fluid at the physiological temperature and 
thus, less leaky. The fluidity of the bilayer appears also to influence the interaction of 
liposomes with macrophages. Liposomes composed with high Tc lipids having a lower uptake 
in the macrophages. Incorporation of cholesterol into the lipid bilayer affects the fluidity. At 
high concentrations (> 30 mol%), cholesterol can eliminate the phase transition, making the 
liposome more stable and less leaky. 
The type and density of charge on the liposome surface are also important parameters. A 
negative charge decreases liposome aggregation and increases encapsulation efficiency, 
which also increasing liposome–cell interactions; however, charged liposomes may be cleared 
faster than neutral liposomes. Unlike anionic liposomes, cationic liposomes deliver their 
contents to cells by actual fusion with the cell membrane. 
Liposomes, like other inhaled particles reaching the alveoli, are cleared by macrophages. 
Unlike other inhaled particles, the fate of liposomes can have a fate similar to that of 
endogenous lipids. The processing, uptake and recycling of liposomal PLs occurs through the 
same mechanism as that of endogenous surfactant via the alveolar type II cells. A search for a 
liposomal formulation that would evade recognition and uptake by the immune system and 
prolong its residence led to the development of liposomes with a polymer surface coating, 
such as PEG. The hydrophilic polymer coating attracts water to the liposome surface, 
preventing the association and binding of opsonins to the liposome, thereby inhibiting the 
body's molecular recognition processes of labelling the molecule as foreign for subsequent 
uptake and removal by macrophages, and subsequently increasing liposomal stability. 
Among various aerosol delivery technologies, nebulisers have been extensively researched for 
the delivery of liposomes, since nebulisers are the most simple delivery devices for 
liposomes, unlike MDI or DPI. Liposomes may be delivered from nebulisers without further 
processing. Characteristics of aerosol produced by nebulisation will depend upon a number of 
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factors such as design of the nebuliser, operating conditions, local environment and aerosol 
output rate. For nebulisation of liposomal systems, the nature of the PL used for preparing the 
liposomal dispersion and its method of preparation will also play important roles in 
determining the nebulisation efficiency. In the last few years, many studies have been 
reported evaluating these various parameters for liposomal systems encapsulating therapeutic 
agents such as anti-inflammatories, antibiotics and bronchodilators. The liposomes used 
showed good nebulization efficiency, encapsulated delivery and lower leakage upon 
nebulization for all the drugs. The approach suggests a new direction for the respiratory 
delivery of liposomes by nebulization and opens new doors for future in vivo testing for the 
treatment of pulmonary diseases [4]. 
 
5.2.3 Inhalational Chemotherapeutic agents for treatment of lung cancer 
In chemotherapy, cytotoxic drugs are used to kill cancerous cells. These drugs are currently 
administered intravenously or orally. Generally, combinations of chemotherapy and other 
drugs are used to mitigate adverse side effects, including skin, gastrointestinal, and bone 
marrow ailments. Such side effects are inevitable, because the drugs used are toxic to healthy 
cells as well as to cancer cells, and circulate throughout the body. 
By delivering chemotherapeutic agents for lung cancer as a magnetically targeted aerosol, it 
may be possible to reduce adverse side effects by administering chemotherapy agents directly 
to the cancerous tissue [5, 6].  
Aerosols provide a means to favourably alter the biodistribution of chemotherapeutic agents. 
This strategy holds promise as a unique way of delivering drug locally to the lung. The 
administration of chemotherapy directly to the lung also holds promise in the treatment of 
neoplasia in the lungs. New therapeutic agents, molecular targets and delivery approaches are 
needed to address the limited effectiveness of current treatment modalities for lung cancer. 
Among treatment avenues being explored as alternatives to systemic drug delivery, direct 
tumour targeted aerosolised delivery of chemotherapeutic agent, alone or in combination with 
other drugs seems a novel promising approach for the treatment of lung cancer. 
Over the last few years, inhalation drug delivery for the treatment of lung cancer has received 
new attention from scientists. Recently, nebulised liposomal formulations of 9- 
nitrocamptothecin (9-NC) and paclitaxel have been studied in the treatment of lung cancer in 
animal models. Knight et al. tested the anticancer properties of liposomes containing 
campothcin and its analogue (9-NC) in different animal models. The drugs were formulated 
into liposomes with dilauroylphosphatidylcholine (DLPC). Aerosol treatment was associated 
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with significant reduction in the size of the implants. This effect was seen in all tumour 
histologies, and breast and lung cancer showed the best responsiveness. When the formulation 
was used also in a pulmonary metastases model created in animals, the treated animals had 
significantly fewer metastases in their lungs and lower overall lung weights when compared 
to the controls treated with empty liposomes or the untreated group [7]. 
In another study, this chemotherapy formulation was used for pulmonary metastatic disease in 
humans. It was administered to six patients with pulmonary metastases of tumours of different 
histologies. No significant toxicity was noted and three of the six patients had stabilisation of 
the disease. In the animal model, results showed that tumour surface areas were significantly 
smaller in cyclosporine-paclitaxel treated animals when compared to untreated control and 
paclitaxel or cyclosporine treated animals (P < 0.01) [6]. 
In another study, Wang et al. demonstrated that nebulised aerosol formulation of anticancer 
agent farnesol induces death of human lung cancer cells, H460 and A549, in vitro. Nearly 
100% of lung cancer cytotoxicity was achieved by nebulisation of farnesol formulation using 
either Pari LC Star or LC plus nebulisers. The anticancer agent gemcitabine has been shown 
to inhibit the growth of primary osteosarcoma and osteosarcoma lung metastases. The 
response of LM7 and LM8 lung metastases to aerosol gemcitibine was dose dependent. The 
efficacy of aerosol vs. IP gemcitabine was compared using 0.5 mg/kg dose with the treatment 
initiated when primary tumour volume reached 130 mm3. The number of micrometastases in 
the lung was significantly reduced only in mice receiving aerosol gemcitabine when 
compared to control and IV treated group [8]. Difluromethylornithine and 5-flurouracil are 
reported as effective chemo-preventive compounds against carcinogenesis of the upper 
respiratory tract by using aerosol delivery. Both compounds increased the percentage of 
animals free of tumours and prevented infiltrating squamous cell carcinoma by >50% [9]. 
Aerosolized delivery of chemopreventive agents, budesonide and isotretinoin, have been 
found to be effective in the chemoprevention of lung cancer in A/J mice [10]. 
 
5.2.4 Nebulisers 
Nebulisers have been used for many years to treat asthma and other respiratory diseases. 
There are two basic types of nebuliser, air-jet and ultrasonic nebulisers. Nebulisers are 
probably the least efficient method of aerosol drug delivery. They are variable, slow, and 
expensive for basic use. Despite the above reservations, nebulisers are still typically the first-
line therapy in acute asthma or COPD exacerbation where a large amount of medication is 
administered and variability is less of an issue. They require less cooperation and effort of an 
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ill patient. Further advantages of nebulisers are their ability to deliver high doses of drug to 
the lungs and the minimal coordination and effort required for inhalation in comparison to 
pMDIs or DPIs.  
 
5.2.4.1 Air-jet nebulisers 
The standard air-jet nebuliser applies basic Venturi principles to nebulise medication. A high 
velocity gas jet of oxygen or air is passed through a constriction and draws up liquid 
medication through a tube due to the relative vacuum. This produces an aerosol that is 
directed at the surfaces of the jet apparatus and is immediately shattered into small particles. 
These particles in turn are passed through the tubing to the patient. The large particles are left 
behind in the jet apparatus to be re-aerosolised. 
With an air-jet nebuliser, aerosol particle size is directly proportional to compressed gas flow. 
It has been shown that more powerful systems that deliver 8 L/min of flow coupled with an 
intermittent (dosimetric) rather than continuous inhalation system produce more desirable 
particle size and less medication is lost to the environment. 
Air-jet nebulisers are driven either by a portable compressor or from a central air supply. 
Essentially, a high-speed airflow through a narrow nozzle orifice entrains and disperses the 
liquid into droplets (primary generation) via a viscosity-induced instability. Droplet 
dispersion is improved by impact of droplets on a baffle structure and shear deformation into 
even smaller droplets (secondary generation). The resulting droplet size distribution still 
contains only a small fraction of respirable aerosol (droplets below 5 µm to 6 µm in size), but 
large droplets are recirculated within the nebuliser by means of secondary impaction 
structures and can eventually contribute to the respirable fraction. 
This process is associated with evaporation effects that cause the gas phase to be nearly 
saturated with vapour, as well as decrease temperature within the nebuliser. A considerable 
part of the vapour arises from the larger recirculating droplets, thus increasing drug 
concentration in the remaining liquid (figure 19A).  
For liposomal formulations, disruption of liposomes can occur due to mechanical stresses 
during nebulisation, possibly during primary generation and/or secondary generation, 
although such disruption is device-specific, it is most pronounced for large liposomes. More 
sophisticated nebulisers are breath-enhanced (e.g., Pari LC Plus and Pari LC Star), which 
entrain inhalation air in the droplet production region and produce aerosol at a higher rate 
during inspiration, but at a lower rate during expiration using a valve system. Due to this 
                                                                                            5. Nebulisation of liposomal formulations 
   
 
                                                                                     
105
effect, approximately 70% of the aerosol will be delivered to the patient during continuous 
nebulisation. 
With air-jet nebulisers, all commercially available inhalation solutions and suspensions can be 
administered. Mechanical damage, which may cause denaturation of sensitive drug 
compounds (i.e., proteins and peptides) is minimised.  
 Enhanced delivery designs increase aerosol output by directing auxiliary air, entrained during 
inspiration, through the nebuliser, causing more of the generated aerosol to be swept out of 
the nebuliser and available for inhalation. Drug wastage during exhalation is reduced to the 
amount of aerosol produced by the jet air flow rate that exceeds the storage volume of the 
nebuliser. Adaptive aerosol delivery monitors a patient's breathing pattern in the first three 
breaths and then targets the aerosol delivery into the first 50% of each inhalation. This ensures 
that the aerosol is delivered to the patient during inspiration only, thereby eliminating drug 
loss during expiration that occurs with continuous output nebulisers. 
 
 
 
A                                                                                                                             B 
 
Figure 19: A) Air-jet nebuliser. B) Ultrasonic-nebuliser [taken from 11].  
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5.2.4.2 Ultrasonic nebulisers 
With the ultrasonic nebuliser, a fountain is created in the nebuliser by the ultrasonic energy 
from a piezoelectric crystal vibrating at a high frequency (usually 1-3 MHz). The higher the 
frequency, the smaller the droplets produced. Droplets are thrown off from the fountain 
(figure 19B). The output is large so nebulisation is faster. This is particularly useful with 
larger volumes. Two disadvantages of the ultrasonic method are the relative expense of the 
equipment and the fact that large-sized particles with a suboptimal deposition profile are 
produced. 
The physical properties of drug formulations may have an effect on nebulisation rates and 
particle size. The viscosity, ionic strength, osmolarity, pH and surface tension may prevent 
the nebulisation of some formulations. If the pH is too low, or if the solution is hyper- or 
hypoosmolar, the aerosol may induce bronchoconstriction, coughing and irritation of the lung 
mucosa. As well, high drug concentrations may decrease the drug output with some 
nebulisers; colomycin at concentrations >75 mg/ml foams in all nebulisers, especially 
ultrasonic ones, making aerosolization of the drug very inefficient if not impossible. 
 
5.2.5 Lung surfactant  
Lung surfactant is a complex mixture of lipids and proteins [12]. The lipids are the major 
surfactant component by weight, making about 85-90% of the whole isolated surfactant. 
Approximately 90% of this lipid fraction consists of a mixture of PLs. The remaining 10% is 
composed of other lipids, mainly chol. Nearly 70% of the fatty acids are saturated under 
normal conditions, the most common saturated acid being palmatic acid. 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) is the surfactant component which is predominantly 
responsible for the reduction of surface tension [12, 13].  
 
5.2.6 Challenges  
Through a reasonably well developed and proven technology, the pulmonary application via 
inhalation is still accompanied by several unique challenges. First of all, the formulations 
need to be converted into an aerosol that can be inhaled by the patient. Nebulisation by air-jet 
and ultrasound are the two predominant methods utilised therapeutically to aerosolise drug 
solutions [9]. Air-jet nebulisers operate with compressed air, transporting liquid through 
nozzles creating small aerosol droplets, whereas ultrasonic nebulisers use the piezoelectric 
effect to generate high-frequency acoustic energy which generates aerosol droplets by 
cavitation. Both types of nebulisers offer various advantages and disadvantages. Air-jet 
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nebulisation can affect liposomes as a result of the high shear forces applied during 
nebulisation, while ultrasonic energy is notorious for altering or damaging some aerosolised 
drug substances [10, 14]. Furthermore, ultrasonic nebulisers are usually more expensive and 
have not yet even been investigated for the aerosolisation of liposomes. A significant 
disadvantage of air-jet nebulisers is the lower output, which results in a prolonged exposure 
time of the formulation to shear forces. 
The next challenge is the preparation of a liposomal formulation which maintains its integrity 
in the lung surfactant lining long enough to be internalised into the tumour. Lung surfactant is 
a complex mixture of lipids and proteins, and there is no guarantee that liposomes will survive 
intact for appropriate time, since they are composed of PLs which are natively present in lung 
surfactant [15, 16].  
In this study, the effect of PEGylation on the stability of previously developed transferrin 
conjugated liposomal systems during nebulisation using two different types of nebulisers, air-
jet and ultrasonic, was investigated. In addition, the stability of the liposomal systems in 
commercial lung surfactant was assessed. This was intended as an in vitro model for the 
situation where liposomes particles have successfully reached target cells in the lung. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                            5. Nebulisation of liposomal formulations 
   
 
                                                                                     
108
5.3 Materials and methods 
 
5.3.1 Liposome preparation 
Liposomes were prepared using a slightly modified protocol according to our previously 
published method [17]. Briefly, liposomes were prepared from DSPC, Chol and the linker 
DSPE-PEG2000-COOH at the ratio 6:3:0.6. For surfactant-stability studies, liposomes with 
DPPC were prepared using the same molar ratios as stated above. PEGylated liposomes were 
prepared by addition of phosphoethanolamine-N-[methoxy(polyethyleneglycol)-5000] 
(MPEG5000-DSPE) at 5 mol%. All lipids were purchased from Avanti Polar Lipids (Alabaster, 
AL, USA). The mixture of PL and chol in chloroform:methanol (2:1) was dried to a thin lipid 
film in a rotary evaporator (Büchi, Essen, Germany). The lipids were re-suspended in an 
appropriate amount of 400 mM citrate/5 mM phosphate buffer (pH 4.0) containing the 
fluorescent dye calcein at 50 mM resulting in a final lipid concentration of 10 mg lipid/ml. 
After vortexing, the sample was incubated for 10 min at 60°C, a temperature above the 
transition temperature of the used lipids (53°C for DSPC:Chol) in a cabinet drier. Unilamellar 
liposomes were prepared by extruding the resulting multilamellar vesicles eleven times 
through a 200-nm polycarbonate membrane, followed by extrusion eleven times through a 
100-nm membrane using a Liposofast Basic Device (Avestin, Mannheim, Germany).  
Conjugation of Tf to the liposomal surfaces was achieved by adding 1 ml PBS (pH 7.5) and 
360 µl of both EDC (0.25 M in H2O) and S-NHS (0.25 M in H2O)  per 10 µmol of lipid. The 
mixture was allowed to incubate for 10 min at room temperature, before adjusting to pH 7.5 
with 1 M NaOH. 125 µg Tf/µmol PL was added and gently stirred for 8 h at 4°C. Unbound 
protein was removed by passing the liposome suspension through a Sepharose CL-4B gel 
column (Sigma).  
PL concentration was determined by the colorimetric method of and the amount of protein 
was determined by the BCA assay [17, 18]. Encapsulation efficacy of doxorubicin (DOX) 
was assayed with a fluorescence plate reader (Cytofluor II, PerSeptive Biosystems, 
Wiesbaden, Germany) at excitation and emission wavelengths of 485 and 530 nm, 
respectively.  
 
5.3.2 Photon correlation spectroscopy 
The mean particle size of the liposomal suspension was investigated by dynamic light 
scattering. Size determination of the liposomal formulations before and after nebulisation was 
carried out using a Zetasizer 3000 HS (Malvern Instruments, Herrenberg, Germany) equipped 
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with a photon correlation spectroscopy unit. The scattered light was detected at a scattering 
angle of 90°. Measurements were performed at 25°C. For all measurements, samples were 
diluted 50-fold in distilled water to obtain appropriate counts. PCS provides information 
about the mean diameter of the bulk population and the width of distribution via the 
polydispersity index (PI). Mean values and standard deviation were calculated from three 
determinations. 
 
5.3.3 ζ-potential measurements 
ζ-potential measurements of the liposomal formulation before and after nebulisation were 
carried out in the standard capillary electrophoresis cell of a Zetasizer 3000 HS at pH 7.4 in 
the presence of NaCl to adjust the conductivity to 50 µS/cm. Measurements were performed 
at 25°C with automatic duration. The instrument was routinely calibrated with a –50 mV latex 
standard (Malvern Instruments). The electrostatic mobility was converted into the ζ-potential 
using the Helmholtz-Smoluchowski equation [19]. The mean values and standard deviation 
were calculated from three independent measurements (3 runs each). 
 
5.3.4 Atomic force microscopy  
The liposomal formulations with and without Tf modification were prepared as described 
above and diluted in ultrapure water (MilliQ, 18.4 MΩ, pH 5.5). Approximately one hour 
after preparation, the liposomes were directly transferred onto a silicon chip by dipping the 
chip into the liposome suspension. Atomic force microscopy was performed on a vibration-
damped Digital Nanoscope IV Bioscope (Veeco Instruments, Santa Barbara, CA). 
Commercial pyramidal Si3N4 tips (NCH-W, Veeco Instruments) on a 125 µm cantilever; a 
resonance frequency of about 220 kHz and a nominal force constant of 36 N/m were used. All 
measurements were performed in tapping mode to avoid damage of the sample surface. The 
scan speed was inversely proportional to the scan size and the scan frequency was between 
0.5 and 1.5 Hz. Images were obtained by displaying the amplitude signal of the cantilever in 
the trace direction, and the height signal in the retrace direction, both signals being 
simultaneously recorded as described previously [20]. The results were visualised either in 
height or in amplitude mode. 
 
5.3.5 Liposome membrane integrity after nebulisation 
The effect of PEGylation on the stability of liposomes undergoing nebulisation was assessed 
in two different systems, an air-jet nebuliser Pari LC star (Pari, Starnberg, Germany) operated 
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with a Pari Boy compressor, and an ultrasonic nebuliser, Optineb (Nebutec, Elsenfeld, 
Germany), operated at a frequency of 2.4 MHz and 12 l/min air flow rate. The filling volumes 
of the nebulisers were 4 ml and the nebulisation to residual volume was performed in 
approximately 10-20 min. The nebulised samples were collected by aerosol deposition on a 
glass plate and subsequent collection in 1.5 ml Eppendorf tubes. All nebulisation studies were 
repeated in triplicate. 
Integrity of the liposomal membranes after nebulisation was assessed by measuring calcein 
fluorescence with a fluorescence plate reader (Cytofluor II, PerSeptive Biosystems, 
Wiesbaden, Germany) at excitation and emission wavelengths of 485 and 530 nm, 
respectively, before and after liposomal disruption by Triton X-100 (1% final concentration).  
The values for integrity of the liposomes were determined from the equation 
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−=
IT
I
N
T
N
FF
FFIntegrity     eqn. 1 
 
where FI and FNI are the calcein fluorescence intensities of each sample before, and FT and 
FNT the calcein fluorescence intensities after nebulisation in the absence and presence of 1% 
Triton X-100, respectively. The values obtained after addition of Triton X-100 were corrected 
for dilution.  
 
5.3.6 Liposome membrane integrity in lung surfactant 
The membrane integrity of plain and PEGylated Tf-modified DPPC and DSPC liposomes 
after incubation in PBS (pH 7.4) or natural bovine surfactant extract (Alveofact®, Boehringer 
Ingelheim, Ingelheim, Germany) was evaluated by calculating the percentage retention of 
liposome-encapsulated calcein, as previously described [21]. Alveofact, a surfactant isolated 
from bovine lung lavage fluids, was used at a final concentration of 3 mg/ml in PBS (pH 7.4), 
to mimic conditions in the human respiratory system. Calcein was encapsulated in the 
liposomes at such a concentration that its ability to fluoresce was quenched, and thereby any 
fluorescence measured was due to calcein leakage and dilution in the exterior aqueous media. 
In brief, nine volumes of Alveofact solution or buffer were mixed with one volume of 
liposomal formulation (adjusted in order to have a final lipid concentration of 1 mg/ml in all 
cases) and samples were incubated at 37°C or 4°C for up to 48 h. At different time intervals, 
the latency and retention of calcein were estimated by measuring fluorescence of a 100 µl-
sample with a fluorescence plate reader (Cytofluor II, PerSeptive Biosystems, Wiesbaden, 
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Germany) at excitation and emission wavelengths of 485 and 530 nm, respectively, before 
and after liposomal disruption by Triton X-100 (1% final concentration).  
The values for calcein latency and retention were determined from the equations 
100% ×−=
T
IT
F
FFLatency     eqn. 2 
and 
%Retention 100
%
%% ×−=
T
IT
Latency
LatencyLatency  eqn. 3 
 
where FI and FT are the calcein fluorescence intensities of each sample in the absence and 
presence of 1% Triton X-100, respectively. The values obtained after addition of Triton X-
100 were corrected for dilution.  
 
5.3.7 Statistical analysis 
Data are presented as mean ± standard deviation (n), where n is the number of observations. 
Differences among group means were determined by one-way analysis of variance followed 
by post-hoc Newman-Keuls-Student procedures and p < 0.05 taken as the level of 
significance. 
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5.4 Results  
 
5.4.1 Characterisation of liposomes 
All different liposomal formulations had an initial size of 190 - 210 nm and a ζ-potential of ~ 
-20 mV (table 6). The initial calcein latency (%) of Tf-conjugated liposomes was measured 
immediately after separation of liposomal and free calcein (when liposomal fractions were 
eluted from the Sephadex column). Latency values were comparable for all investigated 
preparations at 62.38±6.13% (DPPC:chol-Tf), 61.38±1.42% (DSPC:chol-Tf), 66.30±0.42 
(DPPC:chol-PEG-Tf), and 65.81±3.06 (DSPC:chol-PEG-Tf). 
 
Table 6. Physico-chemical properties of liposomal formulations before and after nebulisation 
by air-jet or ultrasound assessed by photon correlation spectroscopy and zetasizer. 
 
 Before nebulisation Collected aerosol droplets 
after nebulisation 
Reservoir content after  
nebulisation 
 
Air-jet nebuliser 
 
Size 
(nm) 
PI ζ-potential 
(mV) 
Size 
(nm) 
PI ζ-potential 
(mV) 
Size 
(nm) 
PI ζ-potential 
(mV) 
DSPC Tf 210.1 0.04 -20 222.1 0.06 -42 217.4 0.03 -58 
DSPC 5% PEG Tf 189.1 0.08 -22 195.8 0.06 -19 192.5 0.07 -22 
 
Ultrasonic nebuliser 
 
         
DSPC Tf 210.1 0.04 -20 214.5 0.06 -32 214.9 0.08 -46 
DSPC 5% PEG Tf 189.1 0.08 -22 173.5 0.12 -22 187.4 0.11 -24 
 
 
5.4.2 Stability after nebulisation 
Liposomes prepared from DSPC:chol-Tf were used in this study either plain (i.e., non 
PEGylated) or PEGylated. Both formulation types were tested in an air-jet and an ultrasonic 
nebuliser. The integrity of the liposomes was assessed by means of calculating the loss of 
encapsulated calcein and by visualising morphological changes by AFM. 
In tables 6 (PCS) and 7 (AFM), changes in size and ζ-potential are summarised. The size of 
both formulations in all devices changed only marginally, as did the ζ-potential in the case of 
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the PEGylated liposomes. Non-PEGylated liposomes showed a reduction in ζ-potential upon 
nebulisation. The integrity, i.e., calcein retention pre- vs. post-nebulisation, also showed no 
marked difference between the type of nebuliser or the formulation (figure 20). Integrity of all 
investigated samples was around 90%. Figure 21 shows the morphology of the liposomes 
before (figure 21A and 21D) and after (figure 21B, 21C, 21E and 21F) nebulisation. 
Generally, plain liposomes (figure 21A, 21B and 21C) as well as PEGylated liposomes 
(figure 21D, 21E and 21F) maintained their spherical morphology. However, PEGylation 
resulted in less fusion and a slightly rounder shape. With regards to the nebuliser technology, 
ultrasound produced less fusion (figure 21C and 21F) compared to air-jet nebulisation (figure 
21B and 21E). Liposomes which were collected from the nebulisation chambers after 
nebulisation did not display altered morphology at all. 
 
Table 7. Physico-chemical properties of liposomal formulations before and after nebulisation 
with air-jet or ultrasound assessed by atomic force microscopy. 
 
 Before nebulisation Collected aerosol droplets 
after nebulisation 
Reservoir content after  
nebulisation 
 
Air-jet nebuliser 
 
Size 
(nm) 
Size range 
(nm) 
Size 
(nm) 
Size range 
(nm)  
Size 
(nm) 
Size range 
(nm) 
DSPC Tf 192.3 ± 17 152 - 267 215.4 ± 34 83 - 401 203.1 ± 16 154 - 247 
DSPC 5% PEG Tf 163.7 ± 18 105 - 187 167.5 ± 23 95 - 227 166.6 ± 12 113 - 184 
 
Ultrasonic nebuliser 
 
  
    
DSPC Tf 192.3 ± 17 152 - 267 254.4 ± 45 127 - 344 199.7 ± 45 157 - 243 
DSPC 5% PEG Tf 163.7 ± 18 105 - 187 145.3 ± 8 132 - 158 172.1 ± 16 122 - 198 
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Figure 20: Integrity of liposomes during nebulisation. Liposomes were collected from droplets after nebulisation 
using an air-jet or ultrasound nebuliser or were taken from the nebulisation chamber of the respective device. 
The integrity of the liposomal membranes was calculated from the retention of calcein (initial value = 100%). 
 
 
 
 
                                                                                            5. Nebulisation of liposomal formulations 
   
 
                                                                                     
115
 
Figure 21: Atomic force microscopy images of surface-deposited liposomal formulations before and after 
nebulisation. A) DSPC:chol-Tf before nebulisation; B) DSPC:chol-Tf after air-jet nebulisation, C) DSPC:chol-
Tf after ultrasonic nebulisation; D) DSPC:chol-PEG-Tf before nebulisation; E) DSPC:chol-PEG-Tf  after air-jet 
nebulisation; F) DSPC:chol-PEG-Tf after ultrasonic nebulisation. 
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5.4.3 Stability in lung surfactant 
Four different liposomal formulations were prepared and compared in terms of stability in 
lung surfactant solution: DPPC:chol-Tf, DPPC:chol-PEG-Tf, DSPC:chol-Tf, and DSPC:chol-
PEG-Tf. As shown in figure 22 A and 22 B, membrane integrity of liposomes made from 
DSPC exhibited higher values than their counterparts prepared from DPPC, when incubated 
in the Alveolfact solution. Furthermore, the liposomal composition had a significant impact 
on the liposomal stability; PEGylated preparations were generally more stable than plain 
liposomes. Incubation at higher temperatures (i.e., 37°C (figure 22A, 22C) vs. 4°C (figure 
22B, 22C)) resulted in higher retention values for the encapsulated calcein. All formulations 
showed almost no release of calcein in presence of buffer as incubation media either at 4°C or 
37°C (figure 22 C and 22D).  
 
Figure 22: %Retention of liposomal content after incubation in Alveofact®. DPPC:chol-Tf (●), DPPC:chol-
PEG-Tf (▼), DSPC:chol-Tf (○), and DSPC:chol-PEG-Tf (∇) liposomes were incubated for 48 hours at 37°C (A, 
B) or 4°C (C, D) and release of calcein from the vesicles was measured. 
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5.5 Discussion 
Conventional approaches to lung cancer treatment, including traditional chemotherapy, have 
shown relatively limited success. Indeed, the overall 5-year survival rate of 14% has not 
changed for 50 years. Thus, it is clear that new therapies or new contributions of therapies are 
needed to create maximum anti-tumour response without damage of normal respiratory tract 
tissues. 
Studies of liposomes for pulmonary drug delivery have shown that liposomes deposited in the 
peripheral airways are retained for prolonged periods of time. This may result in prolonged 
drug presence in the airways, localised drug action in the respiratory tract, and decreased 
incidence of systemic adverse effects. All reported studies of liposome delivery to the human 
lung have employed jet nebulisers. Nebulisers have thus far been preferred to the alternative 
systems for drug delivery, namely pMDIs and DPIs, because they are capable of delivering 
large dose volumes. Moreover, liposomes can be produced by conventional techniques and 
usually require no further processing except removal of unentrapped drug where appropriate. 
However, jet nebulisers, which use compressed gas to generate an aerosol from aqueous 
solutions or suspensions, may structurally damage some liposome formulations due to the 
shearing forces and recycling of liquid that occur within the nebuliser. The major 
determinants of liposome stability to jet nebulisation are the size of the liposomes relative to 
the size of the aerosolised droplets, and the air pressure employed to generate the aerosol. 
Ultrasonic nebulisers are less widely employed for drug delivery than jet nebulisers. With 
these devices, the energy necessary for the atomisation of liquids is generated by high 
frequency vibrations in a piezoelectric crystal, which produce a fountain of droplets in the 
nebuliser chamber, of which the smallest are expelled and inhaled by patients. Operation of 
ultrasonic nebulisers causes an increase in the liquid reservoir temperature by up to 15°C. 
This can cause chemical breakdown of heat-labile materials.  
Targeting drug delivery into the lungs has become one of the most important aspects of 
systemic or local drug delivery systems. Consequently, in the last few years, techniques and 
new devices intended to deliver drugs into the lungs have been widely developed. Due to their 
inherent versatility, liposomes are ideal candidates for pulmonary drug delivery [22]. They 
offer many advantages including suitability of the carrier for lipophilic and hydrophilic drugs, 
superior sustained-release properties, and reduced local irritation and toxicity due to the usage 
of endogenous compounds [23, 24]. By engineering different parameters, formulations can be 
tailored to each specific therapeutic application. Our laboratories are particularly interested in 
inhalation therapy of malignancies involving the lung. This novel approach to treat lung 
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cancer holds promise as a means to avoid systemic toxicity while obtaining improved 
therapeutic effect [7]. The objective of the present study was to assess the effect of 
PEGylation of the liposomal membrane on stability during nebulisation and longevity after 
deposition in lung surfactant fluids. Insertion of PEGylated lipids into liposomal membranes 
(i.e., sterically-stabilised liposomes or Stealth® liposomes) has been reported to prolong 
longevity of circulating liposomes by a drastic reduction of opsonisation events [25, 26]. One 
of the major drawbacks of classical liposomes has been their rapid clearance from blood, due 
to adsorption of plasma proteins (opsonins) to the "naked" PL membrane, triggering 
recognition and uptake of the liposomes by the MPS, also referred to as the RES. A major 
advance in the field of liposomes came with the development of Stealth® liposomes, which 
utilize a surface coating of a hydrophilic carbohydrate or polymer, usually a lipid derivative 
of PEG, to help evade MPS recognition. The inclusion of PEG or other hydrophilic polymers 
extends the half-life of liposomes from less than a few minutes (classical liposomes) to 
several hours (Stealth® liposomes) and changes the pharmacokinetics of the liposomes from 
dose-dependent, saturable pharmacokinetics to dose-independent pharmacokinetics. To date, 
liposomes coupled to antibodies or antibody fragments, folate or Tf have been the most 
extensively researched LTLs. 
Intriguingly, PEGylation has not had a great influence on the integrity during nebulisation. 
Both plain and PEGylated liposomes were equally stable in the air-jet and the ultrasonic 
nebuliser with retention values ~90%. However, AFM revealed less fusion and a slightly 
rounder morphology in case of the PEGylated liposomes. The choice of nebuliser made no 
significant difference in retention values, but again there was a slightly better morphology 
when using ultrasound instead of an air-jet. 
We found that PEGylation significantly increased the stability of the liposomes in a lung 
surfactant assay. PEGylation results in Born-hydration repulsion caused by the establishment 
of a non-diffusive water layer around the liposomes, in addition to steric repulsion caused by 
the PEG-chains. This finding is in agreement with previous reports on the stabilising 
properties of PEG-lipids in liposomal formulations [25]. The choice of PL also had an effect 
on the membrane integrity in lung surfactant, as DPPC-containing liposomes were slightly 
less stable than those produced with DSPC. It can be speculated that the high content of 
DPPC in the lung surfactant results in more rapid disintegration of liposomes prepared from 
the homologous lipid.  
In conclusion, PEGylated and plain Tf-conjugated liposomes are stable enough to undergo 
nebulisation in the course of an inhalation therapy. However, PEGylation is of advantage 
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when it comes to interactions between the liposomes and the surfactant lining of the lungs. 
PEGylated liposomes are significantly more stable and retain >80% of their drug load over 48 
h, which is more than sufficient time for the liposomes to be taken up by TfR-over-expressing 
cancer cells in the lung. 
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1. Summary 
The lungs are the common site of both metastasis and 1 neoplasia. The average lung cancer 
mortality rate is 90% making lung cancer the leading cause of cancer-related deaths in both 
men and women. 
Current lung cancer treatments include surgery, radiation therapy and chemotherapy, but in 
recent years, a novel approach for cancer therapy based on Ehrlich's concept of the ‘magic 
bullet’ has been developed. Cytotoxic conjugates, composed of two components, a carrier 
molecule with high affinity and specificity for cancer cell-associated antigens or other tumour 
targets coupled to a potent cytotoxic drug, are being designed for active anti-cancer drug 
targeting.  
Recent results have shown that the expression of transferrin receptors by human cancer cells 
is directly correlated with the anti-tumour effectiveness of transferrin receptor conjugates. 
Transferrin (Tf) is a glycoprotein involved in iron transport into cells that is internalised upon 
binding to its receptors on the cell surface. It is now widely accepted that the density of 
transferrin receptors (TfR) is a marker for cell proliferation and that tumour cells usually 
over-express TfR. These free TfRs are therefore ideal targets for cancer therapy, especially for 
malignancies that are refractory to conventional therapy, such as lung tumours.  
Receptor-mediated endocytosis pathways can be exploited for specific targeting of liposomes 
to the cells. Coupling liposomes to a ligand, that is directed towards an over-expressed 
receptor in cancer cells and that normally undergoes endocytosis, is a strategy that can 
improve selectivity and facilitate access of liposomes to the intracellular compartment.  
 
Goal of this PhD project was the development of a novel anti-cancer therapy by using 
aerosols of Tf-modified liposomes for a local, thus less problematic, treatment of lung 
tumours. Since not much published data was available, the first step was to estimate the 
expression levels of TfR on cells originating from lung cancer, as well as from healthy lung 
tissues. The data show that TfR expression levels in healthy alveolar epithelial cells in 
primary culture were significantly lower than in A549 cells, a cell line derived from an 
adenocarcinoma of the distal lung. TfR expression levels in the continuously growing 
bronchial epithelial cell lines, Calu-3 and 16HBE14o-, were again significantly higher than 
those observed for the alveolar cell types. 
In general, all cell types showed TfR molecules located predominantly at their basolateral 
membranes, but cells undergoing mitotic proliferation at the time of fixation showed an 
additional strong signal for TfR on their apical aspect as well, due to the loss in cell polarity.  
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After validating the applicability of TfR as a target molecule for our strategy, in an attempt to 
produce Tf-modified liposomes, three different linker lipids (DSPE-PEG2000-maleimide, N-
glutaryl-PE and DSPE-PEG2000-COOH) were used. Many protocols have been published on 
the conjugation of proteins to surfaces of liposomes, but (visual) data on the quality and 
quantity of the claimed modifications are scarce. We successfully used atomic force 
microscopy (AFM) and transmission electron microscopy (TEM) as novel tools to visualise 
the actual conjugation of transferrin to the liposomal carrier. In addition, to quantify the 
conjugation efficiency, BCA-assays were performed and the phospholipid concentration was 
measured spectrophotometrically according to Stewart's method. The obtained date were then 
compared to the AFM and TEM results. AFM and TEM were able to detect Tf at the 
liposomal surface on the molecular level in a fast and reproducible manner. Both microscopic 
techniques can deliver semi-quantitative visual information on the actual functionalisation of 
nano-scale drug carriers with protein or antibody molecules. While the use of AFM does not 
require any fixation or preparation of the sample prior to the measurement, the advantage of 
TEM is the possibility to reach a higher level of specificity when using antibodies raised 
against the protein under investigation. 
 
The third step of the project was to test if the developed Tf-liposomes were actually able to 
delivery the payload to cancer cells at a higher rate than to their healthy counterparts. Again, 
in vitro cell culture techniques of several pulmonary epithelial cell types (both healthy and 
cancerous) were employed to give us some answers. Binding/uptake studies as well as 
cytotoxicity assays were carried out using the most promising candidates from our first study. 
Furthermore, we tested sterically-stabilised liposomes to assess the repulsive effect of the 
PEG-chains on the Tf-mediated uptake. We found that our Tf-liposomes can efficiently 
deliver the model drug, doxorubicin (DOX), to tumour cells and bypass the drug efflux 
mechanisms characteristic to multidrug resistance. The time-dependent uptake of liposomes 
into the cells showed a significantly higher uptake for the Tf-modified liposomes. When 
performed at 4°C or in the presence of excess free Tf, the experiments resulted in significantly 
lower fluorescence signals. The results of the cytotoxicity tests showed that primary cells 
were less affected by DOX encapsulated in Tf-liposomes than all cancerous cell lines used in 
this study. PEGylation generally decreased the binding/uptake, but only at a neglectable level. 
  
In the last part of my work, the liposomal system were tested for their suitability for 
aerosolisation. Plain and PEGylated Tf-liposomes were aerosolised by two different nebuliser 
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types (i.e., air-jet and ultrasound) and their morphology was assessed by AFM and the 
integrity of the liposomal membranes by measuring the loss of encapsulated calcein. In 
additional studies, the stability of the liposomes in buffer solution was compared to the 
stability in an artificial lung surfactant (Alveofact®). The results lead to the conclusion that 
PEGylated and plain Tf-conjugated liposomes were both stable enough to undergo 
nebulisation, however, PEGylation was of advantage when it came to interaction between 
liposomes and the surfactant lining of the lungs. PEGylated liposomes were significantly 
more stable and retained >80% of their drug load over 48 h in artificial lung surfactant, which 
is more than sufficient time for the liposomes to be taken up by transferrin receptor over-
expressing tumours in the lung. 
 
In general conclusion, this work could proof the feasibility to produce transferrin-conjugated 
liposomes, which can successfully deliver high amounts of anti-cancer drugs to pneumocytes 
of cancerous origin while having a low level of cytotoxicity in healthy cells. Furthermore, the 
developed liposomes are stable enough to undergo aerosolisation, a necessary prerequisite of 
oral inhalation. The liposomes also endure prolonged times in lung surfactant solutions 
without being compromised.  
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2. Zusammenfassung 
Bösartige Erkrankungen der Lunge fordern weltweit weiterhin die meisten Todesopfer, 
sowohl bei Männern wie auch Frauen. Ursächlich hierfür ist, dass sich in der Lunge neben 
Primärtumoren (d.h. Tumoren, die vom Lungengewebe ausgehen) auch überproportional viele 
Metastasen im engen Kapillarnetz der Lunge festsetzen und somit für Sekundärtumoren 
verantwortlich sind. Therapieoptionen bei Lungenkrebs sind chirurgische Eingriffe, 
Bestrahlung und seit einiger Zeit auch Chemotherapie. Die verschiedenen Therapieformen 
können auch kombiniert angewendet werden, jedoch ist die Prognose bei Lungenkrebs 
generell eher schlecht, da die Krankheit in der Regel erst in einem späten Stadium 
diagnostiziert wird. 
Seit Paul Ehrlich das Prinzip der selektiven Toxizität postulierte („magic bullet“) versuchen 
Forscher mit immer neuen Mitteln Arzneistoffe gezielt einzusetzen. So gesehen geht das 
moderne drug targeting auf eine 150 Jahre alte Idee zurück. Im konkreten Fall der 
Krebstherapie wird versucht zytotoxische Arzneistoffe möglichst nur im Tumorgewebe 
anzureichern, um somit eine effektive Therapie mit reduzierten systemischen 
Nebenwirkungen zu kombinieren. Hierzu werden die Arzneistoffe oder Arzneistoffträger mit 
Molekülen konjugiert, die eine stark erhöhte Affinität zu Strukturen (z.B. Antigenen) haben, 
die vornehmlich auf Tumorzellen exprimiert werden. Transferrin-Rezeptoren (TfR, CD71) 
gehören zu dieser Gruppe von Antigenen. Transferrin (Tf) ist ein biogenes Glykoprotein, 
welches die Körperzellen mit Eisen versorgt. Zwei Gründe sind für das Interesse an der 
Tf/TfR-Interaktion als Arzneistoff-Target verantwortlich: 1. wird Tf nachdem es am TfR 
gebunden hat internalisiert und 2. ist der TfR auf den meisten entarteten Zellen überexprimiert 
und wird teilweise sogar als Marker für die Aggressivität der Erkrankung herangezogen. 
 
Ziel dieser Arbeit war es eine neuartige Strategie im Kampf gegen den Lungenkrebs zu 
entwickeln. Dazu sollten drug targeting mittels Tf/TfR und Lokaltherapie der Lunge mittels 
Inhalation von Aerosolen kombiniert werden. 
 
Um die Validität der Hypothese zu überprüfen musste das zuerst einmal ermittelt werden, ob 
Krebszellen des Lungenepithels ebenfalls erhöhte TfR Werte haben. Da es in der Literatur 
hierzu nur lückenhafte Hinweise gab, wurde die TfR Dichte verschiedener 
Lungenepitheltypen (normal und entartet) mittels indirekter Immunofluoreszenz (FACS) 
nachgewiesen. Die Ergebnisse der Studie ergaben, dass die Beobachtungen bei anderen 
Tumoren auch für Lungenkrebs zutreffen. Die auf ein Adenokarzinom der distalen Lunge 
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zurückgehende Zelllinie A549 wies eine signifikant höhere TfR Anzahl auf als vergleichbare 
Alveolarepithelzellen in Primärkultur. Weiterhin stellten wir fest, dass beide untersuchten 
Zelllinien des Bronchialepithels (Calu-3 und 16HBE14o-) wiederum signifikant höhere Werte 
lieferten als die Alveolarzelltypen.  
 
Nach diesen Ergebnissen konnte die eigentliche Arbeit – die Entwicklung eines 
Arzneistoffträgers – aufgenommen werden. In der Literatur sind mehrere verschiedene 
Mechanismen beschrieben worden um Tf an Liposomen zu koppeln. Jedoch finden sich fast 
keine Hinweise wie der Erfolg der Kopplungsreaktion überprüft werden kann. In der Regel 
begnügt man sich hier mit einem Protein-Assay (z.B. BCA). Eine zusätzliche optische 
Darstellung der Kopplungseffizienz wurde bisher nicht beschrieben. Deshalb wurden in von 
uns 3 beschriebene Kopplungsmethoden für Tf ausprobiert und die Ergebnisse verglichen. 
Dies geschah mittels BCA-Protein-Assay und Bestimmung der Phospholipide nach Steward. 
Zusätzlich wurde die Proben in einem Rasterkraftmikroskop (oder AFM) und einem 
Transmissionselektronenmikroskop untersucht. Die Ergebnisse konnten nicht nur signifikante 
Unterschiede zwischen der Effizienz der verschiedenen Kopplungsverfahren aufzeigen, wir 
konnten auch weiterhin AFM und TEM als schnelle und zuverlässige Verfahren zur 
Darstellung von Protein-drug carrier Konjugation etablieren. Während AFM den Vorteil 
bietet, dass die zu untersuchende Probe nicht behandelt oder fixiert werden muss, kann beim 
TEM die die Empfindlichkeit des Verfahrens durch Verwendung von Antikörpern gegen das 
Zielprotein noch weiter erhöht werden. 
 
Als nächstes wurde untersucht, ob die Tf-Kopplung tatsächlich zu einer erhöhten Aufnahme 
von Liposomen in die Zellen führt, und wie zytotoxisch die Liposomen generell sind. Dazu 
wurden Bindungs- und Aufnahmeversuche sowie Zytotoxizitäts-Assays in verschiedenen 
Lungenepithelzelltypen in vitro durchgeführt. Zusätzlich wurde der Einfluss von PEG-
Stabilisierung auf die Effektivität der Liposomen untersucht. Wiederum waren die Ergebnisse 
sehr viel versprechend: Die Tf.Kopplung resultierte in einer Vervielfachung der Aufnahme 
von Liposomen in die Krebszellen. Diese Aufnahme war beeinflussbar durch niedrige 
Temperaturen (4°C) und auch durch größere Mengen freies Tf im Versuchsmedium. Die 
einzelnen Werte für die Internalisierung korrelierten sehr gut mit den zuvor gemessenen TrF 
Dichten der einzelnen Zelltypen. PEGylierte Liposomen banden zwar etwas schlechter als 
„nackte“, aber immer noch signifikant besser als Liposomen ohne Tf-Modifizierung. Bei den 
Zytotoxizitäts-Assays sah es ähnlich aus: die Tf-konjugierten Liposomen resultierten in hohen 
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Absterberaten bei den Tumorzellen, während die Primärzellen deutlich weniger beeinflusst 
wurden.  
 
Im letzen Teil der Arbeit sollten schließlich ermittelt werden, ob die Liposomen überhaupt in 
der Lage sind ihre Ladung an den Wirkort zu bringen, d.h. ob sie den Scheerstress bei der 
Vernebelung überstehen und ob die Membranintegrität durch Lungensurfactant nachteilig 
beeinflusst wird. Einfache und PEGylierte Liposomen wurden in zwei verschiedenen 
Systemen (Druckluftdüse und Ultraschall) vernebelt und die Retention von Calcein wurde 
bestimmt. Zusätzlich wurde die Morphologie mittels AFM untersucht. Die liposomalen 
Formulierungen wurden weiterhin mit künstlichen Surfactant (Alveolfact®) inkubiert. Die 
Studien ergaben, dass der Einfluss von PEGylierung auf die Stabilität beim Vernebeln nicht 
allzu groß ist, jedoch war die Latenz von verkapselten Calcein in den Surfactant Versuchen 
deutlich höher.  
 
In der Zusammenfassung aller Versuche kann man schließen, dass die Aerosoltherapie mit 
Transferrin-modifizierte Liposomen ein sehr interessanter und Erfolg versprechender Ansatz 
in der Behandlung des Lungenkrebses ist. Die von uns entwickelten liposomalen 
Formulierungen sind in der Lage das Zielorgan zu erreichen und dort ihre Ladung selektiv an 
Krebszellen/Metastasen abzugeben. Diese Lokaltherapie sollte es ermöglichen die Tumoren 
gezielt zu bekämpfen, ohne den Körper schädigenden Konzentrationen des Zytostatikums 
auszusetzen.    
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3. Outlook 
In this dissertation, different problems were solved and the following conclusions could be 
drawn: 
 
• Like other cancer types, tumours of the lung exhibit elevated levels of transferrin 
receptor at their surfaces. These TfR might have the potential to be exploited for targeted 
drug delivery. 
 
• Conjugation by covalent linkage of transferrin to liposomes can be achieved by a 
variety of different methodologies. The actually coupled Tf can be visualised using AFM 
and TEM techniques.  
 
• It is feasible to produce transferrin-conjugated liposomes, which can successfully 
deliver high payloads of anti-cancer drugs to pneumocytes of cancerous origin while 
showing a low level of cytotoxicity in healthy cells.  
 
• The developed liposomes are stable enough to undergo aerosolisation, a necessary 
prerequisite of oral inhalation. The liposomes also endure prolonged times in lung 
surfactant solutions without being compromised.  
 
Before bringing this exciting new therapeutic strategy to the clinic, as a next step, animal 
xenograft models of lung cancer should be used to obtain important in vivo data. 
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List of abbreviations 
 
 
 
 
 
AFM Atomic force microscopy 
BCA Bicinchoninic acid assay 
BUD Budesonide 
CF 5,6-Carboxyfluorescein 
Chol Cholesterol 
COPD Chronic obstructive pulmonary disease 
CLSM Confocal laser scanning microscopy 
DPPC 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine 
DPPG Dipalmitoyl phosphatidyl glycerol 
DSPC 1,2-Distearoyl-sn-glycero-3-phosphocholine  
DSPE-PEG2000-COOH 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethylene glycol) 2000] 
DSPE-PEG2000-MAL 1,2-Distearoyl-sn-glycero-3-phosphocholine-
(polyethylene glycol) 2000-maleimide 
DOX Doxorubicin 
DPI Dry powder inhaler 
EDC N-(3-dimethylaminopropyl)-N-ethylcarbodiimide     
                                                                Hydrochloride 
EMEM Eagle's minimum essential medium 
FACS Fluorescence-activated cell sorting 
HSPC Hydrogenated soy phosphatidyl choline 
IP Intraperitoneal  
IV Intravenous 
LUVs Large unilamellar vesicles 
LTL Ligand-targeted liposomes 
LED Liposome-encapsulated doxorubicin 
MDR Multi drug resistance 
MLVs Multilamellar vesicles 
N-glutaryl-PE 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-    
                                                               N-glutaryl 
NSCLC Non small cell lung carcinoma 
PC Phosphatidylcholine 
PL Phospholipid 
PEG Polyethylene glycol 
PG Phosphatidyl glycerol 
pMDI Pressurised-metered-dose inhalers 
hAEpC II Primary human alveolar type I-like epithelial cells 
hAEpC I Primary human alveolar type II epithelial cells 
PGE Prostaglandin 
RES Reticuloendothelial system 
SAGM Small airways growth medium 
SCLC Small cell lung carcinoma 
SMLVs Small multilamellar vesicles 
SUVs Small unilamellar vesicles 
S-liposomes Sterically-stabilised liposomes  
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S-NHS Sulpho-N-hydroxysuccinimide 
TEM Transmission electron microscopy 
Tf Transferrin 
TfR Transferrin receptor (CD71) 
TB Tuberculosis 
UVs Unilamellar vesicles 
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